mutation_id virus genotype gene aa_change Ganciclovir Aciclovir Cidofovir Foscarnet Brincidofovir Letermovir Brivudine Penciclovir Tomeglovir Maribavir Cyclopropavir Amenamevir Pritelivir ref_title ref_link ref_doi strain_generation test_method co_gene co_aa created_date created_by note control_strain status 1 HCMV TOWNE UL54 D301N 2.6 3 0.5 Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus https://academic.oup.com/jid/article/188/1/32/821141 doi.org/10.1086/375743 Marker Transfer PRA 17/11/2019 OJCharles A 2 HCMV AD169 UL54 C304S 1.3 1.4 1.1 Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/ doi.org/10.1016/j.jcv.2011.01.004 Recombinant BAC SEAP 16/03/2020 OJCharles A 3 HCMV TOWNE UL54 N408D 4.9 5.6 1.3 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA 17/11/2019 OJCharles A 4 HCMV AD169 UL54 N408K 4.2 21 0.7 Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. https://europepmc.org/article/pmc/pmc1797699 doi.org/10.1128/AAC.00633-06 Recombinant BAC SEAP 17/11/2019 OJCharles A 5 HCMV AD169 UL54 N408S 3.1 7.5 1 Novel DNA polymerase mutations conferring cytomegalovirus resistance: Input of BAC-recombinant phenotyping and 3D model https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259 doi.org/10.1016/j.antiviral.2013.02.002 Recombinant BAC PRA 17/11/2019 OJCharles A 6 HCMV TOWNE UL54 N410K 2.9 3 0.8 Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus https://academic.oup.com/jid/article/188/1/32/821141 doi.org/10.1086/375743 Marker Transfer PRA 17/11/2019 OJCharles A 7 HCMV TOWNE UL54 F412C 4.2 18 1.2 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA 17/11/2019 OJCharles A 8 HCMV AD169 UL54 F412L 4.6 9.4 1.1 Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/ doi.org/10.1016/j.jcv.2011.01.004 Recombinant BAC SEAP 17/11/2019 OJCharles A 9 HCMV AD169 UL54 F412S 5.3 13 0.8 Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/ doi.org/10.1016/j.jcv.2011.01.004 Recombinant BAC SEAP 17/11/2019 OJCharles A 10 HCMV TOWNE UL54 F412V 4.3 15.5 1.1 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA 17/11/2019 OJCharles A 11 HCMV AD169 UL54 D413A 6.5 11 0.8 Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients www.sciencedirect.com/science/article/pii/S1386653206004161 doi.org/10.1016/j.jcv.2006.11.005 Recombinant BAC SEAP 17/11/2019 OJCharles A 12 HCMV TOWNE UL54 D413E 4.8 4.3 0.8 Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus https://academic.oup.com/jid/article/188/1/32/821141 doi.org/10.1086/375743 Marker Transfer PRA 17/11/2019 OJCharles A 13 HCMV AD169 UL54 D413N 3.8 10 1 Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/ doi.org/10.1128/AAC.03214-14 Recombinant BAC SEAP 17/11/2019 OJCharles A 14 HCMV Susceptible Clinical Isolate UL54 P488R 3.5 7.9 0.6 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165324/ doi.org/10.1128/AAC.00334-11 Isolated strain PRA 17/11/2019 OJCharles A 15 HCMV UL54 N495K 1.1 1.1 3.4 A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet https://journals.sagepub.com/doi/abs/10.1177/135965350601100416 doi.org/10.1177/135965350601100416 Lab derived mutant PRA or SEAP 17/11/2019 OJCharles A 16 HCMV AD169 UL54 K500N 3.2 3 1.2 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Recombinant BAC PRA 17/11/2019 OJCharles A 17 HCMV TOWNE UL54 L501I 6 9.1 1.4 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA 17/11/2019 OJCharles A 18 HCMV TOWNE UL54 T503I 2.9 6.1 0.5 Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus https://academic.oup.com/jid/article/188/1/32/821141 doi.org/10.1086/375743 Marker Transfer PRA 17/11/2019 OJCharles A 19 HCMV AD169 UL54 A505V 1.8 2 1.1 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://academic.oup.com/jid/article/209/8/1219/831553 doi.org/10.1093/infdis/jit654 Lab derived mutant PRA or SEAP 17/11/2019 OJCharles minor disparity in fold change ref - rev. ignoring Rev using original reference only A 20 HCMV TOWNE UL54 K513E 5 9.1 1.4 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA 17/11/2019 OJCharles A 21 HCMV AD169 UL54 K513N 6 12.5 1.5 A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture https://www.sciencedirect.com/science/article/pii/S0042682298992996 doi.org/10.1006/viro.1998.9299 Marker Transfer PRA 17/11/2019 OJCharles A 22 HCMV AD169 UL54 K513N 9.8 34 3 A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selected in Vitro by Cidofovir Confers a Slow Replication Phenotype in Cell Culture https://www.sciencedirect.com/science/article/pii/S0042682298992996 doi.org/10.1006/viro.1998.9299 Marker Transfer PRA UL54 V812L 17/11/2019 OJCharles A 23 HCMV AD169 UL54 K513R 3.7 10 1.1 Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/ doi.org/10.1128/AAC.03214-14 Recombinant BAC SEAP 17/11/2019 OJCharles A 24 HCMV Clinical Isolate UL54 D515E 2.7 4.6 Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes https://ashpublications.org/blood/article/96/9/3286/181219/Drug-resistant-human-cytomegalovirus-infection-in?searchresult=1 doi.org/10.1182/blood.V96.9.3286 Lab derived mutant PRA or SEAP UL54 L516M;I521T 17/11/2019 OJCharles A 25 HCMV TOWNE UL54 D515G 1 1 1.2 Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus https://academic.oup.com/jid/article/188/1/32/821141 doi.org/10.1086/375743 Marker Transfer PRA 16/03/2020 OJCharles A 26 HCMV Clinical Isolate UL54 D515Y 6.2 0.9 4.7 Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis https://www.sciencedirect.com/science/article/pii/S0166354216300365 doi.org/10.1016/j.antiviral.2016.02.004 Recombinant BAC GFP fluorescence reduction assay 23/11/2020 OJCharles A 27 HCMV TOWNE UL54 L516R 2.1 5.1 0.8 Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus https://academic.oup.com/jid/article/188/1/32/821141 doi.org/10.1086/375743 Marker Transfer PRA 17/11/2019 OJCharles A 28 HCMV UL54 I521T 2.1 5.1 0.8 Rev. Med. Virol. 2016; 26: 161-182 Lab derived mutant PRA or SEAP 17/11/2019 OJCharles Unable to substantiate review values from their references O 29 HCMV AD169 UL54 I521T 3 3.9 1 Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf doi.org/10.1016/j.jcv.2008.04.005. Marker Transfer SEAP 16/03/2020 OJCharles AD169 A 30 HCMV AD169 UL54 P522A 3 4.1 1 Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf doi.org/10.1016/j.jcv.2008.04.005. Marker Transfer SEAP 17/11/2019 OJCharles AD169 A 31 HCMV AD169 UL54 P522L 1.3 1.2 1.4 Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC2576411&blobtype=pdf doi.org/10.1016/j.jcv.2008.04.005. Marker Transfer SEAP 16/03/2020 OJCharles AD169 A 32 HCMV TOWNE UL54 P522S 3.1 3.6 1.1 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA 17/11/2019 OJCharles A 33 HCMV AD169 UL54 del524 3.5 9.7 1.1 Novel DNA polymerase mutations conferring cytomegalovirus resistance: Input of BAC-recombinant phenotyping and 3D model https://www.sciencedirect.com/science/article/abs/pii/S0166354213000259 doi.org/10.1016/j.antiviral.2013.02.002 Recombinant BAC PRA 17/11/2019 OJCharles A 34 HCMV AD169 UL54 V526L 5.5 2.5 1.8 Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/ doi.org/10.1128/jcm.02205-14 Recombinant BAC GLuc reporter assay 23/11/2020 OJCharles A 35 HCMV AD169 UL54 C539G 3.1 4.4 1 Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/ doi.org/10.1128/AAC.03214-14 17/11/2019 OJCharles A 36 HCMV Susceptible Clinical Isolate UL54 C539R 3.2 13.3 0.7 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Isolated strain PRA 17/11/2019 OJCharles A 37 HCMV UL54 D542E 1.5 12 1.7 Selection and Recombinant Phenotyping of a Novel CMX001 and Cidofovir Resistance Mutation in Human Cytomegalovirus https://aac.asm.org/content/57/7/3321 doi.org/10.1128/AAC.00062-13 Recombinant BAC PRA 23/11/2020 OJCharles A 38 HCMV AD169 UL54 V544A 1 1.1 0.9 Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/ doi.org/10.1016/j.jcv.2011.01.004 Recombinant BAC SEAP 16/03/2020 OJCharles A 39 HCMV TOWNE UL54 L545S 3.5 9.1 1.2 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA 17/11/2019 OJCharles A 40 HCMV AD169 UL54 L545W 4.9 6.3 1.3 Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/ doi.org/10.1016/j.jcv.2011.01.004 Recombinant BAC SEAP 17/11/2019 OJCharles A 41 HCMV AD169 UL54 T552N 1.9 1.2 2.6 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Recombinant BAC PRA 17/11/2019 OJCharles A 42 HCMV AD169 UL54 Q578H 3.3 2.3 4.5 Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/ doi.org/10.1016/j.jcv.2011.01.004 Recombinant BAC SEAP 17/11/2019 OJCharles A 43 HCMV AD169 UL54 S585A 1.5 1.4 2.7 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Recombinant BAC PRA 17/11/2019 OJCharles A 44 HCMV TOWNE UL54 D588E 1.3 1.1 2.3 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA 17/11/2019 OJCharles A 45 HCMV AD169 UL54 D588N 2 1.3 2.8 Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/ doi.org/10.1016/j.jcv.2011.01.004 Recombinant BAC SEAP 16/03/2020 OJCharles A 46 HCMV UL54 D588N 3.8 2.7 9 Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity https://www.sciencedirect.com/science/article/pii/S1386653201001603 doi.org/10.1016/S1386-6532(01)00160-3 Lab derived mutant PRA or SEAP 17/11/2019 OJCharles A 47 HCMV Susceptible Clinical Isolate UL54 F595I 1.3 1.2 2 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Isolated strain PRA 17/11/2019 OJCharles A 48 HCMV TOWNE UL54 A692S 1 1 1 Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus https://academic.oup.com/jid/article/188/1/32/821141 doi.org/10.1086/375743 Marker Transfer PRA 16/03/2020 OJCharles S Chou flagged that there is a 2004 erratum which invalidates this entry and recommendation is to remove it. O 49 HCMV Clinical Isolate UL54 T700A 1.2 1.3 5.8 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA 17/11/2019 OJCharles A 50 HCMV AD169 UL54 A714V 0.8 0.7 0.8 Phenotypic Diversity of Cytomegalovirus DNA Polymerase Gene Variants Observed after Antiviral Therapy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059355/ doi.org/10.1016/j.jcv.2011.01.004 Recombinant BAC SEAP 17/11/2019 OJCharles A 51 HCMV UL54 V715M 1.3 1.1 9.5 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA 17/11/2019 OJCharles A 52 HCMV UL54 V715M 1 1.1 5.5 Rev. Med. Virol. 2016; 26: 161-182 Lab derived mutant PRA or SEAP 17/11/2019 OJCharles Unable to substantiate review values from their references O 53 HCMV AD169 UL54 I726V 1.9 1.9 1.2 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 17/11/2019 OJCharles A 54 HCMV TOWNE UL54 E756D 1.2 0.7 3.4 Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus https://academic.oup.com/jid/article/188/1/32/821141 doi.org/10.1086/375743 Marker Transfer PRA 17/11/2019 OJCharles A 55 HCMV AD169 UL54 E756K 8.1 2.7 8 Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/ doi.org/10.1128/jcm.02205-14 Recombinant BAC GLuc reporter assay 23/11/2020 OJCharles A 56 HCMV TOWNE UL54 E756Q 1.7 1 4.3 Mutations Conferring Foscarnet Resistance in A Cohort of Patients with Acquired Immunodeficiency Syndrome and Cytomegalovirus Retinitis https://academic.oup.com/jid/article/187/5/777/2191368 doi.org/10.1086/368385 Marker Transfer PRA 23/11/2020 OJCharles A 57 HCMV AD169 UL54 L773V 3 2.5 4.4 Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep Sequencing https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135977/ doi.org/10.1128/AAC.03214-14 Recombinant BAC SEAP 17/11/2019 OJCharles A 58 HCMV AD169 UL54 L776M 2.5 1 3.5 Artesunate as a Potent Antiviral Agent in a Patient with Late Drug-Resistant Cytomegalovirus Infection after Hematopoietic Stem Cell Transplantation https://academic.oup.com/cid/article/46/9/1455/330370 doi.org/10.1086/587106 Marker Transfer PRA 23/11/2020 OJCharles A 59 HCMV TOWNE UL54 V781I 1 1.2 5.2 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA 17/11/2019 OJCharles A 60 HCMV UL54 V787A 4.7 0.7 3.2 Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis https://www.sciencedirect.com/science/article/pii/S0166354216300365 doi.org/10.1016/j.antiviral.2016.02.004 Recombinant BAC GFP fluorescence reduction assay 23/11/2020 OJCharles A 61 HCMV TOWNE UL54 V787L 2.4 1 4.1 Mutations Conferring Foscarnet Resistance in A Cohort of Patients with Acquired Immunodeficiency Syndrome and Cytomegalovirus Retinitis https://academic.oup.com/jid/article/187/5/777/2191368 doi.org/10.1086/368385 Marker Transfer PRA 23/11/2020 OJCharles A 62 HCMV TOWNE UL54 L802M 1.1 0.9 3.2 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA 17/11/2019 OJCharles A 63 HCMV AD169 UL54 L802V 1.8 1.1 0.9 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Recombinant BAC PRA 17/11/2019 OJCharles A 64 HCMV TOWNE UL54 K805Q 1 2.2 0.18 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA 17/11/2019 OJCharles A 65 HCMV AD169 UL54 A809V 2.4 1.9 3.3 Growth and Drug Resistance Phenotypes Resulting from Cytomegalovirus DNA Polymerase Region III Mutations Observed in Clinical Specimens https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151462/ doi.org/10.1128/AAC.00736-07 Recombinant BAC SEAP 23/11/2020 OJCharles A 66 HCMV AD169 UL54 A809V 3.6 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 67 HCMV AD169 UL54 V812L 2.5 3.2 2.9 A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Selectedin Vitroby Cidofovir Confers a Slow Replication Phenotype in Cell Culture https://www.sciencedirect.com/science/article/pii/S0042682298992996 doi.org/10.1006/viro.1998.9299 Marker Transfer PRA 23/11/2020 OJCharles A 68 HCMV AD169 UL54 T813S 2.5 2.7 4.9 Growth and Drug Resistance Phenotypes Resulting from Cytomegalovirus DNA Polymerase Region III Mutations Observed in Clinical Specimens https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151462/ doi.org/10.1128/AAC.00736-07 Recombinant BAC SEAP 23/11/2020 OJCharles A 69 HCMV TOWNE UL54 T821I 4.5 1.9 21 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA 17/11/2019 OJCharles A 70 HCMV AD169 UL54 P829S 2 1.6 1.1 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Recombinant BAC PRA 17/11/2019 OJCharles A 71 HCMV AD169 UL54 A834P 5.4 3 6.4 Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. https://europepmc.org/article/pmc/pmc1797699 doi.org/10.1128/AAC.00633-06 Recombinant BAC SEAP 16/03/2020 OJCharles A 72 HCMV AD169 UL54 A834P 22.7 18.8 7.2 Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. https://europepmc.org/article/pmc/pmc1797699 doi.org/10.1128/AAC.00633-06 Recombinant BAC SEAP UL54 N408K 17/11/2019 OJCharles A 73 HCMV TOWNE UL54 T838A 1.8 0.8 2.4 How Evolution of Mutations Conferring Drug Resistance Affects Viral Dynamics and Clinical Outcomes of Cytomegalovirus-Infected Hematopoietic Cell Transplant Recipients https://www.ncbi.nlm.nih.gov/pmc/articles/PMC540138/ doi.org/10.1128/JCM.43.1.208-213.2005 Marker Transfer PRA 23/11/2020 OJCharles A 74 HCMV AD169 UL54 G841A 3.2 2.6 4.3 Growth and Drug Resistance Phenotypes Resulting from Cytomegalovirus DNA Polymerase Region III Mutations Observed in Clinical Specimens https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151462/ doi.org/10.1128/AAC.00736-07 Recombinant BAC SEAP 23/11/2020 OJCharles A 75 HCMV AD169 UL54 M844T 1.4 1.3 2.5 Cyclopropavir Susceptibility of Cytomegalovirus DNA Polymerase Mutants Selected after Antiviral Drug Exposure https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256009/ doi.org/10.1128/AAC.05559-11 Lab derived mutant PRA or SEAP 23/11/2020 OJCharles A 76 HCMV AD169 UL54 M844V 2.3 1.6 2.2 Cyclopropavir Susceptibility of Cytomegalovirus DNA Polymerase Mutants Selected after Antiviral Drug Exposure https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256009/ doi.org/10.1128/AAC.05559-11 Lab derived mutant PRA or SEAP 23/11/2020 OJCharles A 77 HCMV Susceptible Clinical Isolate UL54 L862F 1.7 0.9 1.1 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Isolated strain PRA 17/11/2019 OJCharles A 78 HCMV Susceptible Clinical Isolate UL54 V946L 1.1 0.9 2.4 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Isolated strain PRA 17/11/2019 OJCharles A 79 HCMV AD169 UL54 L957F 2.7 1.4 1.3 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Recombinant BAC PRA 17/11/2019 OJCharles A 80 HCMV TOWNE UL54 G971D 1.4 1 1.2 Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus https://academic.oup.com/jid/article/188/1/32/821141 doi.org/10.1086/375743 Marker Transfer PRA 16/03/2020 OJCharles A 81 HCMV TOWNE UL54 del981-982 8.3 2.8 3.6 Viral DNA Polymerase Mutations Associated with Drug Resistance in Human Cytomegalovirus https://academic.oup.com/jid/article/188/1/32/821141 doi.org/10.1086/375743 Marker Transfer PRA 23/11/2020 OJCharles A 82 HCMV AD169 UL54 A987G 5.1 4.5 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 83 HCMV TOWNE UL54 A987G 5.3 11.3 1.2 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA 17/11/2019 OJCharles A 84 HCMV Susceptible Clinical Isolate UL54 L802M 1.7 1 2.7 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Isolated strain PRA 17/11/2019 OJCharles A 85 HCMV Susceptible Clinical Isolate UL54 P488R 7.5 7.4 1 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Isolated strain PRA 17/11/2019 OJCharles A 86 HCMV Susceptible Clinical Isolate UL54 C539R 6.3 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Isolated strain PRA 17/11/2019 OJCharles A 87 HCMV Susceptible Clinical Isolate UL54 C539R 59 7.4 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Isolated strain PRA UL97 H520Q 17/11/2019 OJCharles A 88 HCMV Susceptible Clinical Isolate UL54 C539R;F595I 28 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Isolated strain PRA UL97 G598D 17/11/2019 OJCharles A 89 HCMV Susceptible Clinical Isolate UL54 C539R; F595I 79 13 6.3 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Isolated strain PRA UL97 H520Q 17/11/2019 OJCharles A 90 HCMV TOWNE UL54 S676G 1.1 1.2 0.9 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA 16/03/2020 OJCharles A 91 HCMV TOWNE UL54 V759M 1.5 1.1 1.1 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA 16/03/2020 OJCharles A 92 HCMV TOWNE UL54 F412C 6.2 16 3.1 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA UL54 L802M 16/03/2020 OJCharles A 93 HCMV TOWNE UL54 K513E 6.6 11.1 2.7 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA UL54 D558E 16/03/2020 OJCharles A 94 HCMV TOWNE UL54 K805Q 4.3 2.1 10.1 Characterization of Drug Resistance-Associated Mutations in the Human Cytomegalovirus DNA Polymerase Gene by Using Recombinant Mutant Viruses Generated from Overlapping DNA Fragments https://www.ncbi.nlm.nih.gov/pmc/articles/PMC110397/ doi.org/10.1128/jvi.72.7.5927-5936.1998 Marker Transfer PRA UL54 T821I 16/03/2020 OJCharles A 95 HCMV AD169 UL54 L545S 5 11.9 1 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Recombinant BAC PRA 16/03/2020 OJCharles A 96 HCMV AD169 UL54 D879G 1.2 0.9 0.9 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Recombinant BAC PRA 16/03/2020 OJCharles A 97 HCMV AD169 UL54 L545S 7.3 4.5 1.8 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Recombinant BAC PRA UL54 P829S 16/03/2020 OJCharles A 98 HCMV AD169 UL54 N408D 4 4.2 1.3 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Recombinant BAC PRA 16/03/2020 OJCharles A 99 HCMV AD169 UL54 N408D 4.2 1.9 4 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Recombinant BAC PRA UL54 T552N 16/03/2020 OJCharles A 100 HCMV AD169 UL54 N408D 4.9 4.5 3.3 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Recombinant BAC PRA UL54 L957F 16/03/2020 OJCharles A 101 HCMV AD169 UL54 T552N 1.6 0.9 5.5 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Recombinant BAC PRA UL54 L957F 16/03/2020 OJCharles A 102 HCMV AD169 UL54 N757K 1.3 0.8 1.3 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Recombinant BAC PRA 16/03/2020 OJCharles A 103 HCMV AD169 UL54 L802M 1.7 1 2.7 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Recombinant BAC PRA 16/03/2020 OJCharles A 104 HCMV AD169 UL54 L926V 1.3 1.1 0.9 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Recombinant BAC PRA 16/03/2020 OJCharles A 105 HCMV AD169 UL54 K500N 2.4 2.4 2.7 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Recombinant BAC PRA UL54 S585A 16/03/2020 OJCharles A 106 HCMV Susceptible Clinical Isolate UL54 V787L 1.8 0.9 2.4 Recombinant Phenotyping of Cytomegalovirus UL54 Mutations That Emerged during Cell Passages in the Presence of either Ganciclovir or Foscarnet https://journals.asm.org/doi/10.1128/aac.00334-11 doi.org/10.1128/aac.00334-11 Isolated strain PRA 16/03/2020 OJCharles A 107 HCMV AD169 UL97 del590-593 4.8 1 New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/ doi.org/10.1128/AAC.49.12.4860-4866.2005 Lab derived mutant PRA 16/03/2020 OJCharles A 108 HCMV AD169 UL54 L545S 7.4 16 1.5 New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/ doi.org/10.1128/AAC.49.12.4860-4866.2005 Lab derived mutant PRA 16/03/2020 OJCharles A 109 HCMV AD169 UL54 L545S 16 6.5 1.3 New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/ doi.org/10.1128/AAC.49.12.4860-4866.2005 Lab derived mutant PRA UL97 M460I 16/03/2020 OJCharles A 110 HCMV AD169 UL54 T552N 3.2 2.1 5.8 New Reporter Cell Line To Evaluate the Sequential Emergence of Multiple Human Cytomegalovirus Mutations during In Vitro Drug Exposure https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315956/ doi.org/10.1128/AAC.49.12.4860-4866.2005 Lab derived mutant PRA 16/03/2020 OJCharles A 111 HCMV TOWNE UL54 L737M 1.1 2 1 Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. https://europepmc.org/article/pmc/pmc1797699 doi.org/10.1128/AAC.00633-06 Marker Transfer PRA 16/03/2020 OJCharles A 112 HCMV TOWNE UL54 A834P 6.1 6 7.7 Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. https://europepmc.org/article/pmc/pmc1797699 doi.org/10.1128/AAC.00633-06 Marker Transfer PRA 16/03/2020 OJCharles A 113 HCMV AD169 UL54 Q229K 1.2 1 1.2 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 114 HCMV AD169 UL54 D247N 0.9 0.9 1.3 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 115 HCMV AD169 UL54 D262N 1.1 1 1.2 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 116 HCMV AD169 UL54 T271A 1 0.7 0.9 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 117 HCMV AD169 UL54 V284E 1.2 1.1 1.2 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 118 HCMV AD169 UL54 D288N 1.2 1.2 1.2 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 119 HCMV AD169 UL54 F396L 1.4 0.9 0.9 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 120 HCMV AD169 UL54 L424V 1.3 1.3 1.2 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 121 HCMV AD169 UL54 T437M 1 1 0.8 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 122 HCMV AD169 UL54 F460L 1.2 1.2 1.2 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 123 HCMV AD169 UL54 A505V 1.9 1.9 1 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 124 HCMV AD169 UL54 A543S 1 1 1 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 125 HCMV AD169 UL54 S612N 0.9 1 0.7 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 126 HCMV AD169 UL54 V654G 1.1 1.1 1.1 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 127 HCMV AD169 UL54 S660G 1 0.9 1.1 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 128 HCMV AD169 UL54 S660N 1.2 1 0.8 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 129 HCMV AD169 UL54 G667N 0.9 0.8 1 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 130 HCMV AD169 UL54 A692G 0.8 0.9 1 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 131 HCMV AD169 UL54 I726T 2 1.7 1.1 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 132 HCMV AD169 UL54 E793V 0.9 0.7 1.1 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 133 HCMV AD169 UL54 Q795P 0.9 0.9 1.1 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 134 HCMV AD169 UL54 Q795R 1 0.9 1 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 135 HCMV AD169 UL54 G841S 2.2 1.1 2.1 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 136 HCMV AD169 UL54 P859A 0.8 1 0.8 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 137 HCMV AD169 UL54 V902G 1.2 1 1 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 138 HCMV AD169 UL54 E903G 1.1 1 0.9 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 139 HCMV AD169 UL54 K947E 1 1 1.1 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 140 HCMV AD169 UL54 M959T 1.2 0.9 1.2 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 141 HCMV AD169 UL54 N345S 1.2 0.7 0.9 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 142 HCMV AD169 UL54 V476G 0.9 0.8 0.4 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 143 HCMV AD169 UL54 Q578L 1.9 0.8 3 Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969548/ doi.org/10.1093/infdis/jit654 Recombinant BAC PRA 16/03/2020 OJCharles A 144 HCMV UL97 D605E Polymorphism Rev. Med. Virol. 2016; 26: 161-182 Lab derived mutant PRA or SEAP 17/11/2019 OJCharles Typo? O 148 HCMV UL97 L405P 2.5 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 17/11/2019 OJCharles A 149 HCMV UL97 D456N 12 Rev. Med. Virol. 2016; 26: 161-182 Lab derived mutant PRA or SEAP 17/11/2019 OJCharles Review value does not match reference O 150 HCMV Clinical Isolate UL97 M460I 2.2 1 1 Analysis and Characterization of Antiviral Drug–Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients https://academic.oup.com/jid/article/186/6/760/2191110 doi.org/10.1086/342844 Isolated strain PRA 07/08/2023 OJCharles A 151 HCMV AD169 UL97 M460T 9.3 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 152 HCMV AD169 UL97 M460V 8.3 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 153 HCMV UL97 V466G 3.5 Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis https://www.sciencedirect.com/science/article/abs/pii/S1386653210000181 doi.org/10.1016/j.jcv.2010.01.009 Recombinant BAC PRA 17/11/2019 OJCharles A 155 HCMV AD169 UL97 C518Y 12 A new mutation in the human cytomegalovirus UL97 gene may confer ganciclovir resistance in Chinese kidney transplant recipients https://link.springer.com/article/10.1007/s00705-012-1479-4 doi.org/10.1007/s00705-012-1479-4 Marker Transfer PRA 17/11/2019 OJCharles AD169 A 161 HCMV Towne UL97 A591V 1.3 Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir https://academic.oup.com/jid/article/185/2/162/2191141 doi.org/10.1086/338362 Marker Transfer PRA 17/11/2019 OJCharles Towne A 164 HCMV AD169 UL97 C592G 4.05 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 165 HCMV AD169 UL97 A594E 3 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 166 HCMV AD169 UL97 A594G 13.5 Value of a ligase chain reaction assay for detection of ganciclovir resistance-related mutation 594 in UL97 gene of human cytomegalovirus https://linkinghub.elsevier.com/retrieve/pii/S0166-0934(97)00093-1 doi.org/10.1016/S0166-0934(97)00093-1 Marker Transfer PRA 17/11/2019 OJCharles AD169 A 168 HCMV Towne UL97 A594T 2.7 Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir https://academic.oup.com/jid/article/185/2/162/2191141 doi.org/10.1086/338362 Marker Transfer PRA 17/11/2019 OJCharles Towne A 169 HCMV AD169 UL97 A594V 6.4 Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/ doi.org/10.1128/jcm.02205-14 Recombinant BAC GLuc reporter assay 23/11/2020 OJCharles A 170 HCMV AD169 UL97 L595F 11.4 Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/ doi.org/10.1128/jcm.02205-14 Recombinant BAC GLuc reporter assay 23/11/2020 OJCharles A 171 HCMV UL97 L595S 5.5 Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma https://www.jci.org/articles/view/117648 doi.org/10.1172/jci117648 Isolated strain PRA 17/11/2019 OJCharles A 172 HCMV Towne UL97 L595W 5.1 Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir https://academic.oup.com/jid/article/185/2/162/2191141 doi.org/10.1086/338362 Marker Transfer PRA 17/11/2019 OJCharles Towne A 174 HCMV Towne UL97 del595-603 8.4 A Nine-Codon Deletion Mutation in the Cytomegalovirus UL97 Phosphotransferase Gene Confers Resistance to Ganciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC89650 doi.org/10.1128/aac.44.1.183-185.2000 Marker Transfer PRA 17/11/2019 OJCharles Towne A 176 HCMV Towne UL97 E596G 2.3 Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir https://academic.oup.com/jid/article/185/2/162/2191141 doi.org/10.1086/338362 Marker Transfer PRA 17/11/2019 OJCharles Towne A 177 HCMV TB40 UL97 E596Y 6.4 Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay https://www.sciencedirect.com/science/article/abs/pii/S1386653215002759 doi.org/10.1016/j.jcv.2015.06.090 Recombinant BAC PRA 17/11/2019 OJCharles TB40 A 180 HCMV Clinical Isolate UL97 K599T 5.3 Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant https://www.sciencedirect.com/science/article/abs/pii/S0166354298000515 doi.org/10.1016/S0166-3542(98)00051-5 Isolated strain PRA 17/11/2019 OJCharles AD169 A 181 HCMV Towne UL97 del600 1.9 Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir https://academic.oup.com/jid/article/185/2/162/2191141 doi.org/10.1086/338362 Marker Transfer PRA 17/11/2019 OJCharles Towne A 183 HCMV UL97 C603R 3.6 Rev. Med. Virol. 2016; 26: 161-182 Lab derived mutant PRA or SEAP 17/11/2019 OJCharles Review value does not match reference ref51 has no useable data ref61 is in here with a different ratio and ref65 has a different ratio too with an unusable datapoint O 184 HCMV AD169 UL97 C603S 1.9 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 185 HCMV AD169 UL97 C603W 7.9 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 186 HCMV UL97 C607F 1.9 Rev. Med. Virol. 2016; 26: 161-182 Lab derived mutant PRA or SEAP 17/11/2019 OJCharles Cannot find value 1.9 in references ref72 does no tests ref77 no tests. Following ref trail leads to nowhere concrete O 187 HCMV UL97 C607Y 12.5 The Cys607→Tyr Change in the UL97 Phosphotransferase Confers Ganciclovir Resistance to Two Human Cytomegalovirus Strains Recovered from Two Immunocompromised Patients https://www.ncbi.nlm.nih.gov/pmc/articles/PMC105432/ doi.org/10.1128/aac.42.2.444 Marker Transfer PRA 17/11/2019 OJCharles AD169 A 188 HCMV UL97 I610T 2.8 Rev. Med. Virol. 2016; 26: 161-182 Lab derived mutant PRA or SEAP 17/11/2019 OJCharles typ0 2.8 should be 2.6? O 189 HCMV TB40 UL97 A613V 2.3 Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation https://www.sciencedirect.com/science/article/abs/pii/S0166354213002866 doi.org/10.1016/j.antiviral.2013.09.026 Recombinant BAC PRA 17/11/2019 OJCharles TB40 A 191 HCMV AD169 UL97 E655K 1.7 Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/ doi.org/10.1128/jcm.02205-14 Recombinant BAC GLuc reporter assay 23/11/2020 OJCharles A 192 HCMV AD169 UL89 D344E 1.8 1.7 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-17 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 193 HCMV AD169 UL89 C347S 0.6 0.3 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-18 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 194 HCMV AD169 UL89 R351H 0.7 0.4 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-19 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 195 HCMV AD169 UL56 E769D 1 0.8 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-20 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 196 HCMV AD169 UL56 Q204R 1.5 2.7 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-21 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 197 HCMV AD169 UL56 Q204R 2.5 5.8 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-22 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP UL89 D344E 17/11/2019 OJCharles A 198 HCMV AD169 UL56 N232Y 17 2.7 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-23 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 199 HCMV AD169 UL56 K258E 14 0.3 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-24 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 200 HCMV AD169 UL56 F261L 2.5 1 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-25 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 201 HCMV AD169 UL56 F261L 4.8 2.1 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-26 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP UL89 D344E 17/11/2019 OJCharles A 202 HCMV AD169 UL56 M329T 4.5 1.1 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-27 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 203 HCMV AD169 UL56 M329T 8 2.2 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-28 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP UL89 D344E 17/11/2019 OJCharles A 204 HCMV AD169 UL56 E237D 16 0.3 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-29 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 205 HCMV AD169 UL56 E237D 34 0.6 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-30 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP UL89 D344E 17/11/2019 OJCharles A 206 HCMV AD169 UL89 N320H 1.8 6.5 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-31 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 207 HCMV AD169 UL89 M359I 1.5 7.4 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-32 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 208 HCMV AD169 UL89 I334V 1.1 0.9 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-33 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 209 HCMV AD169 UL89 N329S 2 15 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-34 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 210 HCMV AD169 UL89 T350M 2.8 8.7 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-35 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 211 HCMV AD169 UL89 V362M 1.2 98 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-36 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 212 HCMV AD169 UL89 H389N 1.1 29 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-37 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 213 HCMV AD169 UL89 N405D 1 15 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-38 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 214 HCMV AD169 UL89 I334V 1.2 12 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-39 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP UL89 N405D 17/11/2019 OJCharles A 215 HCMV AD169 UL56 L208M 0.8 3.4 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-40 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 216 HCMV AD169 UL56 E407D 1.3 6 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-41 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 217 HCMV AD169 UL56 H637Q 0.9 2 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-42 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 218 HCMV AD169 UL56 V639M 1 10 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-43 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 219 HCMV AD169 UL56 H637Q 1.2 17 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-44 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP UL56 V639M 17/11/2019 OJCharles A 220 HCMV AD169 UL56 L764M 1.1 0.4 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-45 doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 221 HCMV AD169 UL54 del981-982 7.3 3.8 3.1 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf doi.org/10.1128/AAC.00922-18 Recombinant BAC SEAP 16/03/2020 OJCharles AD169 A 222 HCMV AD169 UL56 C25F 5.4 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf doi.org/10.1128/AAC.00922-18 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 223 HCMV AD169 UL56 L51M 0.8 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP 16/03/2020 OJCharles A 224 HCMV AD169 UL56 S229F 1.8 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 225 HCMV AD169 UL56 V231A 2.1 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP 17/11/2019 OJCharles A 226 HCMV AD169 UL56 V231L 5.1 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP 17/11/2019 OJCharles A 227 HCMV UL56 N232Y 17 Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds https://aac.asm.org/content/61/11/e01325-17.short doi.org/10.1128/AAC.01325-17 Recombinant BAC SEAP 17/11/2019 OJCharles A 228 HCMV AD169 UL56 V236A 2.9 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf doi.org/10.1128/AAC.00922-18 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 229 HCMV AD169 UL56 V236L 14 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP 17/11/2019 OJCharles A 230 HCMV AD169 UL56 V236M 32 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 231 HCMV AD169 UL56 E237D 10 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP 17/11/2019 OJCharles A 232 HCMV AD169 UL56 L241P 96 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP 17/11/2019 OJCharles A 233 HCMV AD169 UL56 T244K 3.3 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP 17/11/2019 OJCharles A 234 HCMV UL56 L254F 3.2 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 235 HCMV AD169 UL56 L257F 8.6 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 236 HCMV AD169 UL56 L257I 4.9 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP 17/11/2019 OJCharles A 238 HCMV AD169 UL56 F261C 4.4 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP 17/11/2019 OJCharles A 239 HCMV AD169 UL56 F261L 2.8 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP 17/11/2019 OJCharles A 240 HCMV AD169 UL56 Y321C 4.6 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP 17/11/2019 OJCharles A 241 HCMV AD169 UL56 C325F 3000 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP 17/11/2019 OJCharles A 242 HCMV AD169 UL56 C325R 3000 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP 17/11/2019 OJCharles A 243 HCMV AD169 UL56 C325Y 3000 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP 17/11/2019 OJCharles A 244 HCMV AD169 UL56 C325W 9300 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf doi.org/10.1128/AAC.00922-18 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 245 HCMV AD169 UL56 L328V 1.9 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf doi.org/10.1128/AAC.00922-18 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 246 HCMV AD169 UL56 M329T 4.4 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP 17/11/2019 OJCharles A 247 HCMV AD169 UL56 A365S 2 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf doi.org/10.1128/AAC.00922-18 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 248 HCMV AD169 UL56 N368D 2 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 249 HCMV AD169 UL56 V231L 5 Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure https://aac.asm.org/content/aac/58/1/610.full.pdf doi.org/10.1128/AAC.01794-13 Recombinant BAC GFP fluorescence reduction assay 17/11/2019 OJCharles A 250 HCMV AD169 UL56 L241P 218 Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure https://aac.asm.org/content/aac/58/1/610.full.pdf doi.org/10.1128/AAC.01794-13 Recombinant BAC GFP fluorescence reduction assay 17/11/2019 OJCharles A 251 HCMV AD169 UL56 V236M 45 Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure https://aac.asm.org/content/aac/58/1/610.full.pdf doi.org/10.1128/AAC.01794-13 Recombinant BAC GFP fluorescence reduction assay 17/11/2019 OJCharles A 252 HCMV AD169 UL56 R369G 44 Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure https://aac.asm.org/content/aac/58/1/610.full.pdf doi.org/10.1128/AAC.01794-13 Recombinant BAC GFP fluorescence reduction assay 17/11/2019 OJCharles A 253 HCMV AD169 UL56 R369M 13 Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure https://aac.asm.org/content/aac/58/1/610.full.pdf doi.org/10.1128/AAC.01794-13 Recombinant BAC GFP fluorescence reduction assay 17/11/2019 OJCharles A 254 HCMV AD169 UL56 R369S 48 Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure https://aac.asm.org/content/aac/58/1/610.full.pdf doi.org/10.1128/AAC.01794-13 Recombinant BAC GFP fluorescence reduction assay 17/11/2019 OJCharles A 255 HCMV AD169 UL56 C25F 46 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf doi.org/10.1128/AAC.00922-18 Recombinant BAC SEAP UL56 V231L 17/11/2019 OJCharles AD169 A 256 HCMV AD169 UL56 T244K 8.2 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP UL56 F261L 17/11/2019 OJCharles A 257 HCMV AD169 UL56 E237D 104 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP UL56 T244K; F261L 17/11/2019 OJCharles A 258 HCMV AD169 UL56 V236L 260 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP UL56 L257I 17/11/2019 OJCharles A 259 HCMV AD169 UL56 V236M 3000 Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance https://aac.asm.org/content/aac/59/10/6588.full.pdf doi.org/10.1128/AAC.01623-15 Recombinant BAC SEAP UL56 L257I; M329T 17/11/2019 OJCharles A 260 HCMV AD169 UL56 S229F 54 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP UL56 L254F; L257I 17/11/2019 OJCharles AD169 A 265 HCMV AD169 UL56 E237D 34 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP UL89 D344E 17/11/2019 OJCharles AD169 A 266 HCMV AD169 UL56 F261L 4.8 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP UL89 D344E 17/11/2019 OJCharles AD169 A 267 HCMV AD169 UL56 M329T 8 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP UL89 D344E 17/11/2019 OJCharles AD169 A 268 HCMV AD169 UL56 Q204R 2.5 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP UL89 D344E 17/11/2019 OJCharles AD169 A 269 HCMV AD169 UL51 P91S 2.1 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 270 HCMV AD169 UL51 P91S 6.3 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP UL56 S229F 17/11/2019 OJCharles AD169 A 271 HCMV AD169 UL51 P91S 28 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP UL56 V236M 17/11/2019 OJCharles AD169 A 272 HCMV AD169 UL51 P91S 126 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP UL56 R369M 17/11/2019 OJCharles AD169 A 273 HCMV AD169 UL51 P91S 4 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP UL89 D344E 17/11/2019 OJCharles AD169 A 274 HCMV AD169 UL97 L337M 1 3.5 Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo https://www.sciencedirect.com/science/article/pii/S0166354212001283 doi.org/10.1016/j.antiviral.2012.05.013 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 275 HCMV AD169 UL97 F342S 7.8 18 17 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf doi.org/10.1128/AAC.00511-13 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 276 HCMV UL97 V353A 1 14 Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance https://academic.oup.com/jid/article/196/1/91/844651 doi.org/10.1086/518514 Marker Transfer SEAP 17/11/2019 OJCharles AD169 A 277 HCMV AD169 UL97 del355 16 304 23 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf doi.org/10.1128/AAC.00511-13 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 278 HCMV AD169 UL97 V356G 5.5 108 7 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf doi.org/10.1128/AAC.00511-13 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 279 HCMV AD169 UL97 L397R 1.5 200 Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance https://academic.oup.com/jid/article-lookup/doi/10.1086/518514 doi.org/10.1086/518514 Marker Transfer SEAP 17/11/2019 OJCharles A 280 HCMV AD169 UL97 T409M 0.9 81 Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance https://academic.oup.com/jid/article/196/1/91/844651 doi.org/10.1086/518514 Marker Transfer SEAP 17/11/2019 OJCharles AD169 A 281 HCMV AD169 UL97 H411L 0.7 69 Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant https://jvi.asm.org/content/82/1/246.short doi.org/10.1128/JVI.01787-07 Marker transfer SEAP 17/11/2019 OJCharles AD169 A 282 HCMV AD169 UL97 H411N 1 9 Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant https://jvi.asm.org/content/82/1/246.short doi.org/10.1128/JVI.01787-07 Marker transfer SEAP 17/11/2019 OJCharles AD169 A 283 HCMV AD169 UL97 H411Y 0.5 12 Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant https://jvi.asm.org/content/82/1/246.short doi.org/10.1128/JVI.01787-07 Marker transfer SEAP 17/11/2019 OJCharles AD169 A 284 HCMV AD169 UL97 D456N 12 278 Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions https://journals.asm.org/doi/full/10.1128/aac.01726-13 doi.org/10.1128/aac.01726-13 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 285 HCMV AD169 UL97 V466G 11 321 17 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf doi.org/10.1128/AAC.00511-13 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 286 HCMV AD169 UL97 C480R 9 243 Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions https://journals.asm.org/doi/full/10.1128/aac.01726-13 doi.org/10.1128/aac.01726-13 Lab derived mutant PRA or SEAP 17/11/2019 OJCharles AD169 A 287 HCMV AD169 UL97 P521L 17 445 20 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf doi.org/10.1128/AAC.00511-13 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 288 HCMV AD169 UL97 del617 10 372 22 Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions https://journals.asm.org/doi/full/10.1128/aac.01726-13 doi.org/10.1128/aac.01726-13 Lab derived mutant PRA or SEAP 17/11/2019 OJCharles AD169 A 289 HCMV AD169 UL97 V353A 1 227 Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant https://jvi.asm.org/content/82/1/246.short doi.org/10.1128/JVI.01787-07 Marker transfer SEAP UL97 H411L 17/11/2019 OJCharles AD169 A 290 HCMV AD169 UL97 V353A 0.7 164 Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant https://jvi.asm.org/content/82/1/246.short doi.org/10.1128/JVI.01787-07 Marker transfer SEAP UL97 H411Y 17/11/2019 OJCharles AD169 A 291 HCMV AD169 UL27 E22* 2 Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir https://aac.asm.org/content/53/1/81 doi.org/10.1128/AAC.01177-08 Recombinant BAC SEAP 17/11/2019 OJCharles A 292 HCMV AD169 UL27 W153R 1.7 Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir https://aac.asm.org/content/53/1/81 doi.org/10.1128/AAC.01177-08 Recombinant BAC SEAP 17/11/2019 OJCharles A 293 HCMV AD169 UL27 L193F 2.6 Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir https://aac.asm.org/content/53/1/81 doi.org/10.1128/AAC.01177-08 Recombinant BAC SEAP 17/11/2019 OJCharles A 294 HCMV AD169 UL27 del218 2.5 Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir https://aac.asm.org/content/53/1/81 doi.org/10.1128/AAC.01177-08 Recombinant BAC SEAP 17/11/2019 OJCharles A 295 HCMV AD169 UL27 R233S 1.8 Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo https://www.sciencedirect.com/science/article/pii/S0166354212001283 doi.org/10.1016/j.antiviral.2012.05.013 Recombinant BAC SEAP 17/11/2019 OJCharles AD169 A 296 HCMV AD169 UL27 A269T 2 Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir https://aac.asm.org/content/53/1/81 doi.org/10.1128/AAC.01177-08 Recombinant BAC SEAP 17/11/2019 OJCharles A 297 HCMV AD169 UL27 del301-311 3.1 Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir https://aac.asm.org/content/53/1/81 doi.org/10.1128/AAC.01177-08 Recombinant BAC SEAP 17/11/2019 OJCharles A 298 HCMV Clinical Isolate UL27 L335P 1.2 23 Resistance of Human Cytomegalovirus to the Benzimidazole l-Ribonucleoside Maribavir Maps to UL27 https://journals.asm.org/doi/full/10.1128/jvi.77.21.11499-11506.2003#T1 doi.org/10.1128/jvi.77.21.11499-11506.2003 Lab derived mutant PRA 17/11/2019 OJCharles Towne A 299 HCMV AD169 UL27 V353E 2.1 Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir https://aac.asm.org/content/53/1/81 doi.org/10.1128/AAC.01177-08 Recombinant BAC SEAP 17/11/2019 OJCharles A 300 HCMV AD169 UL27 W362R 1.9 Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir https://aac.asm.org/content/53/1/81 doi.org/10.1128/AAC.01177-08 Recombinant BAC SEAP 17/11/2019 OJCharles A 301 HCMV AD169 UL27 W362* 2.2 Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir https://aac.asm.org/content/53/1/81 doi.org/10.1128/AAC.01177-08 Recombinant BAC SEAP 17/11/2019 OJCharles A 302 HCMV AD169 UL27 L426F 2.2 Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir https://aac.asm.org/content/53/1/81 doi.org/10.1128/AAC.01177-08 Recombinant BAC SEAP 17/11/2019 OJCharles A 303 HCMV AD169 UL27 C415* 3.5 Mutations in the Human Cytomegalovirus UL27 Gene That Confer Resistance to Maribavir https://journals.asm.org/doi/full/10.1128/jvi.78.13.7124-7130.2004 doi.org/10.1128/jvi.78.13.7124-7130.2004 Marker Transfer PRA UL27 A406V 17/11/2019 OJCharles AD169 A 304 HCMV UL27 R233S 7.2 Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo https://www.sciencedirect.com/science/article/pii/S0166354212001283 doi.org/10.1016/j.antiviral.2012.05.013 Lab derived mutant PRA or SEAP UL97 L337M 17/11/2019 OJCharles A 305 HCMV UL27 R233S 27 Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo https://www.sciencedirect.com/science/article/pii/S0166354212001283 doi.org/10.1016/j.antiviral.2012.05.013 Lab derived mutant PRA or SEAP UL97 V353A 17/11/2019 OJCharles AD169 A 306 HCMV UL97 C670Y Resistant Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches https://www.tandfonline.com/doi/full/10.1080/09273948.2019.1645188 doi.org/10.1080/09273948.2019.1645188 Isolated strain 19/11/2019 OJCharles Anecdotal O 307 HCMV AD169 UL97 F342Y 6 4.5 Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection https://www.sciencedirect.com/science/article/pii/S0166354219304115 doi.org/10.1016/j.antiviral.2019.104616 Recombinant BAC SEAP 21/11/2019 OJCharles A 308 HCMV AD169 UL97 C592G 3 Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection https://www.sciencedirect.com/science/article/pii/S0166354219304115 doi.org/10.1016/j.antiviral.2019.104616 Recombinant BAC SEAP 16/03/2020 OJCharles A 309 HCMV AD169 UL97 H411Y 18 Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection https://www.sciencedirect.com/science/article/pii/S0166354219304115 doi.org/10.1016/j.antiviral.2019.104616 Recombinant BAC SEAP 16/03/2020 OJCharles A 310 HCMV AD169 UL97 T409M 90 Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection https://www.sciencedirect.com/science/article/pii/S0166354219304115 doi.org/10.1016/j.antiviral.2019.104616 Recombinant BAC SEAP 21/11/2019 OJCharles A 311 HCMV AD169 UL97 K359E 3.8 1.2 Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection https://www.sciencedirect.com/science/article/pii/S0166354219304115 doi.org/10.1016/j.antiviral.2019.104616 Recombinant BAC SEAP 21/11/2019 OJCharles A 312 HCMV AD169 UL97 K359Q 3.7 1.3 Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection https://www.sciencedirect.com/science/article/pii/S0166354219304115 doi.org/10.1016/j.antiviral.2019.104616 Recombinant BAC SEAP 21/11/2019 OJCharles A 313 HCMV AD169 UL97 F342Y 5.9 56 Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection https://www.sciencedirect.com/science/article/pii/S0166354219304115 doi.org/10.1016/j.antiviral.2019.104616 Recombinant BAC SEAP UL97 H411Y 21/11/2019 OJCharles A 320 HCMV TB40 UL54 L516W Resistant Resistant Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance https://www.sciencedirect.com/science/article/abs/pii/S0166354216300870 doi.org/10.1016/j.antiviral.2016.04.002 Recombinant BAC PRA or SEAP 21/11/2019 OJCharles TB40 A 321 HCMV TB40 UL54 V715A Polymorphism Resistant Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance https://www.sciencedirect.com/science/article/abs/pii/S0166354216300870 doi.org/10.1016/j.antiviral.2016.04.002 Recombinant BAC PRA or SEAP 21/11/2019 OJCharles TB40 A 341 HCMV Susceptible Clinical Isolate UL97 A594V Resistant Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response. https://www.ncbi.nlm.nih.gov/pubmed/14739146 doi.org/10.1093/jac/dkh065 Isolated strain 16/03/2020 OJCharles Anecdotal O 342 HCMV Susceptible Clinical Isolate UL54 P522S Resistant Resistant Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response. https://www.ncbi.nlm.nih.gov/pubmed/14739146 doi.org/10.1093/jac/dkh065 Isolated strain 16/03/2020 OJCharles Anecdotal O 343 HCMV AD169 UL56 V236M 1 1.9 1.1 46 Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract doi.org/10.1093/infdis/jiv352 Recombinant BAC GFP fluorescence reduction assay 16/03/2020 OJCharles A 344 HCMV AD169 UL56 D414N 0.4 0.3 0.4 0.9 Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract doi.org/10.1093/infdis/jiv352 Recombinant BAC GFP fluorescence reduction assay 16/03/2020 OJCharles A 345 HCMV AD169 UL56 S227I 0.4 0.3 0.4 0.2 Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract doi.org/10.1093/infdis/jiv352 Recombinant BAC GFP fluorescence reduction assay 16/03/2020 OJCharles A 346 HCMV AD169 UL56 R410G 0.8 0.2 0.4 0.4 Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir https://www.ncbi.nlm.nih.gov/pubmed/26113373?dopt=Abstract doi.org/10.1093/infdis/jiv352 Recombinant BAC GFP fluorescence reduction assay 16/03/2020 OJCharles A 347 HCMV UL56 E237G Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles cannot find key supporting data O 348 HCMV UL56 M31I Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 349 HCMV UL56 M31V Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 350 HCMV UL56 F41L Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 351 HCMV UL56 L26P Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 352 HCMV UL56 I48M Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 353 HCMV UL56 A103V Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 354 HCMV UL56 E141* Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 355 HCMV UL56 N148D Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 356 HCMV UL56 E157G Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 357 HCMV UL56 Q182K Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 358 HCMV UL56 Q213R Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 359 HCMV UL56 S255L Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 360 HCMV UL56 S269G Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 361 HCMV UL56 E276G Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 362 HCMV UL56 I313V Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 363 HCMV UL56 C325W Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 364 HCMV UL56 S378N Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 365 HCMV UL56 S445N Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 366 HCMV UL56 E485G Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 367 HCMV UL56 I535V Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 368 HCMV UL56 del542 Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 369 HCMV UL56 Y575C Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 370 HCMV UL56 M641T Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 371 HCMV UL56 L658S Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 372 HCMV UL56 Y667H Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 373 HCMV UL56 S705F Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 374 HCMV UL56 V706A Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 375 HCMV UL56 L750P Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 376 HCMV UL56 Y757H Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 377 HCMV UL56 T775I Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 378 HCMV UL56 R816W Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 379 HCMV UL56 P846L Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 380 HCMV UL89 K41E Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 381 HCMV UL89 N74S Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 382 HCMV UL89 S102F Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 383 HCMV UL89 F124L Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 384 HCMV UL89 T132A Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 385 HCMV UL89 V146I Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 386 HCMV UL89 P176S Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 387 HCMV UL89 H243R Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 388 HCMV UL89 H246R Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 389 HCMV UL89 D309G Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 390 HCMV UL89 L323P Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 391 HCMV UL89 T331A Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 392 HCMV UL89 S373G Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 393 HCMV UL89 M406V Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 394 HCMV UL89 N426D Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 395 HCMV UL89 L458P Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 396 HCMV UL89 S521G Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 397 HCMV UL89 L522P Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 398 HCMV UL89 A532T Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 399 HCMV UL89 I572V Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 400 HCMV UL89 Q625* Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 401 HCMV UL89 T637A Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 402 HCMV UL89 V656A Resistant In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products https://www.sciencedirect.com/science/article/pii/S0166354219302128 doi.org/10.1080/14656566.2019.1637418 Isolated strain 21/11/2019 OJCharles Anecdotal O 403 HCMV AD169 UL54 V787A 2.9 1.3 5.25 Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis https://academic.oup.com/jid/article/220/8/1302/5519111 doi.org/10.1093/infdis/jiz298 Recombinant BAC GLuc reporter assay 16/03/2020 OJCharles A 404 HCMV AD169 UL54 V787E 8.5 2.9 3.4 Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis https://academic.oup.com/jid/article/220/8/1302/5519111 doi.org/10.1093/infdis/jiz298 Recombinant BAC GLuc reporter assay 21/11/2019 OJCharles A 405 HCMV AD169 UL54 V787K 3.2 1.8 9.4 Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis https://academic.oup.com/jid/article/220/8/1302/5519111 doi.org/10.1093/infdis/jiz298 Recombinant BAC GLuc reporter assay 21/11/2019 OJCharles A 406 HCMV UL54 L501F Resistant Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands https://academic.oup.com/jac/article/74/8/2370/5489804 doi.org/10.1093/jac/dkz196 Isolated strain 21/11/2019 OJCharles Anecdotal O 407 HCMV UL54 A505T Resistant Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands https://academic.oup.com/jac/article/74/8/2370/5489804 doi.org/10.1093/jac/dkz196 Isolated strain 21/11/2019 OJCharles Anecdotal O 408 HCMV UL97 H469Y Resistant Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands https://academic.oup.com/jac/article/74/8/2370/5489804 doi.org/10.1093/jac/dkz196 Isolated strain 21/11/2019 OJCharles Anecdotal O 409 HCMV UL97 A590V Resistant Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands https://academic.oup.com/jac/article/74/8/2370/5489804 doi.org/10.1093/jac/dkz196 Isolated strain 21/11/2019 OJCharles Anecdotal O 410 HCMV UL54 D1129N Resistant Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands https://academic.oup.com/jac/article/74/8/2370/5489804 doi.org/10.1093/jac/dkz196 Isolated strain 21/11/2019 OJCharles Anecdotal O 411 HCMV UL54 V321I Resistant Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands https://academic.oup.com/jac/article/74/8/2370/5489804 doi.org/10.1093/jac/dkz196 Isolated strain 21/11/2019 OJCharles Anecdotal O 412 HCMV UL97 L609F Resistant Resistant Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands https://academic.oup.com/jac/article/74/8/2370/5489804 doi.org/10.1093/jac/dkz196 Isolated strain 21/11/2019 OJCharles Anecdotal O 413 HCMV UL54 R1030C Resistant Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands https://academic.oup.com/jac/article/74/8/2370/5489804 doi.org/10.1093/jac/dkz196 Isolated strain 21/11/2019 OJCharles Anecdotal O 414 HCMV UL54 G1031A Resistant Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands https://academic.oup.com/jac/article/74/8/2370/5489804 doi.org/10.1093/jac/dkz196 Isolated strain 21/11/2019 OJCharles Anecdotal O 415 HCMV UL54 L394F Resistant Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands https://academic.oup.com/jac/article/74/8/2370/5489804 doi.org/10.1093/jac/dkz196 Isolated strain 21/11/2019 OJCharles Anecdotal O 416 HCMV UL54 E877K Resistant Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands https://academic.oup.com/jac/article/74/8/2370/5489804 doi.org/10.1093/jac/dkz196 Isolated strain 21/11/2019 OJCharles Anecdotal O 417 HCMV UL97 L609F Resistant Resistant Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands https://academic.oup.com/jac/article/74/8/2370/5489804 doi.org/10.1093/jac/dkz196 Isolated strain 21/11/2019 OJCharles Anecdotal O 418 HCMV UL54 T892A Resistant Antiviral-resistant cytomegalovirus infections in solid organ transplantation in the Netherlands https://academic.oup.com/jac/article/74/8/2370/5489804 doi.org/10.1093/jac/dkz196 Isolated strain 21/11/2019 OJCharles Anecdotal O 419 HCMV UL97 M460I 7.8 12 Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility https://aac.asm.org/content/55/1/382 doi.org/10.1128/AAC.01259-10 Recombinant BAC SEAP 22/11/2019 OJCharles A 420 HCMV UL97 M460T 9.3 10 Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility https://aac.asm.org/content/55/1/382 doi.org/10.1128/AAC.01259-10 Recombinant BAC SEAP 22/11/2019 OJCharles A 421 HCMV UL97 M460V 8.3 4 Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility https://aac.asm.org/content/55/1/382 doi.org/10.1128/AAC.01259-10 Recombinant BAC SEAP 22/11/2019 OJCharles A 422 HCMV UL97 H520Q 7.8 20 Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility https://aac.asm.org/content/55/1/382 doi.org/10.1128/AAC.01259-10 Recombinant BAC SEAP 22/11/2019 OJCharles A 423 HCMV UL97 C592G 3 3.3 Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility https://aac.asm.org/content/55/1/382 doi.org/10.1128/AAC.01259-10 Recombinant BAC SEAP 22/11/2019 OJCharles A 424 HCMV UL97 A594V 8.6 4.5 Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility https://aac.asm.org/content/55/1/382 doi.org/10.1128/AAC.01259-10 Recombinant BAC SEAP 22/11/2019 OJCharles A 425 HCMV UL97 L595S 8.5 1.3 Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility https://aac.asm.org/content/55/1/382 doi.org/10.1128/AAC.01259-10 Recombinant BAC SEAP 22/11/2019 OJCharles A 426 HCMV UL97 C603R 8.3 8.4 Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility https://aac.asm.org/content/55/1/382 doi.org/10.1128/AAC.01259-10 Recombinant BAC SEAP 22/11/2019 OJCharles A 427 HCMV UL97 C603S 1.9 2.8 Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility https://aac.asm.org/content/55/1/382 doi.org/10.1128/AAC.01259-10 Recombinant BAC SEAP 22/11/2019 OJCharles A 428 HCMV UL97 C603W 7.9 4.6 Cytomegalovirus UL97 Mutations Affecting Cyclopropavir and Ganciclovir Susceptibility https://aac.asm.org/content/55/1/382 doi.org/10.1128/AAC.01259-10 Recombinant BAC SEAP 22/11/2019 OJCharles A 429 HCMV AD169 UL54 D515Y 3.2 2.6 Emergence of letermovir resistance in a lung transplant recipient with ganciclovir?resistant cytomegalovirus infection https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135 doi.org/10.1111/ajt.15135 Recombinant BAC SEAP 22/11/2019 OJCharles A 430 HCMV AD169 UL54 L516P 4.4 5.9 Emergence of letermovir resistance in a lung transplant recipient with ganciclovir?resistant cytomegalovirus infection https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135 doi.org/10.1111/ajt.15135 Recombinant BAC SEAP 22/11/2019 OJCharles A 431 HCMV AD169 UL54 del981-982 7 3.2 2.7 Emergence of letermovir resistance in a lung transplant recipient with ganciclovir?resistant cytomegalovirus infection https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.15135 doi.org/10.1111/ajt.15135 Recombinant BAC SEAP 16/03/2020 OJCharles A 432 HCMV UL54 L415N Resistant Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial https://academic.oup.com/cid/article/68/4/632/5049442 doi.org/10.1093/cid/ciy549 Isolated strain 22/11/2019 OJCharles Anecdotal O 433 HCMV UL54 S734P Resistant Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial https://academic.oup.com/cid/article/68/4/632/5049442 doi.org/10.1093/cid/ciy549 Isolated strain 22/11/2019 OJCharles Anecdotal O 434 HCMV AD169 UL54 A543P 4.7 16 0.6 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf doi.org/10.1128/AAC.00922-18 Recombinant BAC SEAP 22/11/2019 OJCharles A 435 HCMV AD169 UL54 S290R 1.7 1.4 2.3 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/ doi.org/10.1016/j.antiviral.2016.12.003 Recombinant BAC SEAP 16/03/2020 OJCharles A 436 HCMV AD169 UL54 K426E 1.1 1 1.1 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/ doi.org/10.1016/j.antiviral.2016.12.003 Recombinant BAC SEAP 16/03/2020 OJCharles A 437 HCMV AD169 UL54 N495K 1.3 1 2.6 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/ doi.org/10.1016/j.antiviral.2016.12.003 Recombinant BAC SEAP 16/03/2020 OJCharles A 438 HCMV AD169 UL54 N495K 1.7 1.2 3.5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/ doi.org/10.1016/j.antiviral.2016.12.003 Recombinant BAC SEAP UL54 Q738R 16/03/2020 OJCharles A 439 HCMV AD169 UL54 T552N 1.8 1 2.5 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/ doi.org/10.1016/j.antiviral.2016.12.003 Recombinant BAC SEAP 16/03/2020 OJCharles A 440 HCMV AD169 UL54 Q783R 1.8 0.9 1.7 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/ doi.org/10.1016/j.antiviral.2016.12.003 Recombinant BAC SEAP 16/03/2020 OJCharles A 441 HCMV AD169 UL54 V798A 1.5 1.1 1.7 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/ doi.org/10.1016/j.antiviral.2016.12.003 Recombinant BAC SEAP 16/03/2020 OJCharles A 442 HCMV AD169 UL54 E951D 1.8 1.2 3.9 Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209250/ doi.org/10.1016/j.antiviral.2016.12.003 Recombinant BAC SEAP 16/03/2020 OJCharles A 443 HCMV TOWNE UL54 T419M 1 8 Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase https://www.sciencedirect.com/science/article/pii/S138665320200046X doi.org/10.1016/S1386-6532(02)00046-X Drug induced lab mutant CMV antigen ELISA 16/03/2020 OJCharles A 444 HCMV TOWNE UL54 Q578H 2 10 Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase https://www.sciencedirect.com/science/article/pii/S138665320200046X doi.org/10.1016/S1386-6532(02)00046-X Drug induced lab mutant CMV antigen ELISA 16/03/2020 OJCharles A 445 HCMV TOWNE UL54 L773V 2 5 Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase https://www.sciencedirect.com/science/article/pii/S138665320200046X doi.org/10.1016/S1386-6532(02)00046-X Drug induced lab mutant CMV antigen ELISA 16/03/2020 OJCharles A 446 HCMV TOWNE UL97 M460V 10 1 Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase https://www.sciencedirect.com/science/article/pii/S138665320200046X doi.org/10.1016/S1386-6532(02)00046-X Drug induced lab mutant CMV antigen ELISA 16/03/2020 OJCharles A 448 HCMV UL97 D68N Polymorphism Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 16/03/2020 OJCharles occurs with many other mutations unable to establish its solo phenotype O 449 HCMV UL97 Q126L Polymorphism Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 16/03/2020 OJCharles occurs with many other mutations unable to establish its solo phenotype O 450 HCMV UL97 V244I Polymorphism Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 16/03/2020 OJCharles occurs with many other mutations unable to establish its solo phenotype O 451 HCMV AD169 UL97 D329H Polymorphism Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir https://academic.oup.com/jid/article/185/2/162/2191141 doi.org/10.1086/338362 Marker Transfer PRA 16/03/2020 OJCharles Towne A 452 HCMV AD169 UL97 A427V 1 Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome https://academic.oup.com/jid/article/194/5/579/2191670 doi.org/10.1086/505882 Lab derived mutant PRA 16/03/2020 OJCharles A 453 HCMV AD169 UL97 Q449K Polymorphism Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance https://academic.oup.com/jid/article-lookup/doi/10.1086/518514 doi.org/10.1086/518514 Lab derived mutant SEAP 16/03/2020 OJCharles AD169 A 454 HCMV AD169 UL97 V466M 1.3 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 16/03/2020 OJCharles AD169 A 455 HCMV AD169 UL97 H469Y 1.2 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 16/03/2020 OJCharles AD169 A 456 HCMV AD169 UL97 A478V 0.8 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 16/03/2020 OJCharles AD169 A 457 HCMV AD169 UL97 N510S 1.2 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 16/03/2020 OJCharles AD169 A 458 HCMV AD169 UL97 M550I 0.85 Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome https://academic.oup.com/jid/article/194/5/579/2191670 doi.org/10.1086/505882 Lab derived mutant PRA 16/03/2020 OJCharles A 459 HCMV AD169 UL97 A582V 0.82 Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome https://academic.oup.com/jid/article/194/5/579/2191670 doi.org/10.1086/505882 Lab derived mutant PRA 16/03/2020 OJCharles A 460 HCMV AD169 UL97 H587Y 1 1 0.8 Phenotyping of Cytomegalovirus Drug Resistance Mutations by Using Recombinant Viruses Incorporating a Reporter Gene https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168698/ doi.org/10.1128/AAC.49.7.2710-2715.2005 Lab derived mutant SEAP 16/03/2020 OJCharles A 461 HCMV AD169 UL97 A588V 1.1 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 16/03/2020 OJCharles AD169 A 462 HCMV UL97 A591V Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Lab derived mutant PRA or SEAP 16/03/2020 OJCharles unable to find referred mutation O 463 HCMV AD169 UL97 N597D 1.4 Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786239/ doi.org/10.1002/jmv.21397 Lab derived mutant SEAP 16/03/2020 OJCharles A 464 HCMV AD169 UL97 K599R 0.9 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 16/03/2020 OJCharles AD169 A 465 HCMV AD169 UL97 L600I 1.4 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 16/03/2020 OJCharles AD169 A 468 HCMV AD169 UL97 Y617H 0.84 Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome https://academic.oup.com/jid/article/194/5/579/2191670 doi.org/10.1086/505882 Lab derived mutant PRA 16/03/2020 OJCharles A 469 HCMV AD169 UL97 G623S 1.1 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 16/03/2020 OJCharles AD169 A 471 HCMV AD169 UL97 T659I 1.3 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 16/03/2020 OJCharles AD169 A 473 HCMV AD169 UL97 A674T 0.92 Characterization of Human Cytomegalovirus (HCMV) UL97 Mutations Found in a Valganciclovir/Oral Ganciclovir Prophylactic Trial by Use of a Bacterial Artificial Chromosome Containing the HCMV Genome https://academic.oup.com/jid/article/194/5/579/2191670 doi.org/10.1086/505882 Lab derived mutant PRA 16/03/2020 OJCharles A 474 HCMV Clinical Isolate UL97 Q19E Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 475 HCMV Clinical Isolate UL97 T95S Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 476 HCMV Clinical Isolate UL97 S108N Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 477 HCMV Clinical Isolate UL97 R112C Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 478 HCMV Clinical Isolate UL97 R137C Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 479 HCMV Clinical Isolate UL97 E227D Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 480 HCMV Clinical Isolate UL97 A582T Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 481 HCMV UL54 D515G Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Lab derived mutant PRA or SEAP 16/03/2020 OJCharles Ref never shows this O 485 HCMV Clinical Isolate UL54 A15T Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 486 HCMV Clinical Isolate UL54 S24L Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 487 HCMV Clinical Isolate UL54 S32P Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 488 HCMV Clinical Isolate UL54 V95E Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 489 HCMV Clinical Isolate UL54 H142Y Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 490 HCMV Clinical Isolate UL54 G143S Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 491 HCMV Clinical Isolate UL54 I341T Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 492 HCMV Clinical Isolate UL54 N345S Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 493 HCMV Clinical Isolate UL54 G347D Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 494 HCMV Clinical Isolate UL54 V355A Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 495 HCMV Clinical Isolate UL54 S464F Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 496 HCMV Clinical Isolate UL54 A626V Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 497 HCMV Clinical Isolate UL54 P628L Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 498 HCMV Clinical Isolate UL54 G629S Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 499 HCMV Clinical Isolate UL54 A631G Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 500 HCMV Clinical Isolate UL54 S633F Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 501 HCMV Clinical Isolate UL54 M640R Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 502 HCMV Clinical Isolate UL54 S655L Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 503 HCMV Clinical Isolate UL54 S663N Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 504 HCMV Clinical Isolate UL54 F669L Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 505 HCMV Clinical Isolate UL54 S676G Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 506 HCMV Clinical Isolate UL54 G678S Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 507 HCMV Clinical Isolate UL54 del 681-688 Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 508 HCMV Clinical Isolate UL54 N685S Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 509 HCMV Clinical Isolate UL54 A688V Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 510 HCMV Clinical Isolate UL54 T691A Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 511 HCMV Clinical Isolate UL54 A693T Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 512 HCMV Clinical Isolate UL54 S695T Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 513 HCMV Clinical Isolate UL54 Q697H Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 514 HCMV Clinical Isolate UL54 L737M Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 515 HCMV Clinical Isolate UL54 V759M Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 516 HCMV Clinical Isolate UL54 Q868R Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 517 HCMV Clinical Isolate UL54 D870H Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 518 HCMV Clinical Isolate UL54 V873L Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 519 HCMV Clinical Isolate UL54 G874R Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 520 HCMV Clinical Isolate UL54 S884Insert T Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 521 HCMV Clinical Isolate UL54 A885S Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 522 HCMV Clinical Isolate UL54 A885T Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 523 HCMV Clinical Isolate UL54 P887S Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 524 HCMV Clinical Isolate UL54 L890F Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 525 HCMV Clinical Isolate UL54 T892I Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 527 HCMV Clinical Isolate UL54 N898D Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 528 HCMV Clinical Isolate UL54 E899K Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 529 HCMV Clinical Isolate UL54 V927M Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 530 HCMV Clinical Isolate UL54 V953A Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 531 HCMV Clinical Isolate UL54 A1012V Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 532 HCMV Clinical Isolate UL54 L1020I Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 533 HCMV Clinical Isolate UL54 T1108A Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 534 HCMV Clinical Isolate UL54 N1116H Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 535 HCMV Clinical Isolate UL54 A1122T Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 536 HCMV Clinical Isolate UL54 G1133S Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 537 HCMV Clinical Isolate UL54 S1146N Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 538 HCMV Clinical Isolate UL54 N1147S Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 539 HCMV Clinical Isolate UL54 R1149T Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 540 HCMV Clinical Isolate UL54 del1151 Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 541 HCMV Clinical Isolate UL54 P1153S Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 542 HCMV Clinical Isolate UL54 A1154P Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 543 HCMV Clinical Isolate UL54 del1156 Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 544 HCMV Clinical Isolate UL54 P1162L Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 545 HCMV Clinical Isolate UL54 S1235T Polymorphism Antiviral Drug Resistance of Human Cytomegalovirus https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952978/ doi.org/10.1128/CMR.00009-10 Isolated strain Genotyping sensitive clinical isolates 16/03/2020 OJCharles Anecdotal O 546 HCMV Clinical Isolate UL97 C603W 1.1 0.9 1.5 High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes https://academic.oup.com/jid/article/176/1/69/901024 doi.org/10.1086/514041 Isolated strain PRA 16/03/2020 OJCharles A 547 HCMV Clinical Isolate UL97 H469Y 1.3 1.5 1.9 High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes https://academic.oup.com/jid/article/176/1/69/901024 doi.org/10.1086/514041 Isolated strain PRA 16/03/2020 OJCharles A 548 HCMV Clinical Isolate UL97 C603W 2 0.8 2 High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes https://academic.oup.com/jid/article/176/1/69/901024 doi.org/10.1086/514041 Isolated strain PRA 16/03/2020 OJCharles A 549 HCMV AD169 UL54 del413 3.8 5.8 1.3 5.2 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/ doi.org/10.1128/AAC.00214-16 Recombinant BAC SEAP 16/03/2020 OJCharles A 550 HCMV AD169 UL54 A809V 4.3 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/ doi.org/10.1128/AAC.00214-16 Recombinant BAC SEAP 16/03/2020 OJCharles A 551 HCMV AD169 UL54 E303G 7.3 20 0.8 11 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/ doi.org/10.1128/AAC.00214-16 Recombinant BAC SEAP 16/03/2020 OJCharles A 552 HCMV AD169 UL54 E303D 6.3 16 0.8 9.7 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/ doi.org/10.1128/AAC.00214-16 Recombinant BAC SEAP 16/03/2020 OJCharles A 553 HCMV AD169 UL54 N408K 3.9 21 0.8 11 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/ doi.org/10.1128/AAC.00214-16 Recombinant BAC SEAP 16/03/2020 OJCharles A 554 HCMV AD169 UL54 D413Y 4.4 9.3 1 6 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/ doi.org/10.1128/AAC.00214-16 Recombinant BAC SEAP 16/03/2020 OJCharles A 555 HCMV AD169 UL54 V812L 2.1 3.1 2 2.4 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/ doi.org/10.1128/AAC.00214-16 Recombinant BAC SEAP 16/03/2020 OJCharles A 556 HCMV AD169 UL54 E303G 10 34 1.4 17 Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879386/ doi.org/10.1128/AAC.00214-16 Recombinant BAC SEAP UL54 V812L 16/03/2020 OJCharles A 557 HCMV AD169 UL56 M3V 1 Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients https://academic.oup.com/jid/article/221/7/1117/5645458 doi.org/10.1093/infdis/jiz577 Recombinant BAC SEAP 14/05/2020 OJCharles A 558 HCMV AD169 UL56 V236M 50.2 Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients https://academic.oup.com/jid/article/221/7/1117/5645458 doi.org/10.1093/infdis/jiz577 Recombinant BAC SEAP 14/05/2020 OJCharles A 559 HCMV AD169 UL56 E237G 2.1 1.4 1.3 13 Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients https://academic.oup.com/jid/article/221/7/1117/5645458 doi.org/10.1093/infdis/jiz577 Recombinant BAC SEAP 14/05/2020 OJCharles A 560 HCMV AD169 UL56 S255L 1.1 Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients https://academic.oup.com/jid/article/221/7/1117/5645458 doi.org/10.1093/infdis/jiz577 Recombinant BAC SEAP 14/05/2020 OJCharles A 561 HCMV AD169 UL56 C325W 1.2 1 1.1 8262 Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients https://academic.oup.com/jid/article/221/7/1117/5645458 doi.org/10.1093/infdis/jiz577 Recombinant BAC SEAP 14/05/2020 OJCharles A 562 HCMV AD169 UL56 R369T 1.5 1.2 1.1 52 Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients https://academic.oup.com/jid/article/221/7/1117/5645458 doi.org/10.1093/infdis/jiz577 Recombinant BAC SEAP 14/05/2020 OJCharles A 563 HCMV AD169 UL56 del445-447 1 Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients https://academic.oup.com/jid/article/221/7/1117/5645458 doi.org/10.1093/infdis/jiz577 Recombinant BAC SEAP UL56 E485G 14/05/2020 OJCharles A 564 HCMV AD169 UL56 E485G 0.9 Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients https://academic.oup.com/jid/article/221/7/1117/5645458 doi.org/10.1093/infdis/jiz577 Recombinant BAC SEAP 14/05/2020 OJCharles A 565 HCMV AD169 UL56 Y575C 0.9 Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients https://academic.oup.com/jid/article/221/7/1117/5645458 doi.org/10.1093/infdis/jiz577 Recombinant BAC SEAP 14/05/2020 OJCharles A 566 HCMV AD169 UL56 F626S 0.5 Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients https://academic.oup.com/jid/article/221/7/1117/5645458 doi.org/10.1093/infdis/jiz577 Recombinant BAC SEAP 14/05/2020 OJCharles A 567 HCMV AD169 UL56 L726V 1 Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients https://academic.oup.com/jid/article/221/7/1117/5645458 doi.org/10.1093/infdis/jiz577 Recombinant BAC SEAP 14/05/2020 OJCharles A 568 HCMV AD169 UL56 T775I 1 Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients https://academic.oup.com/jid/article/221/7/1117/5645458 doi.org/10.1093/infdis/jiz577 Recombinant BAC SEAP 14/05/2020 OJCharles A 569 HCMV AD169 UL56 del789-791 1 Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients https://academic.oup.com/jid/article/221/7/1117/5645458 doi.org/10.1093/infdis/jiz577 Recombinant BAC SEAP 14/05/2020 OJCharles A 570 HCMV AD169 UL56 V814A 1 Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients https://academic.oup.com/jid/article/221/7/1117/5645458 doi.org/10.1093/infdis/jiz577 Recombinant BAC SEAP 14/05/2020 OJCharles A 571 HCMV AD169 UL56 R816W 0.9 Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients https://academic.oup.com/jid/article/221/7/1117/5645458 doi.org/10.1093/infdis/jiz577 Recombinant BAC SEAP 14/05/2020 OJCharles A 572 HCMV AD169 UL89 I531T 1 Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients https://academic.oup.com/jid/article/221/7/1117/5645458 doi.org/10.1093/infdis/jiz577 Recombinant BAC SEAP 14/05/2020 OJCharles A 573 HCMV AD169 UL54 Q579I 0.16 0.06 Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase https://aac.asm.org/content/aac/64/4/e01910-19.full.pdf doi.org/10.1128/AAC.01910-19 Recombinant BAC GLuc reporter assay 22/07/2020 OJCharles A 574 HCMV AD169 UL54 K805Q 1 0.19 Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase https://aac.asm.org/content/aac/64/4/e01910-19.full.pdf doi.org/10.1128/AAC.01910-19 Recombinant BAC GLuc reporter assay 22/07/2020 OJCharles A 575 HCMV AD169 UL54 E756K 12.7 2.9 5.3 Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/ doi.org/10.1128/jcm.02205-14 Recombinant BAC GLuc reporter assay UL54 A594V 23/11/2020 OJCharles A 576 HCMV AD169 UL54 V526L 13.2 2.7 1.7 Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/ doi.org/10.1128/jcm.02205-14 Recombinant BAC GLuc reporter assay UL54 A594V 23/11/2020 OJCharles A 577 HCMV AD169 UL54 V526L 18.9 3.5 1.9 Characterization of Multiple Cytomegalovirus Drug Resistance Mutations Detected in a Hematopoietic Stem Cell Transplant Recipient by Recombinant Phenotyping https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313248/ doi.org/10.1128/jcm.02205-14 Recombinant BAC GLuc reporter assay UL54 L595F 23/11/2020 OJCharles A 578 HCMV AD169 UL54 P744T 0.9 1.1 1.1 Cyclopropavir Susceptibility of Cytomegalovirus DNA Polymerase Mutants Selected after Antiviral Drug Exposure https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256009/ doi.org/10.1128/AAC.05559-11 Lab derived mutant PRA or SEAP 23/11/2020 OJCharles A 579 HCMV AD169 UL54 W780V 1.5 1.9 Contrasting Effects of W781V and W780V Mutations in Helix N of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Antiviral Drug Susceptibility https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442382/ doi.org/10.1128/JVI.03360-14 Marker Transfer PRA 24/11/2020 OJCharles A 580 HSV1 Clinical isolate UL23 C6G Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 23/11/2020 OJCharles A 581 HSV1 Clinical isolate UL23 H7P Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 24/11/2020 OJCharles mutations not resolved by sequence MacIntyre A 582 HSV1 Clinical isolate UL23 A12P Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 25/11/2020 OJCharles KOS A 583 HSV1 Clinical isolate UL23 A12T Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 26/11/2020 OJCharles mutations not resolved by sequence MacIntyre A 584 HSV1 Clinical isolate UL23 D14V Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 27/11/2020 OJCharles A 585 HSV1 Clinical isolate UL23 D14Y Polymorphism Polymorphism Genotypic detection of acyclovir-resistant HSV-1: Characterization of 67 ACV-sensitive and 14 ACV-resistant viruses https://www.sciencedirect.com/science/article/pii/S016635420800199X doi.org/10.1016/j.antiviral.2008.01.153 Isolated strain dye uptake assay 28/11/2020 OJCharles A 586 HSV1 Clinical isolate UL23 Q15L Polymorphism Identification and characterization of acyclovir-resistant clinical HSV-1 isolates from children https://www.sciencedirect.com/science/article/pii/S1386653211002575 doi.org/10.1016/j.jcv.2011.06.009 Isolated strain ICP10 Luciferase assay 29/11/2020 OJCharles A 587 HSV1 Clinical isolate UL23 C6G Polymorphism Genetic Characterization of Thymidine Kinase from Acyclovir-Resistant and -Susceptible Herpes Simplex Virus Type 1 Isolated from Bone Marrow Transplant Recipients https://academic.oup.com/jid/article/182/1/290/883239 doi.org/10.1086/315696 Isolated strain dye uptake assay 30/11/2020 OJCharles A 588 HSV1 Clinical isolate UL23 R18C Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 01/12/2020 OJCharles mutations not resolved by sequence MacIntyre A 589 HSV1 Clinical isolate UL23 S19P Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 02/12/2020 OJCharles Only occurs with other unknown - cannot logically reconstruct its phenotype KOS A 590 HSV1 Clinical isolate UL23 R20H Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 03/12/2020 OJCharles mutations not resolved by sequence MacIntyre A 591 HSV1 Clinical isolate UL23 R20S Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 04/12/2020 OJCharles KOS A 592 HSV1 Clinical isolate UL23 M85I Polymorphism Genetic Characterization of Thymidine Kinase from Acyclovir-Resistant and -Susceptible Herpes Simplex Virus Type 1 Isolated from Bone Marrow Transplant Recipients https://academic.oup.com/jid/article/182/1/290/883239 doi.org/10.1086/315696 Isolated strain dye uptake assay 05/12/2020 OJCharles A 593 HSV1 Clinical isolate UL23 R26H Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 06/12/2020 OJCharles mutations not resolved by sequence MacIntyre A 594 HSV1 Clinical isolate UL23 A28V Polymorphism Identification and characterization of acyclovir-resistant clinical HSV-1 isolates from children https://www.sciencedirect.com/science/article/pii/S1386653211002575 doi.org/10.1016/j.jcv.2011.06.009 Isolated strain ICP10 Luciferase assay 07/12/2020 OJCharles A 595 HSV1 Clinical isolate UL23 L29V Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 08/12/2020 OJCharles A 596 HSV1 Clinical isolate UL23 R30C Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 09/12/2020 OJCharles KOS A 597 HSV1 Clinical isolate UL23 R32C Polymorphism Polymorphism Genotypic detection of acyclovir-resistant HSV-1: Characterization of 67 ACV-sensitive and 14 ACV-resistant viruses https://www.sciencedirect.com/science/article/pii/S016635420800199X doi.org/10.1016/j.antiviral.2008.01.153 Isolated strain dye uptake assay 10/12/2020 OJCharles A 598 HSV1 Clinical isolate UL23 delQ35 Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 11/12/2020 OJCharles mutations not resolved by sequence MacIntyre A 599 HSV1 Clinical isolate UL23 K36D Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 12/12/2020 OJCharles KOS A 600 HSV1 Clinical isolate UL23 delK36 Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 13/12/2020 OJCharles mutations not resolved by sequence MacIntyre A 601 HSV1 Clinical isolate UL23 R89Q Polymorphism Genetic Characterization of Thymidine Kinase from Acyclovir-Resistant and -Susceptible Herpes Simplex Virus Type 1 Isolated from Bone Marrow Transplant Recipients https://academic.oup.com/jid/article/182/1/290/883239 doi.org/10.1086/315696 Isolated strain dye uptake assay 14/12/2020 OJCharles A 602 HSV1 Clinical isolate UL23 R41H Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 15/12/2020 OJCharles A 603 HSV1 Clinical isolate UL23 L42P Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 16/12/2020 OJCharles A 604 HSV1 Clinical isolate UL23 Q44H Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 17/12/2020 OJCharles unkown co-mutations A 605 HSV1 Clinical isolate UL23 G61A Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 18/12/2020 OJCharles KOS A 606 HSV1 Clinical isolate UL23 Q67R Polymorphism Identification and characterization of acyclovir-resistant clinical HSV-1 isolates from children https://www.sciencedirect.com/science/article/pii/S1386653211002575 doi.org/10.1016/j.jcv.2011.06.009 Isolated strain ICP10 Luciferase assay 19/12/2020 OJCharles A 607 HSV1 Clinical isolate UL23 L72V Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 20/12/2020 OJCharles mutations not resolved by sequence MacIntyre A 608 HSV1 Clinical isolate UL23 R75C Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 21/12/2020 OJCharles mutations not resolved by sequence MacIntyre A 609 HSV1 Clinical isolate UL23 D76N Polymorphism Polymorphism Resistance of herpes simplex viruses to acyclovir: An update from a ten-year survey in France https://www.sciencedirect.com/science/article/pii/S0166354214002502 doi.org/10.1016/j.antiviral.2014.08.013 Isolated strain dye uptake assay 22/12/2020 OJCharles sc16 A 610 HSV1 Clinical isolate UL23 D77N Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 23/12/2020 OJCharles A 611 HSV1 Clinical isolate UL23 I78F Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 24/12/2020 OJCharles KOS A 612 HSV1 Clinical isolate UL23 R89Q Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 25/12/2020 OJCharles A 613 HSV1 Clinical isolate UL23 A98T Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 26/12/2020 OJCharles mutations not resolved by sequence MacIntyre A 614 HSV1 Clinical isolate UL23 I100T Polymorphism Polymorphism Resistance of herpes simplex viruses to acyclovir: An update from a ten-year survey in France https://www.sciencedirect.com/science/article/pii/S0166354214002502 doi.org/10.1016/j.antiviral.2014.08.013 Isolated strain dye uptake assay 27/12/2020 OJCharles sc16 A 615 HSV1 Clinical isolate UL23 E111K Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 28/12/2020 OJCharles KOS A 616 HSV1 Clinical isolate UL23 A118V Polymorphism Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 29/12/2020 OJCharles mutations not resolved by sequence MacIntyre A 617 HSV1 Clinical isolate UL23 A137T Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 30/12/2020 OJCharles mutations not resolved by sequence MacIntyre A 618 HSV1 Clinical isolate UL23 V138F Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 31/12/2020 OJCharles mutations not resolved by sequence MacIntyre A 619 HSV1 Clinical isolate UL23 V138I Polymorphism Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis https://academic.oup.com/jid/article/200/9/1402/851413 doi.org/10.1086/606028 Isolated strain PCR DNA hybridization assay 01/01/2021 OJCharles Only sequences TK, so any Pol mutations are unnacounted for A 620 HSV1 Clinical isolate UL23 A140V Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 02/01/2021 OJCharles A 621 HSV1 Clinical isolate UL23 H142Y Polymorphism Polymorphism Resistance of herpes simplex viruses to acyclovir: An update from a ten-year survey in France https://www.sciencedirect.com/science/article/pii/S0166354214002502 doi.org/10.1016/j.antiviral.2014.08.013 Isolated strain dye uptake assay 03/01/2021 OJCharles sc16 A 622 HSV1 Clinical isolate UL23 E146G Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 04/01/2021 OJCharles KOS A 623 HSV1 Clinical isolate UL23 H151Y Polymorphism Polymorphism Genotypic detection of acyclovir-resistant HSV-1: Characterization of 67 ACV-sensitive and 14 ACV-resistant viruses https://www.sciencedirect.com/science/article/pii/S016635420800199X doi.org/10.1016/j.antiviral.2008.01.153 Isolated strain dye uptake assay 05/01/2021 OJCharles A 624 HSV1 Clinical isolate UL23 A156P Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 06/01/2021 OJCharles mutations not resolved by sequence MacIntyre A 625 HSV1 Clinical isolate UL23 A156V Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 07/01/2021 OJCharles mutations not resolved by sequence MacIntyre A 626 HSV1 Clinical isolate UL23 F161L Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 08/01/2021 OJCharles A 627 HSV1 Clinical isolate UL23 V191A Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 09/01/2021 OJCharles KOS A 628 HSV1 Clinical isolate UL23 A192V Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 10/01/2021 OJCharles A 629 HSV1 Clinical isolate UL23 I214T 0.25 0.5 Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients. https://journals.sagepub.com/doi/10.1177/135965350400900413 doi.org/10.1177/135965350400900413 Isolated strain yield reduction assay (ELVIRA) 11/01/2021 OJCharles KOS A 630 HSV1 Clinical isolate UL23 D215A Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 12/01/2021 OJCharles mutations not resolved by sequence MacIntyre A 631 HSV1 Clinical isolate UL23 D215H Polymorphism Polymorphism Resistance of herpes simplex viruses to acyclovir: An update from a ten-year survey in France https://www.sciencedirect.com/science/article/pii/S0166354214002502 doi.org/10.1016/j.antiviral.2014.08.013 Isolated strain dye uptake assay 13/01/2021 OJCharles sc16 A 632 HSV1 Clinical isolate UL23 D215N Polymorphism Identification and characterization of acyclovir-resistant clinical HSV-1 isolates from children https://www.sciencedirect.com/science/article/pii/S1386653211002575 doi.org/10.1016/j.jcv.2011.06.009 Isolated strain ICP10 Luciferase assay 14/01/2021 OJCharles A 633 HSV1 Clinical isolate UL23 K219T Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 15/01/2021 OJCharles unkown co-mutations A 634 HSV1 Clinical isolate UL23 A233S Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 16/01/2021 OJCharles mutations not resolved by sequence MacIntyre A 635 HSV1 Clinical isolate UL23 G240E Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 17/01/2021 OJCharles A 636 HSV1 Clinical isolate UL23 A243S Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 18/01/2021 OJCharles KOS A 637 HSV1 Clinical isolate UL23 A243S Polymorphism Polymorphism Genotypic detection of acyclovir-resistant HSV-1: Characterization of 67 ACV-sensitive and 14 ACV-resistant viruses https://www.sciencedirect.com/science/article/pii/S016635420800199X doi.org/10.1016/j.antiviral.2008.01.153 Isolated strain dye uptake assay 18/01/2021 OJCharles A 638 HSV1 Clinical isolate UL23 G251C Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 19/01/2021 OJCharles A 639 HSV1 Clinical isolate UL23 W259R Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 20/01/2021 OJCharles unkown co-mutations A 640 HSV1 Clinical isolate UL23 A265T Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 21/01/2021 OJCharles A 641 HSV1 Clinical isolate UL23 V267L Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 22/01/2021 OJCharles A 642 HSV1 Clinical isolate UL23 P268L Polymorphism Polymorphism Resistance of herpes simplex viruses to acyclovir: An update from a ten-year survey in France https://www.sciencedirect.com/science/article/pii/S0166354214002502 doi.org/10.1016/j.antiviral.2014.08.013 Isolated strain dye uptake assay 23/01/2021 OJCharles sc16 A 643 HSV1 Clinical isolate UL23 P268M Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 24/01/2021 OJCharles mutations not resolved by sequence MacIntyre A 644 HSV1 Clinical isolate UL23 P268T Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 25/01/2021 OJCharles A 645 HSV1 Clinical isolate UL23 G271D Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 26/01/2021 OJCharles mutations not resolved by sequence MacIntyre A 646 HSV1 Clinical isolate UL23 A272T Polymorphism Polymorphism Genotypic detection of acyclovir-resistant HSV-1: Characterization of 67 ACV-sensitive and 14 ACV-resistant viruses https://www.sciencedirect.com/science/article/pii/S016635420800199X doi.org/10.1016/j.antiviral.2008.01.153 Isolated strain dye uptake assay 27/01/2021 OJCharles A 647 HSV1 Clinical isolate UL23 E273K Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 28/01/2021 OJCharles KOS A 648 HSV1 Clinical isolate UL23 E273Q Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 29/01/2021 OJCharles KOS A 649 HSV1 Clinical isolate UL23 P274T Polymorphism Polymorphism Genotypic detection of acyclovir-resistant HSV-1: Characterization of 67 ACV-sensitive and 14 ACV-resistant viruses https://www.sciencedirect.com/science/article/pii/S016635420800199X doi.org/10.1016/j.antiviral.2008.01.153 Isolated strain dye uptake assay 30/01/2021 OJCharles A 650 HSV1 Clinical isolate UL23 Q275P Polymorphism Polymorphism Identification and characterization of acyclovir-resistant clinical HSV-1 isolates from children https://www.sciencedirect.com/science/article/pii/S1386653211002575 doi.org/10.1016/j.jcv.2011.06.009 Isolated strain ICP10 Luciferase assay 31/01/2021 OJCharles A 651 HSV1 Clinical isolate UL23 S276G Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/02/2021 OJCharles A 652 HSV1 Clinical isolate UL23 S276R Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 02/02/2021 OJCharles unkown co-mutations A 653 HSV1 Clinical isolate UL23 N277K Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 03/02/2021 OJCharles mutations not resolved by sequence MacIntyre A 654 HSV1 Clinical isolate UL23 N277S Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 04/02/2021 OJCharles mutations not resolved by sequence MacIntyre A 655 HSV1 Clinical isolate UL23 A192V Polymorphism Genetic Characterization of Thymidine Kinase from Acyclovir-Resistant and -Susceptible Herpes Simplex Virus Type 1 Isolated from Bone Marrow Transplant Recipients https://academic.oup.com/jid/article/182/1/290/883239 doi.org/10.1086/315696 Isolated strain dye uptake assay 05/02/2021 OJCharles A 656 HSV1 Clinical isolate UL23 D286E Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 06/02/2021 OJCharles A 657 HSV1 Clinical isolate UL23 R293W Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 07/02/2021 OJCharles KOS A 658 HSV1 Clinical isolate UL23 A294V Polymorphism Polymorphism Genotypic detection of acyclovir-resistant HSV-1: Characterization of 67 ACV-sensitive and 14 ACV-resistant viruses https://www.sciencedirect.com/science/article/pii/S016635420800199X doi.org/10.1016/j.antiviral.2008.01.153 Isolated strain dye uptake assay 08/02/2021 OJCharles A 659 HSV1 Clinical isolate UL23 P295T Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 09/02/2021 OJCharles unkown co-mutations A 660 HSV1 Clinical isolate UL23 A299S Polymorphism Polymorphism Resistance of herpes simplex viruses to acyclovir: An update from a ten-year survey in France https://www.sciencedirect.com/science/article/pii/S0166354214002502 doi.org/10.1016/j.antiviral.2014.08.013 Isolated strain dye uptake assay 10/02/2021 OJCharles sc16 A 661 HSV1 Clinical isolate UL23 G302S Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 11/02/2021 OJCharles A 662 HSV1 Clinical isolate UL23 D303N Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 12/02/2021 OJCharles A 663 HSV1 Clinical isolate UL23 A309V Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 13/02/2021 OJCharles mutations not resolved by sequence MacIntyre A 664 HSV1 Clinical isolate UL23 A316V Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 14/02/2021 OJCharles mutations not resolved by sequence MacIntyre A 665 HSV1 Clinical isolate UL23 H323Y Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 15/02/2021 OJCharles KOS A 666 HSV1 Clinical isolate UL23 L327M Polymorphism Polymorphism Genotypic detection of acyclovir-resistant HSV-1: Characterization of 67 ACV-sensitive and 14 ACV-resistant viruses https://www.sciencedirect.com/science/article/pii/S016635420800199X doi.org/10.1016/j.antiviral.2008.01.153 Isolated strain dye uptake assay 16/02/2021 OJCharles A 667 HSV1 Clinical isolate UL23 D328E Polymorphism Polymorphism Genotypic detection of acyclovir-resistant HSV-1: Characterization of 67 ACV-sensitive and 14 ACV-resistant viruses https://www.sciencedirect.com/science/article/pii/S016635420800199X doi.org/10.1016/j.antiviral.2008.01.153 Isolated strain dye uptake assay 17/02/2021 OJCharles A 668 HSV1 Clinical isolate UL23 S332L Polymorphism Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis https://academic.oup.com/jid/article/200/9/1402/851413 doi.org/10.1086/606028 Isolated strain PCR DNA hybridization assay 18/02/2021 OJCharles Only sequences TK, so any Pol mutations are unnacounted for KOS A 669 HSV1 Clinical isolate UL23 S332P Polymorphism Polymorphism Genotypic detection of acyclovir-resistant HSV-1: Characterization of 67 ACV-sensitive and 14 ACV-resistant viruses https://www.sciencedirect.com/science/article/pii/S016635420800199X doi.org/10.1016/j.antiviral.2008.01.153 Isolated strain dye uptake assay 19/02/2021 OJCharles A 670 HSV1 Clinical isolate UL23 A334T Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 20/02/2021 OJCharles KOS A 671 HSV1 Clinical isolate UL23 G335D Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 21/02/2021 OJCharles mutations not resolved by sequence MacIntyre A 672 HSV1 Clinical isolate UL23 L341R Polymorphism Polymorphism Resistance of herpes simplex viruses to acyclovir: An update from a ten-year survey in France https://www.sciencedirect.com/science/article/pii/S0166354214002502 doi.org/10.1016/j.antiviral.2014.08.013 Isolated strain dye uptake assay 22/02/2021 OJCharles sc16 A 673 HSV1 Clinical isolate UL23 G346W Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 24/02/2021 OJCharles mutations not resolved by sequence MacIntyre A 674 HSV1 Clinical isolate UL23 V348I 0.3 0.8 Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients. https://journals.sagepub.com/doi/10.1177/135965350400900413 doi.org/10.1177/135965350400900413 Isolated strain yield reduction assay (ELVIRA) 25/02/2021 OJCharles As Susceptible and assume r+S -> S not sequencing Pol is fine to infer a susctpeitble mutant A 675 HSV1 Clinical isolate UL23 T350I Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 26/02/2021 OJCharles mutations not resolved by sequence MacIntyre A 676 HSV1 Clinical isolate UL23 T350S Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 27/02/2021 OJCharles KOS A 677 HSV1 Clinical isolate UL23 V352I Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 28/02/2021 OJCharles mutations not resolved by sequence MacIntyre A 678 HSV1 Clinical isolate UL23 S357C Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/03/2021 OJCharles KOS A 679 HSV1 Clinical isolate UL23 I358V Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 02/03/2021 OJCharles A 680 HSV1 Clinical isolate UL23 D363N Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 03/03/2021 OJCharles mutations not resolved by sequence MacIntyre A 681 HSV1 Clinical isolate UL23 G240E Polymorphism Genetic Characterization of Thymidine Kinase from Acyclovir-Resistant and -Susceptible Herpes Simplex Virus Type 1 Isolated from Bone Marrow Transplant Recipients https://academic.oup.com/jid/article/182/1/290/883239 doi.org/10.1086/315696 Isolated strain dye uptake assay 04/03/2021 OJCharles A 682 HSV1 Clinical isolate UL23 G251C Polymorphism Genetic Characterization of Thymidine Kinase from Acyclovir-Resistant and -Susceptible Herpes Simplex Virus Type 1 Isolated from Bone Marrow Transplant Recipients https://academic.oup.com/jid/article/182/1/290/883239 doi.org/10.1086/315696 Isolated strain dye uptake assay 05/03/2021 OJCharles A 683 HSV1 Clinical isolate UL23 G373E Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 06/03/2021 OJCharles mutations not resolved by sequence MacIntyre A 684 HSV1 Clinical isolate UL23 V267L Polymorphism Genetic Characterization of Thymidine Kinase from Acyclovir-Resistant and -Susceptible Herpes Simplex Virus Type 1 Isolated from Bone Marrow Transplant Recipients https://academic.oup.com/jid/article/182/1/290/883239 doi.org/10.1086/315696 Isolated strain dye uptake assay 07/03/2021 OJCharles A 685 HSV1 Clinical isolate UL23 A375P Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 08/03/2021 OJCharles A 686 HSV1 Clinical isolate UL23 N376H Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 09/03/2021 OJCharles A 687 HSV1 Clinical isolate UL23 N376P Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 10/03/2021 OJCharles KOS A 688 HSV1 Clinical isolate UL23 N376H Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 11/03/2021 OJCharles KOS A 689 HSV1 Clinical isolate UL23 N23S Polymorphism Phenotypic and genotypic characterization of induced acyclovir-resistant clinical isolates of herpes simplex virus type 1 https://www.sciencedirect.com/science/article/pii/S0166354213002544 doi.org/10.1016/j.antiviral.2013.09.008 Isolated strain PRA 12/03/2021 OJCharles A 690 HSV1 Clinical isolate UL23 R51W Resistant Polymorphism Polymorphism Resistant Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 14/03/2021 OJCharles KOS A 691 HSV1 Clinical isolate UL23 Y53C Resistant Polymorphism Polymorphism Resistant Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain dye uptake assay 15/03/2021 OJCharles A 692 HSV1 Clinical isolate UL23 Y53D Resistant Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 16/03/2021 OJCharles KOS A 693 HSV1 Clinical isolate UL23 Y53H Resistant Polymorphism Polymorphism Resistant Resistant Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 17/03/2021 OJCharles Only occurs with other resistant mutation R163H KOS O 694 HSV1 Clinical isolate UL23 Y53* Resistant Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 18/03/2021 OJCharles A 695 HSV1 TAS UL23 D55N 110 0.1 Genotypic and phenotypic characterization of the thymidine kinase of ACV-resistant HSV-1 derived from an acyclovir-sensitive herpes simplex virus type 1 strain https://www.sciencedirect.com/science/article/pii/S0166354202001316 doi.org/10.1016/S0166-3542(02)00131-6 Lab induced strain PRA 19/03/2021 OJCharles there are only extreme values - concern? A 696 HSV1 Clinical isolate UL23 G56S Resistant Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis https://academic.oup.com/jid/article/200/9/1402/851413 doi.org/10.1086/606028 Isolated strain PCR DNA hybridization assay 20/03/2021 OJCharles Only sequences TK, so any Pol mutations are unnacounted for KOS A 697 HSV1 Clinical isolate UL23 P57H 3.8 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain PCR DNA hybridization assay 21/03/2021 OJCharles A2 A 698 HSV1 Clinical isolate UL23 H58N Resistant Polymorphism Polymorphism Resistant Resistant Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes https://www.sciencedirect.com/science/article/pii/S0166354214000898 doi.org/10.1016/j.antiviral.2014.03.015 Isolated strain dye uptake assay 22/03/2021 OJCharles A 699 HSV1 Clinical isolate UL23 H58R 45 0.6 Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients. https://journals.sagepub.com/doi/10.1177/135965350400900413 doi.org/10.1177/135965350400900413 Isolated strain yield reduction assay (ELVIRA) 23/03/2021 OJCharles A 700 HSV1 Clinical isolate UL23 G59R Resistant Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis https://academic.oup.com/jid/article/200/9/1402/851413 doi.org/10.1086/606028 Isolated strain PCR DNA hybridization assay 24/03/2021 OJCharles co-occuring E83K is also resistance causing KOS O 701 HSV1 KOS UL23 G59W* Resistant Polymorphism Polymorphism Resistant Resistant Characterization of Herpes Simplex Virus Type 1 Thymidine Kinase Mutants Selected under a Single Round of High-Dose Brivudin https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1082774/#r5 doi.org/10.1128/JVI.79.9.5863-5869.2005 Lab induced strain PRA 25/03/2021 OJCharles KOS A 702 HSV1 UL23 K62N 42 Thymidine Kinase Mutations Conferring Acyclovir Resistance in Herpes Simplex Type 1 Recombinant Viruses https://aac.asm.org/content/aac/50/11/3889.full.pdf doi.org/10.1128/AAC.00889-06 Marker transfer PRA 26/03/2021 OJCharles A 703 HSV1 UL23 T63A Resistant Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain PRA 27/03/2021 OJCharles frameshift in tested strain O 704 HSV1 Clinical isolate UL23 T63I 10 Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Isolated strain PCR DNA hybridization assay 28/03/2021 OJCharles ref wrong E 705 HSV1 TAS UL23 T65N 8 0.5 Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain PRA 29/03/2021 OJCharles ref wrong E 706 HSV1 Clinical isolate UL23 Q67* Resistant Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Isolated strain PRA 30/03/2021 OJCharles ref wrong O 707 HSV1 Clinical isolate UL23 S74* Resistant Polymorphism Polymorphism Resistant Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain dye uptake assay 31/03/2021 OJCharles A 708 HSV1 Clinical isolate UL23 Y80N Resistant Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis https://academic.oup.com/jid/article/200/9/1402/851413 doi.org/10.1086/606028 Isolated strain PCR DNA hybridization assay 01/04/2021 OJCharles M128L is unknown KOS O 709 HSV1 UL23 E83K Resistant Polymorphism Resistant Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain PRA 02/04/2021 OJCharles frameshift in tested strain O 710 HSV1 Clinical isolate UL23 P84L Resistant Polymorphism Polymorphism Resistant Resistant Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 03/04/2021 OJCharles Only occurs with other resistant mutation R163H and deletion KOS O 711 HSV1 UL23 P84L Resistant Polymorphism Resistant Resistant Resistant Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Isolated strain PRA 03/04/2021 OJCharles ref wrong E 712 HSV1 TAS UL23 P84S 27 0.3 Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain PRA 04/04/2021 OJCharles ref wrong E 713 HSV1 Clinical isolate UL23 M85* Resistant Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain PCR DNA hybridization assay 05/04/2021 OJCharles A2 A 714 HSV1 Clinical isolate UL23 Y87H Resistant Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis https://academic.oup.com/jid/article/200/9/1402/851413 doi.org/10.1086/606028 Isolated strain PCR DNA hybridization assay 07/04/2021 OJCharles co-occuring R41H (H41R in pub) is subsequently shown to be resistant KOS O 715 HSV1 Clinical isolate UL23 W88R Resistant Resistant Mutations in the DNA Polymerase and Thymidine Kinase Genes of Herpes Simplex Virus Clinical Isolates Resistant to Antiherpetic Drugs https://link.springer.com/article/10.1134/S0026893310030118 doi.org/10.1134/S0026893310030118 Isolated strain PRA 08/04/2021 OJCharles co-occurs with resistant R220H L2 O 716 HSV1 Clinical isolate UL23 R89W Resistant Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis https://academic.oup.com/jid/article/200/9/1402/851413 doi.org/10.1086/606028 Isolated strain PCR DNA hybridization assay 09/04/2021 OJCharles co-occuring G200D is subsequently shown to be resistant KOS O 717 HSV1 Clinical isolate UL23 T103P Resistant Polymorphism Polymorphism Resistant Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain dye uptake assay 11/04/2021 OJCharles A 718 HSV1 TAS UL23 T103* Resistant Polymorphism Polymorphism Genotypic and phenotypic characterization of the thymidine kinase of ACV-resistant HSV-1 derived from an acyclovir-sensitive herpes simplex virus type 1 strain https://www.sciencedirect.com/science/article/pii/S0166354202001316 doi.org/10.1016/S0166-3542(02)00131-6 Lab induced strain PRA 12/04/2021 OJCharles there are only extreme values - concern? A 719 HSV1 Clinical isolate UL23 Q104H Resistant Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain PCR DNA hybridization assay UL23 L297S 13/04/2021 OJCharles co-occurs with resmut A2 O 720 HSV1 Clinical isolate UL23 Q104* Resistant Polymorphism Polymorphism Resistant Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain dye uptake assay 14/04/2021 OJCharles A 721 HSV1 Clinical isolate UL23 Q104* Resistant Polymorphism Polymorphism Resistant Resistant Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 14/04/2021 OJCharles KOS A 722 HSV1 UL23 D116N 42 70 Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1 https://www.sciencedirect.com/science/article/pii/S0166354206000313 doi.org/10.1016/j.antiviral.2006.01.010 Marker Transfer TK functional kinetic assay 18/04/2021 OJCharles The mutation is a frameshift causing deletion, which is not possible to reconstruct O 723 HSV1 Clinical isolate UL23 V120* Resistant Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 19/04/2021 OJCharles A 724 HSV1 Clinical isolate UL23 M121R Resistant Polymorphism Polymorphism Resistant Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain dye uptake assay 20/04/2021 OJCharles A 725 HSV1 Clinical isolate UL23 S123R Resistant Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis https://academic.oup.com/jid/article/200/9/1402/851413 doi.org/10.1086/606028 Isolated strain PCR DNA hybridization assay 21/04/2021 OJCharles S123R and R123S - return to WT is resistant? Really? Likely pol muts KOS O 726 HSV1 Clinical isolate UL23 Q125H Resistant Polymorphism Polymorphism Neonatal Herpes Encephalitis Caused by a Virologically Confirmed Acyclovir-Resistant Herpes Simplex Virus 1 Strain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536242/ doi.org/10.1128/JCM.02247-12 Isolated strain PRA 22/04/2021 OJCharles A 727 HSV1 Clinical isolate UL23 M128L Resistant Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis https://academic.oup.com/jid/article/200/9/1402/851413 doi.org/10.1086/606028 Isolated strain PCR DNA hybridization assay 23/04/2021 OJCharles co-occuring Y80N is unknwon KOS O 728 HSV1 Clinical isolate UL23 G129D 102 0.7 Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients. https://journals.sagepub.com/doi/10.1177/135965350400900413 doi.org/10.1177/135965350400900413 Isolated strain yield reduction assay (ELVIRA) 24/04/2021 OJCharles A 729 HSV1 UL23 P131S Resistant Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain PRA 25/04/2021 OJCharles co-occurs with resistant mutation O 730 HSV1 Clinical isolate UL23 D162A Resistant Polymorphism Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Isolated strain PRA 27/04/2021 OJCharles ref wrong E 731 HSV1 Clinical isolate UL23 D162N Resistant Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#b0165 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 29/04/2021 OJCharles co-occuring 365I later shown to be polymorphc A 732 HSV1 UL23 A167V Resistant Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain PRA 01/05/2021 OJCharles frameshift in tested strain O 733 HSV1 KOS UL23 A168T Polymorphism Polymorphism Polymorphism Resistant Polymorphism Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain PRA 02/05/2021 OJCharles ref wrong KOS E 734 HSV1 UL23 L170P Resistant Polymorphism Polymorphism Resistant Resistant Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain PRA 03/05/2021 OJCharles ref wrong E 735 HSV1 Clinical isolate UL23 Y172C Resistant Polymorphism Polymorphism Resistant Resistant Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain PRA 04/05/2021 OJCharles ref wrong E 736 HSV1 UL23 P173L Resistant Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain PRA 05/05/2021 OJCharles frameshift in tested strain O 737 HSV1 TAS UL23 P173R 140 0.1 Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain PRA 06/05/2021 OJCharles ref wrong E 738 HSV1 Clinical isolate UL23 A174P Resistant Polymorphism Polymorphism Resistant Resistant Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain PRA 07/05/2021 OJCharles ref wrong E 739 HSV1 Clinical isolate UL23 A175V Resistant Polymorphism Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Isolated strain PRA 08/05/2021 OJCharles ref wrong E 740 HSV1 Clinical isolate UL23 R176Q Resistant Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 09/05/2021 OJCharles A 741 HSV1 Clinical isolate UL23 R176* Resistant Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 10/05/2021 OJCharles A 742 HSV1 UL23 R176W Resistant Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Marker Transfer TK functional kinetic assay 11/05/2021 OJCharles A 743 HSV1 Clinical isolate UL23 L178R Resistant Acyclovir-Resistant Corneal HSV-1 Isolates from Patients with Herpetic Keratitis https://academic.oup.com/jid/article/198/5/659/865508 doi.org/10.1086/590668 Isolated strain PRA 12/05/2021 OJCharles A 744 HSV1 Clinical isolate UL23 S181N Resistant Resistant Acyclovir-Resistant Corneal HSV-1 Isolates from Patients with Herpetic Keratitis https://academic.oup.com/jid/article/198/5/659/865508 doi.org/10.1086/590668 Isolated strain PRA 13/05/2021 OJCharles A 745 HSV1 Clinical isolate UL23 M182* Resistant Polymorphism Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients. https://journals.sagepub.com/doi/10.1177/135965350400900413 doi.org/10.1177/135965350400900413 Isolated strain yield reduction assay (ELVIRA) 14/05/2021 OJCharles A 746 HSV1 Clinical isolate UL23 T183* Resistant Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain dye uptake assay 17/05/2021 OJCharles A2 A 747 HSV1 UL23 Q185R 26 70 Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1 https://www.sciencedirect.com/science/article/pii/S0166354206000313 doi.org/10.1016/j.antiviral.2006.01.010 Marker Transfer TK functional kinetic assay 18/05/2021 OJCharles The mutation is a frameshift causing deletion, which is not possible to reconstruct O 748 HSV1 Clinical isolate UL23 V187M Resistant Recurrent Acyclovir-Resistant Herpes Simplex in an Immunocompromised Patient: Can Strain Differences Compensate for Loss of Thymidine Kinase in Pathogenesis? https://academic.oup.com/jid/article/178/3/618/927942 doi.org/10.1086/515375 Isolated strain dye uptake assay 19/05/2021 OJCharles A 749 HSV1 Clinical isolate UL23 A189V Resistant Polymorphism Resistant Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PCR DNA hybridization assay 20/05/2021 OJCharles co-occuring unknown L227F O 750 HSV1 Clinical isolate UL23 delI194 Resistant Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis https://academic.oup.com/jid/article/200/9/1402/851413 doi.org/10.1086/606028 Isolated strain PCR DNA hybridization assay 21/05/2021 OJCharles Only sequences TK, so any Pol mutations are unnacounted for- but all early deletions shown to be resistant causing KOS A 751 HSV1 TAS UL23 G200C 15 1 Genotypic and phenotypic characterization of the thymidine kinase of ACV-resistant HSV-1 derived from an acyclovir-sensitive herpes simplex virus type 1 strain https://www.sciencedirect.com/science/article/pii/S0166354202001316 doi.org/10.1016/S0166-3542(02)00131-6 Lab induced strain PRA 22/05/2021 OJCharles there are only extreme values - concern? A 752 HSV1 Clinical isolate UL23 G200S Resistant Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 24/05/2021 OJCharles KOS A 753 HSV1 Clinical isolate UL23 T201P 2 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain PCR DNA hybridization assay 25/05/2021 OJCharles A2 A 754 HSV1 KOS UL23 V204G 12 Polymorphism Common and New Acyclovir Resistant Herpes Simplex Virus-1 Mutants Causing Bilateral Recurrent Herpetic Keratitis in an Immunocompetent Patient https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883165/ doi.org/10.1093/infdis/jit437 Isolated strain PRA 26/05/2021 OJCharles KOS A 755 HSV1 KOS UL23 G206R Resistant Polymorphism Polymorphism Resistant Resistant Characterization of Herpes Simplex Virus Type 1 Thymidine Kinase Mutants Selected under a Single Round of High-Dose Brivudin https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1082774/#r5 doi.org/10.1128/JVI.79.9.5863-5869.2005 Lab induced strain PRA 27/05/2021 OJCharles KOS A 756 HSV1 Clinical isolate UL23 A207P Resistant Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 28/05/2021 OJCharles KOS A 757 HSV1 Clinical isolate UL23 L208F Resistant Phenotypic and genotypic characterization of induced acyclovir-resistant clinical isolates of herpes simplex virus type 1 https://www.sciencedirect.com/science/article/pii/S0166354213002544 doi.org/10.1016/j.antiviral.2013.09.008 Isolated strain PRA 29/05/2021 OJCharles co-occuring resistant mutant O 758 HSV1 Clinical isolate UL23 L208H Resistant Polymorphism Polymorphism Resistant Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain dye uptake assay 30/05/2021 OJCharles A 759 HSV1 Clinical isolate UL23 R216C Resistant Resistant Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain dye uptake assay 31/05/2021 OJCharles A2 O 760 HSV1 Clinical isolate UL23 R216H Resistant Polymorphism Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients. https://journals.sagepub.com/doi/10.1177/135965350400900413 doi.org/10.1177/135965350400900413 Isolated strain yield reduction assay (ELVIRA) 01/06/2021 OJCharles A 761 HSV1 UL23 R216S Resistant Polymorphism Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain PRA 02/06/2021 OJCharles co-occurs with resistant mutation co-occurs with resistant mutation O 762 HSV1 Clinical isolate UL23 R220C Resistant Polymorphism Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Isolated strain PRA 03/06/2021 OJCharles ref wrong E 763 HSV1 KOS UL23 R220H Resistant Polymorphism Polymorphism Resistant Resistant Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain PRA 04/06/2021 OJCharles KOS O 764 HSV1 UL23 R222C Resistant Polymorphism Polymorphism Resistant Resistant Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain dye uptake assay 05/06/2021 OJCharles ref wrong E 765 HSV1 Clinical isolate UL23 R222H Resistant Polymorphism Polymorphism Resistant Resistant Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes https://www.sciencedirect.com/science/article/pii/S0166354214000898 doi.org/10.1016/j.antiviral.2014.03.015 Isolated strain dye uptake assay 06/06/2021 OJCharles Only sequences TK, so any Pol mutations are unnacounted for A 766 HSV1 Clinical isolate UL23 G224frameshift Resistant Polymorphism Polymorphism Resistant Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain dye uptake assay 07/06/2021 OJCharles A 767 HSV1 Clinical isolate UL23 L227F Resistant Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PCR DNA hybridization assay 08/06/2021 OJCharles co-occuring unknown A189V O 768 HSV1 UL23 D228* Resistant Polymorphism Polymorphism Resistant Resistant Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 09/06/2021 OJCharles A 769 HSV1 Clinical isolate UL23 D228* Resistant Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 11/06/2021 OJCharles KOS A 770 HSV1 Clinical isolate UL23 D228* Resistant Polymorphism Polymorphism Resistant Resistant Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 12/06/2021 OJCharles KOS A 771 HSV1 Clinical isolate UL23 D228* Resistant Polymorphism Polymorphism Resistant Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain dye uptake assay 13/06/2021 OJCharles A 772 HSV1 KOS UL23 Y239S* Resistant Polymorphism Polymorphism Resistant Resistant Characterization of Herpes Simplex Virus Type 1 Thymidine Kinase Mutants Selected under a Single Round of High-Dose Brivudin https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1082774/#r5 doi.org/10.1128/JVI.79.9.5863-5869.2005 Lab induced strain PRA 14/06/2021 OJCharles KOS A 773 HSV1 TAS UL23 T245M 120 0.1 Polymorphism Resistant Resistant Genotypic and phenotypic characterization of the thymidine kinase of ACV-resistant HSV-1 derived from an acyclovir-sensitive herpes simplex virus type 1 strain https://www.sciencedirect.com/science/article/pii/S0166354202001316 doi.org/10.1016/S0166-3542(02)00131-6 Lab induced strain PRA 15/06/2021 OJCharles there are only extreme values - concern? A 774 HSV1 Clinical isolate UL23 T245P Resistant Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis https://academic.oup.com/jid/article/200/9/1402/851413 doi.org/10.1086/606028 Isolated strain PCR DNA hybridization assay 16/06/2021 OJCharles co-occuring T354P is unknown KOS O 775 HSV1 Clinical isolate UL23 L249P Resistant Resistance of herpes simplex viruses to acyclovir: An update from a ten-year survey in France https://www.sciencedirect.com/science/article/pii/S0166354214002502 doi.org/10.1016/j.antiviral.2014.08.013 Isolated strain dye uptake assay 17/06/2021 OJCharles sc16 A 776 HSV1 Clinical isolate UL23 Q250* Resistant Polymorphism Polymorphism Resistant Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain dye uptake assay 18/06/2021 OJCharles A 777 HSV1 Clinical isolate UL23 R256W Resistant Polymorphism Polymorphism Resistant Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain dye uptake assay 19/06/2021 OJCharles Occurs with a resistant mutation O 778 HSV1 Clinical isolate UL23 E257K 59 1.2 Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 20/06/2021 OJCharles mutations not resolved by sequence MacIntyre A 779 HSV1 Clinical isolate UL23 Q261R Resistant Polymorphism Longitudinal Characterization of Herpes Simplex Virus (HSV) Isolates Acquired From Different Sites in an Immune-Compromised Child: A New HSV Thymidine Kinase Mutation Associated With Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656553/ doi.org/10.1093/jpids/pis009 Isolated strain PRA UL23 A93V 21/06/2021 OJCharles co-occurs with resistant mutation strain 17 O 780 HSV1 KOS UL23 Q261* Resistant Polymorphism Polymorphism Resistant Resistant Characterization of Herpes Simplex Virus Type 1 Thymidine Kinase Mutants Selected under a Single Round of High-Dose Brivudin https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1082774/#r5 doi.org/10.1128/JVI.79.9.5863-5869.2005 Lab induced strain PRA 22/06/2021 OJCharles KOS A 781 HSV1 Clinical isolate UL23 S263* Resistant Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 23/06/2021 OJCharles mutations not resolved by sequence MacIntyre A 782 HSV1 TAS UL23 V267frameshift Resistant Polymorphism Genotypic and phenotypic characterization of the thymidine kinase of ACV-resistant HSV-1 derived from an acyclovir-sensitive herpes simplex virus type 1 strain https://www.sciencedirect.com/science/article/pii/S0166354202001316 doi.org/10.1016/S0166-3542(02)00131-6 Lab induced strain PRA 24/06/2021 OJCharles there are only extreme values - concern? A 783 HSV1 KOS UL23 R281* Resistant Polymorphism Polymorphism Resistant Resistant Characterization of Herpes Simplex Virus Type 1 Thymidine Kinase Mutants Selected under a Single Round of High-Dose Brivudin https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1082774/#r5 doi.org/10.1128/JVI.79.9.5863-5869.2005 Lab induced strain PRA 25/06/2021 OJCharles KOS A 784 HSV1 Clinical isolate UL23 D286frameshift Resistant Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 26/06/2021 OJCharles KOS A 785 HSV1 KOS UL23 T287M 67 0.1 Polymorphism Resistant Resistant Characterization of Herpes Simplex Virus Type 1 Thymidine Kinase Mutants Selected under a Single Round of High-Dose Brivudin https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1082774/#r5 doi.org/10.1128/JVI.79.9.5863-5869.2005 Lab induced strain PRA 27/06/2021 OJCharles there are only extreme values - concern? KOS A 786 HSV1 Clinical isolate UL23 L291R Resistant Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis https://academic.oup.com/jid/article/200/9/1402/851413 doi.org/10.1086/606028 Isolated strain PCR DNA hybridization assay 29/06/2021 OJCharles Only sequences TK, so any Pol mutations are unnacounted for - co-occuring E36del is polymorphism In later papers KOS A 787 HSV1 Clinical isolate UL23 L297S Resistant Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain PCR DNA hybridization assay UL23 Q104H 01/07/2021 OJCharles co-occurs with resmut A2 O 788 HSV1 UL23 N301* Resistant Polymorphism Polymorphism Resistant Resistant Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 03/07/2021 OJCharles A 789 HSV1 UL23 N306* Resistant Polymorphism Polymorphism Resistant Resistant Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 04/07/2021 OJCharles A 790 HSV1 UL23 N306* Resistant Polymorphism Polymorphism Resistant Resistant Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 05/07/2021 OJCharles A 791 HSV1 UL23 N306* Resistant Polymorphism Polymorphism Resistant Resistant Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 06/07/2021 OJCharles A 792 HSV1 UL23 N306* Resistant Polymorphism Polymorphism Resistant Resistant Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 07/07/2021 OJCharles A 793 HSV1 UL23 V307frameshift Resistant Polymorphism Polymorphism Resistant Resistant Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 08/07/2021 OJCharles A 794 HSV1 Clinical isolate UL23 L315S Resistant Polymorphism Polymorphism Resistant Resistant Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 09/07/2021 OJCharles KOS A 795 HSV1 UL23 M322K 37 71 Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1 https://www.sciencedirect.com/science/article/pii/S0166354206000313 doi.org/10.1016/j.antiviral.2006.01.010 Marker Transfer TK functional kinetic assay 10/07/2021 OJCharles A 796 HSV1 Clinical isolate UL23 P334* Resistant Polymorphism Genotypic detection of acyclovir-resistant HSV-1: Characterization of 67 ACV-sensitive and 14 ACV-resistant viruses https://www.sciencedirect.com/science/article/pii/S016635420800199X doi.org/10.1016/j.antiviral.2008.01.153 Isolated strain dye uptake assay 11/07/2021 OJCharles cannot see in paper O 797 HSV1 Clinical isolate UL23 T354P Resistant Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis https://academic.oup.com/jid/article/200/9/1402/851413 doi.org/10.1086/606028 Isolated strain PCR DNA hybridization assay 14/07/2021 OJCharles co-occuring T245P is unknown KOS O 798 HSV1 TAS UL23 P355frameshift Resistant Polymorphism Genotypic and phenotypic characterization of the thymidine kinase of ACV-resistant HSV-1 derived from an acyclovir-sensitive herpes simplex virus type 1 strain https://www.sciencedirect.com/science/article/pii/S0166354202001316 doi.org/10.1016/S0166-3542(02)00131-6 Lab induced strain PRA 15/07/2021 OJCharles there are only extreme values - concern? A 799 HSV1 Clinical isolate UL23 G356frameshift Resistant Polymorphism Polymorphism Resistant Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain dye uptake assay 16/07/2021 OJCharles A 800 HSV1 Clinical isolate UL23 A365T Resistant Identification and characterization of acyclovir-resistant clinical HSV-1 isolates from children https://www.sciencedirect.com/science/article/pii/S1386653211002575 doi.org/10.1016/j.jcv.2011.06.009 Isolated strain ICP10 Luciferase assay 17/07/2021 OJCharles A 801 HSV1 Clinical isolate UL23 E374frameshift Resistant Polymorphism Polymorphism Resistant Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain dye uptake assay 18/07/2021 OJCharles A 802 HSV1 Clinical isolate UL23 N376* Resistant Phenotypic and genotypic characterization of induced acyclovir-resistant clinical isolates of herpes simplex virus type 1 https://www.sciencedirect.com/science/article/pii/S0166354213002544 doi.org/10.1016/j.antiviral.2013.09.008 Isolated strain PRA 20/07/2021 OJCharles A 803 HSV1 UL23 N376* Resistant Polymorphism Polymorphism Resistant Resistant Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 21/07/2021 OJCharles A 804 HSV1 UL23 N376* Resistant Polymorphism Polymorphism Resistant Resistant Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 22/07/2021 OJCharles A 805 HSV1 Clinical isolate UL30 S3A Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 24/07/2021 OJCharles unkown co-mutations A 806 HSV1 Clinical isolate UL30 G12E Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 25/07/2021 OJCharles KOS A 807 HSV1 Clinical isolate UL30 S15A Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 26/07/2021 OJCharles mutations not resolved by sequence MacIntyre A 808 HSV1 Clinical isolate UL30 A17T Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 27/07/2021 OJCharles A 809 HSV1 Clinical isolate UL30 A17V Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 28/07/2021 OJCharles mutations not resolved by sequence MacIntyre A 810 HSV1 Clinical isolate UL30 F23I Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 30/07/2021 OJCharles KOS A 811 HSV1 Clinical isolate UL30 A25V Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 31/07/2021 OJCharles unkown co-mutations A 812 HSV1 Clinical isolate UL30 A27T Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 01/08/2021 OJCharles Cannot be inferred KOS O 813 HSV1 Clinical isolate UL30 P29H Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 02/08/2021 OJCharles unkown co-mutations A 814 HSV1 Clinical isolate UL30 R30C Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 03/08/2021 OJCharles mutations not resolved by sequence MacIntyre A 815 HSV1 Clinical isolate UL30 A32I Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 04/08/2021 OJCharles A 816 HSV1 Clinical isolate UL30 S33G Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PCR DNA hybridization assay 05/08/2021 OJCharles A 817 HSV1 Clinical isolate UL30 S33R Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 06/08/2021 OJCharles unkown co-mutations A 818 HSV1 Clinical isolate UL30 Q42K Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 07/08/2021 OJCharles KOS A 819 HSV1 Clinical isolate UL30 K57N Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 08/08/2021 OJCharles mutations not resolved by sequence MacIntyre A 820 HSV1 Clinical isolate UL30 P61S Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 09/08/2021 OJCharles mutations not resolved by sequence MacIntyre A 821 HSV1 Clinical isolate UL30 E70D Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 10/08/2021 OJCharles KOS A 822 HSV1 Clinical isolate UL30 D72N Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 11/08/2021 OJCharles Cannot be inferred KOS O 823 HSV1 Clinical isolate UL30 A78D Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 11/08/2021 OJCharles Cannot be inferred KOS O 824 HSV1 Clinical isolate UL30 A78V Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 13/08/2021 OJCharles KOS A 825 HSV1 Clinical isolate UL30 R80L Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 14/08/2021 OJCharles mutations not resolved by sequence MacIntyre A 826 HSV1 Clinical isolate UL30 K90R Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 15/08/2021 OJCharles A 827 HSV1 Clinical isolate UL30 H98N Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 16/08/2021 OJCharles mutations not resolved by sequence MacIntyre A 828 HSV1 Clinical isolate UL30 A102T Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 17/08/2021 OJCharles KOS A 829 HSV1 Clinical isolate UL30 K104Q Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Testing of herpes simplex virus for resistance to antiviral drugs https://www.tandfonline.com/doi/abs/10.4161/viru.1.6.13806 doi.org/10.4161/viru.1.6.13806 Isolated strain dye uptake assay 18/08/2021 OJCharles no data O 830 HSV1 Clinical isolate UL30 G108R Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 19/08/2021 OJCharles mutations not resolved by sequence MacIntyre A 831 HSV1 Clinical isolate UL30 E111K Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 20/08/2021 OJCharles mutations not resolved by sequence MacIntyre A 832 HSV1 Clinical isolate UL30 R116H Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 22/08/2021 OJCharles KOS A 833 HSV1 Clinical isolate UL30 S127L Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 23/08/2021 OJCharles mutations not resolved by sequence MacIntyre A 834 HSV1 Clinical isolate UL30 G132C Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 24/08/2021 OJCharles KOS A 835 HSV1 Clinical isolate UL30 P137G Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 25/08/2021 OJCharles mutations not resolved by sequence MacIntyre A 836 HSV1 Clinical isolate UL30 P137Q Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 26/08/2021 OJCharles KOS A 837 HSV1 Clinical isolate UL30 A138V Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 27/08/2021 OJCharles KOS A 838 HSV1 Clinical isolate UL30 V144I Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 28/08/2021 OJCharles mutations not resolved by sequence MacIntyre A 839 HSV1 Clinical isolate UL30 T145A Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 29/08/2021 OJCharles unkown co-mutations A 840 HSV1 Clinical isolate UL30 V146I Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 30/08/2021 OJCharles unkown co-mutations A 841 HSV1 Clinical isolate UL30 N155T Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 31/08/2021 OJCharles mutations not resolved by sequence MacIntyre A 842 HSV1 Clinical isolate UL30 A159V Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 01/09/2021 OJCharles mutations not resolved by sequence MacIntyre A 843 HSV1 Clinical isolate UL30 A164T Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 02/09/2021 OJCharles A 844 HSV1 Clinical isolate UL30 F167L Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 03/09/2021 OJCharles unkown co-mutations A 845 HSV1 Clinical isolate UL30 F171S Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PCR DNA hybridization assay 04/09/2021 OJCharles A 846 HSV1 Clinical isolate UL30 M207I Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 05/09/2021 OJCharles mutations not resolved by sequence MacIntyre A 847 HSV1 Clinical isolate UL30 K209T Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 06/09/2021 OJCharles mutations not resolved by sequence MacIntyre A 848 HSV1 Clinical isolate UL30 V212A Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 07/09/2021 OJCharles mutations not resolved by sequence MacIntyre A 849 HSV1 Clinical isolate UL30 R219S Polymorphism Polymorphism Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2 https://pubmed.ncbi.nlm.nih.gov/22155911/ doi.org/10.3851/IMP1870 Isolated strain dye uptake assay 08/09/2021 OJCharles A 850 HSV1 Clinical isolate UL30 A220T Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 09/09/2021 OJCharles mutations not resolved by sequence MacIntyre A 851 HSV1 Clinical isolate UL30 A229T Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 10/09/2021 OJCharles Cannot be inferred KOS O 852 HSV1 Clinical isolate UL30 A230V Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 11/09/2021 OJCharles mutations not resolved by sequence MacIntyre A 853 HSV1 Clinical isolate UL30 I243T Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 12/09/2021 OJCharles A 854 HSV1 Clinical isolate UL30 F248L Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 13/09/2021 OJCharles KOS A 855 HSV1 Clinical isolate UL30 R264H Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 14/09/2021 OJCharles mutations not resolved by sequence MacIntyre A 856 HSV1 Clinical isolate UL30 L267M Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 15/09/2021 OJCharles KOS A 857 HSV1 Clinical isolate UL30 S280A Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 16/09/2021 OJCharles unkown co-mutations A 858 HSV1 Clinical isolate UL30 C287Y Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 17/09/2021 OJCharles mutations not resolved by sequence MacIntyre A 859 HSV1 Clinical isolate UL30 A289D Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 18/09/2021 OJCharles unkown co-mutations A 860 HSV1 Clinical isolate UL30 V297A Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 19/09/2021 OJCharles mutations not resolved by sequence MacIntyre A 861 HSV1 Clinical isolate UL30 F303L Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 20/09/2021 OJCharles mutations not resolved by sequence MacIntyre A 862 HSV1 Clinical isolate UL30 P320S Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 21/09/2021 OJCharles mutations not resolved by sequence MacIntyre A 863 HSV1 Clinical isolate UL30 R322Q Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 22/09/2021 OJCharles mutations not resolved by sequence MacIntyre A 864 HSV1 Clinical isolate UL30 R330A Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PCR DNA hybridization assay 23/09/2021 OJCharles A 865 HSV1 Clinical isolate UL30 I352V Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 24/09/2021 OJCharles KOS A 866 HSV1 Clinical isolate UL30 G354V Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 25/09/2021 OJCharles mutations not resolved by sequence MacIntyre A 867 HSV1 Clinical isolate UL30 M356I Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 26/09/2021 OJCharles A 868 HSV1 Clinical isolate UL30 E376D Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 27/09/2021 OJCharles mutations not resolved by sequence MacIntyre A 869 HSV1 Clinical isolate UL30 E376G Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 28/09/2021 OJCharles mutations not resolved by sequence MacIntyre A 870 HSV1 Clinical isolate UL30 V383L Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 29/09/2021 OJCharles mutations not resolved by sequence MacIntyre A 871 HSV1 Clinical isolate UL30 H386Y Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 30/09/2021 OJCharles co-occurs with unknwon mutation phenotype O 872 HSV1 Clinical isolate UL30 E421D Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/10/2021 OJCharles KOS A 873 HSV1 Clinical isolate UL30 N425T Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 02/10/2021 OJCharles KOS A 874 HSV1 Clinical isolate UL30 A428V Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 03/10/2021 OJCharles unkown co-mutations A 875 HSV1 Clinical isolate UL30 A429T Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2 https://pubmed.ncbi.nlm.nih.gov/22155911/ doi.org/10.3851/IMP1870 Isolated strain dye uptake assay 04/10/2021 OJCharles A 876 HSV1 Clinical isolate UL30 R430K Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 05/10/2021 OJCharles A 877 HSV1 Clinical isolate UL30 T434M Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 06/10/2021 OJCharles KOS A 878 HSV1 Clinical isolate UL30 G458S Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 07/10/2021 OJCharles mutations not resolved by sequence MacIntyre A 879 HSV1 Clinical isolate UL30 L479M Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 08/10/2021 OJCharles unkown co-mutations A 880 HSV1 Clinical isolate UL30 T480M Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 09/10/2021 OJCharles mutations not resolved by sequence MacIntyre A 881 HSV1 Clinical isolate UL30 G495V Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 10/10/2021 OJCharles mutations not resolved by sequence MacIntyre A 882 HSV1 Clinical isolate UL30 V498G Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2 https://pubmed.ncbi.nlm.nih.gov/22155911/ doi.org/10.3851/IMP1870 Isolated strain dye uptake assay 11/10/2021 OJCharles A 883 HSV1 Clinical isolate UL30 V498M Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 12/10/2021 OJCharles unkown co-mutations A 884 HSV1 Clinical isolate UL30 G505D Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 13/10/2021 OJCharles mutations not resolved by sequence MacIntyre A 885 HSV1 Clinical isolate UL30 S507R Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 14/10/2021 OJCharles unkown co-mutations A 886 HSV1 Clinical isolate UL30 V521M Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes https://www.sciencedirect.com/science/article/pii/S0166354214000898 doi.org/10.1016/j.antiviral.2014.03.015 Isolated strain dye uptake assay 15/10/2021 OJCharles A 887 HSV1 Clinical isolate UL30 N522S Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PCR DNA hybridization assay 16/10/2021 OJCharles A 888 HSV1 Clinical isolate UL30 A562T Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 17/10/2021 OJCharles unkown co-mutations A 889 HSV1 Clinical isolate UL30 A566T Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PCR DNA hybridization assay 18/10/2021 OJCharles A 890 HSV1 Clinical isolate UL30 K591R Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 19/10/2021 OJCharles mutations not resolved by sequence MacIntyre A 891 HSV1 Clinical isolate UL30 D630A Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 20/10/2021 OJCharles mutations not resolved by sequence MacIntyre A 892 HSV1 Clinical isolate UL30 G633D Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 21/10/2021 OJCharles A 893 HSV1 Clinical isolate UL30 T639I Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PCR DNA hybridization assay 22/10/2021 OJCharles A 894 HSV1 Clinical isolate UL30 A646T Polymorphism Polymorphism Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients. https://journals.sagepub.com/doi/10.1177/135965350400900413 doi.org/10.1177/135965350400900413 Isolated strain yield reduction assay (ELVIRA) 23/10/2021 OJCharles A 895 HSV1 Clinical isolate UL30 E649D 0.8 0.5 Rapid susceptibility testing for herpes simplex virus type 1 using real-time PCR https://www.sciencedirect.com/science/article/pii/S1386653212003502 doi.org/10.1016/j.jcv.2012.09.004 Isolated strain PCR DNA hybridization assay 24/10/2021 OJCharles A 896 HSV1 Clinical isolate UL30 E659D Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 25/10/2021 OJCharles mutations not resolved by sequence MacIntyre A 897 HSV1 Clinical isolate UL30 D660E Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 26/10/2021 OJCharles KOS A 898 HSV1 Clinical isolate UL30 E661K Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 27/10/2021 OJCharles mutations not resolved by sequence MacIntyre A 899 HSV1 Clinical isolate UL30 E662D Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 28/10/2021 OJCharles mutations not resolved by sequence MacIntyre A 900 HSV1 Clinical isolate UL30 P664T Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 29/10/2021 OJCharles mutations not resolved by sequence MacIntyre A 901 HSV1 Clinical isolate UL30 del667 Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 30/10/2021 OJCharles mutations not resolved by sequence MacIntyre A 902 HSV1 Clinical isolate UL30 del668 Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 31/10/2021 OJCharles mutations not resolved by sequence MacIntyre A 903 HSV1 Clinical isolate UL30 G668E Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 01/11/2021 OJCharles mutations not resolved by sequence MacIntyre A 904 HSV1 Clinical isolate UL30 E669D Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 02/11/2021 OJCharles mutations not resolved by sequence MacIntyre A 905 HSV1 Clinical isolate UL30 E669G Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 03/11/2021 OJCharles mutations not resolved by sequence MacIntyre A 906 HSV1 Clinical isolate UL30 E671K Polymorphism Resistance of herpes simplex viruses to acyclovir: An update from a ten-year survey in France https://www.sciencedirect.com/science/article/pii/S0166354214002502 doi.org/10.1016/j.antiviral.2014.08.013 Isolated strain dye uptake assay 04/11/2021 OJCharles sc16 A 907 HSV1 Clinical isolate UL30 D672N Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 05/11/2021 OJCharles KOS A 908 HSV1 Clinical isolate UL30 E673K Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 06/11/2021 OJCharles mutations not resolved by sequence MacIntyre A 909 HSV1 Clinical isolate UL30 R674H Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 07/11/2021 OJCharles mutations not resolved by sequence MacIntyre A 910 HSV1 Clinical isolate UL30 E675A Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 08/11/2021 OJCharles KOS A 911 HSV1 Clinical isolate UL30 E675K Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 09/11/2021 OJCharles mutations not resolved by sequence MacIntyre A 912 HSV1 Clinical isolate UL30 E684A Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 10/11/2021 OJCharles unkown co-mutations A 913 HSV1 Clinical isolate UL30 E684D Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PCR DNA hybridization assay 11/11/2021 OJCharles A 914 HSV1 Clinical isolate UL30 E688K Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 12/11/2021 OJCharles unkown co-mutations A 915 HSV1 Clinical isolate UL30 D703N Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 13/11/2021 OJCharles KOS A 916 HSV1 Clinical isolate UL30 N711K Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 14/11/2021 OJCharles KOS A 917 HSV1 Clinical isolate UL30 R739S Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 15/11/2021 OJCharles mutations not resolved by sequence MacIntyre A 918 HSV1 Clinical isolate UL30 A740S Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 16/11/2021 OJCharles unkown co-mutations A 919 HSV1 Clinical isolate UL30 V743M Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients. https://journals.sagepub.com/doi/10.1177/135965350400900413 doi.org/10.1177/135965350400900413 Isolated strain yield reduction assay (ELVIRA) 17/11/2021 OJCharles Cannot be inferred O 920 HSV1 Clinical isolate UL30 E747K Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 18/11/2021 OJCharles mutations not resolved by sequence MacIntyre A 921 HSV1 Clinical isolate UL30 G749D Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 19/11/2021 OJCharles KOS A 922 HSV1 Clinical isolate UL30 L753M Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 20/11/2021 OJCharles KOS A 923 HSV1 Clinical isolate UL30 Q794H Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 21/11/2021 OJCharles mutations not resolved by sequence MacIntyre A 924 HSV1 Clinical isolate UL30 A857V Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 22/11/2021 OJCharles mutations not resolved by sequence MacIntyre A 925 HSV1 Clinical isolate UL30 E860K Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 23/11/2021 OJCharles mutations not resolved by sequence MacIntyre A 926 HSV1 Clinical isolate UL30 Q861R Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 24/11/2021 OJCharles A 927 HSV1 Clinical isolate UL30 L862F Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 25/11/2021 OJCharles A 928 HSV1 Clinical isolate UL30 E868G Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 26/11/2021 OJCharles A 929 HSV1 Clinical isolate UL30 A870G Polymorphism Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 27/11/2021 OJCharles KOS A 930 HSV1 Clinical isolate UL30 A870V Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 28/11/2021 OJCharles mutations not resolved by sequence MacIntyre A 931 HSV1 Clinical isolate UL30 D871N Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2 https://pubmed.ncbi.nlm.nih.gov/22155911/ doi.org/10.3851/IMP1870 Isolated strain dye uptake assay 29/11/2021 OJCharles A 932 HSV1 Clinical isolate UL30 R873C Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 30/11/2021 OJCharles mutations not resolved by sequence MacIntyre A 933 HSV1 Clinical isolate UL30 A874T Polymorphism Resistance of herpes simplex viruses to acyclovir: An update from a ten-year survey in France https://www.sciencedirect.com/science/article/pii/S0166354214002502 doi.org/10.1016/j.antiviral.2014.08.013 Isolated strain dye uptake assay 01/12/2021 OJCharles sc16 A 934 HSV1 Clinical isolate UL30 P875S Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 02/12/2021 OJCharles KOS A 935 HSV1 Clinical isolate UL30 V905M Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 03/12/2021 OJCharles KOS A 936 HSV1 Clinical isolate UL30 V905M Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PCR DNA hybridization assay 04/02/2021 OJCharles paper erronsously described this as position 906 A 937 HSV1 Clinical isolate UL30 K908R Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PCR DNA hybridization assay 04/12/2021 OJCharles A 938 HSV1 TAS UL30 A910V Polymorphism Polymorphism Polymorphism Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/ doi.org/10.1128/AAC.49.2.606-611.2005 Lab induced strain PRA 04/02/2021 OJCharles A 939 HSV1 Clinical isolate UL30 A916T Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 06/12/2021 OJCharles unkown co-mutations A 940 HSV1 Clinical isolate UL30 P920F Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 07/12/2021 OJCharles mutations not resolved by sequence MacIntyre A 941 HSV1 Clinical isolate UL30 I922T Polymorphism Polymorphism Polymorphism Polymorphism Heterogeneity and Evolution of Thymidine Kinase and DNA Polymerase Mutants of Herpes Simplex Virus Type 1: Implications for Antiviral Therapy https://pubmed.ncbi.nlm.nih.gov/23315323/ doi.org/10.1093/infdis/jit019 Isolated strain PRA 09/12/2021 OJCharles co-occurs with resmut O 942 HSV1 Clinical isolate UL30 E927D Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 10/12/2021 OJCharles A 943 HSV1 Clinical isolate UL30 T931A Polymorphism Resistance of herpes simplex viruses to acyclovir: An update from a ten-year survey in France https://www.sciencedirect.com/science/article/pii/S0166354214002502 doi.org/10.1016/j.antiviral.2014.08.013 Isolated strain dye uptake assay 11/12/2021 OJCharles sc16 A 944 HSV1 Clinical isolate UL30 T931I Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 12/12/2021 OJCharles mutations not resolved by sequence MacIntyre A 945 HSV1 Clinical isolate UL30 I942L Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 13/12/2021 OJCharles A 946 HSV1 Clinical isolate UL30 Y946F Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 14/12/2021 OJCharles mutations not resolved by sequence MacIntyre A 947 HSV1 Clinical isolate UL30 G948C Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2 https://pubmed.ncbi.nlm.nih.gov/22155911/ doi.org/10.3851/IMP1870 Isolated strain dye uptake assay 15/12/2021 OJCharles A 948 HSV1 Clinical isolate UL30 R993L Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 17/12/2021 OJCharles A 949 HSV1 Clinical isolate UL30 A995T Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 18/12/2021 OJCharles KOS A 950 HSV1 Clinical isolate UL30 E1005K 0.5 0.7 Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients. https://journals.sagepub.com/doi/10.1177/135965350400900413 doi.org/10.1177/135965350400900413 Isolated strain yield reduction assay (ELVIRA) 19/12/2021 OJCharles unkown co-mutations A 951 HSV1 Clinical isolate UL30 A1012V Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 20/12/2021 OJCharles unkown co-mutations A 952 HSV1 Clinical isolate UL30 R1019G Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 21/12/2021 OJCharles unkown co-mutations A 953 HSV1 Clinical isolate UL30 R1020C Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2 https://pubmed.ncbi.nlm.nih.gov/22155911/ doi.org/10.3851/IMP1870 Isolated strain dye uptake assay 22/12/2021 OJCharles A 954 HSV1 Clinical isolate UL30 R1020H Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 23/12/2021 OJCharles A 955 HSV1 Clinical isolate UL30 T1022A Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 24/12/2021 OJCharles mutations not resolved by sequence MacIntyre A 956 HSV1 Clinical isolate UL30 V1077L Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 25/12/2021 OJCharles KOS A 957 HSV1 Clinical isolate UL30 Q1079K Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 26/12/2021 OJCharles co-occurs with unknwon mutation phenotype O 958 HSV1 Clinical isolate UL30 E1082K Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 27/12/2021 OJCharles KOS A 959 HSV1 Clinical isolate UL30 E1084A Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 28/12/2021 OJCharles co-occurs with unknwon mutation phenotype O 960 HSV1 Clinical isolate UL30 E1084K Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 29/12/2021 OJCharles occurs with C336Y known res O 961 HSV1 Clinical isolate UL30 E1085D Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 30/12/2021 OJCharles mutations not resolved by sequence MacIntyre A 962 HSV1 Clinical isolate UL30 E1085K Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 31/12/2021 OJCharles mutations not resolved by sequence MacIntyre A 963 HSV1 Clinical isolate UL30 T1086M Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 01/01/2022 OJCharles unkown co-mutations A 964 HSV1 Clinical isolate UL30 A1099T Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 02/01/2022 OJCharles KOS A 965 HSV1 Clinical isolate UL30 A1100T Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 03/01/2022 OJCharles unkown co-mutations A 966 HSV1 Clinical isolate UL30 D1103H Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients. https://journals.sagepub.com/doi/10.1177/135965350400900413 doi.org/10.1177/135965350400900413 Isolated strain yield reduction assay (ELVIRA) 04/01/2022 OJCharles Cannot be inferred O 967 HSV1 Clinical isolate UL30 E1104D Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 05/01/2022 OJCharles KOS A 968 HSV1 Clinical isolate UL30 E1104K Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 06/01/2022 OJCharles mutations not resolved by sequence MacIntyre A 969 HSV1 Clinical isolate UL30 A1109T Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 07/01/2022 OJCharles mutations not resolved by sequence MacIntyre A 970 HSV1 Clinical isolate UL30 P1112L Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 08/01/2022 OJCharles A 971 HSV1 Clinical isolate UL30 S1113C Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 09/01/2022 OJCharles KOS A 972 HSV1 Clinical isolate UL30 P1114A Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 10/01/2022 OJCharles mutations not resolved by sequence MacIntyre A 973 HSV1 Clinical isolate UL30 P1114L Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 11/01/2022 OJCharles mutations not resolved by sequence MacIntyre A 974 HSV1 Clinical isolate UL30 R1117I Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 12/01/2022 OJCharles A 975 HSV1 Clinical isolate UL30 R1117L Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 13/01/2022 OJCharles mutations not resolved by sequence MacIntyre A 976 HSV1 Clinical isolate UL30 R1117S Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 14/01/2022 OJCharles A 977 HSV1 Clinical isolate UL30 T1121M Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 15/01/2022 OJCharles mutations not resolved by sequence MacIntyre A 978 HSV1 Clinical isolate UL30 S1123A Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 16/01/2022 OJCharles unkown co-mutations A 979 HSV1 Clinical isolate UL30 S1123L Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 17/01/2022 OJCharles KOS A 980 HSV1 Clinical isolate UL30 P1124H Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PCR DNA hybridization assay 18/01/2022 OJCharles A 981 HSV1 Clinical isolate UL30 P1128L Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 19/01/2022 OJCharles unkown co-mutations A 982 HSV1 Clinical isolate UL30 G1129R Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 20/01/2022 OJCharles mutations not resolved by sequence MacIntyre A 983 HSV1 Clinical isolate UL30 G1129V Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 21/01/2022 OJCharles KOS A 984 HSV1 Clinical isolate UL30 A1147T Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2 https://pubmed.ncbi.nlm.nih.gov/22155911/ doi.org/10.3851/IMP1870 Isolated strain dye uptake assay 22/01/2022 OJCharles A 985 HSV1 Clinical isolate UL30 A1147V Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 23/01/2022 OJCharles mutations not resolved by sequence MacIntyre A 986 HSV1 Clinical isolate UL30 H1152N Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 24/01/2022 OJCharles mutations not resolved by sequence MacIntyre A 987 HSV1 Clinical isolate UL30 D1159A Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 25/01/2022 OJCharles mutations not resolved by sequence MacIntyre A 988 HSV1 Clinical isolate UL30 L1166W Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 26/01/2022 OJCharles A 989 HSV1 Clinical isolate UL30 A1168V Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Testing of herpes simplex virus for resistance to antiviral drugs https://www.tandfonline.com/doi/abs/10.4161/viru.1.6.13806 doi.org/10.4161/viru.1.6.13806 Isolated strain dye uptake assay 27/01/2022 OJCharles no data O 990 HSV1 Clinical isolate UL30 A1175D Polymorphism Polymorphism Testing of herpes simplex virus for resistance to antiviral drugs https://www.tandfonline.com/doi/abs/10.4161/viru.1.6.13806 doi.org/10.4161/viru.1.6.13806 Isolated strain dye uptake assay 28/01/2022 OJCharles no data O 991 HSV1 Clinical isolate UL30 A1181T Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 29/01/2022 OJCharles unkown co-mutations A 992 HSV1 Clinical isolate UL30 E1194D Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 30/01/2022 OJCharles KOS A 993 HSV1 Clinical isolate UL30 P1199L Polymorphism Polymorphism Longitudinal Characterization of Herpes Simplex Virus (HSV) Isolates Acquired From Different Sites in an Immune-Compromised Child: A New HSV Thymidine Kinase Mutation Associated With Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656553/ doi.org/10.1093/jpids/pis009 Isolated strain PRA 31/01/2022 OJCharles unkown co-mutations strain 17 O 994 HSV1 Clinical isolate UL30 P1199Q Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/02/2022 OJCharles KOS A 995 HSV1 Clinical isolate UL30 V1202M Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 02/02/2022 OJCharles A 996 HSV1 Clinical isolate UL30 A1203T Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PCR DNA hybridization assay 03/02/2022 OJCharles A 997 HSV1 Clinical isolate UL30 A1204T Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 04/02/2022 OJCharles KOS A 998 HSV1 Clinical isolate UL30 T1208A Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PCR DNA hybridization assay 05/02/2022 OJCharles A 999 HSV1 Clinical isolate UL30 A1209T Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 06/02/2022 OJCharles KOS A 1000 HSV1 Clinical isolate UL30 A1218S Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 07/02/2022 OJCharles mutations not resolved by sequence MacIntyre A 1001 HSV1 Clinical isolate UL30 T1219M Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 08/02/2022 OJCharles KOS A 1002 HSV1 Clinical isolate UL30 A1220V Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 09/02/2022 OJCharles mutations not resolved by sequence MacIntyre A 1003 HSV1 Clinical isolate UL30 M1226I Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 10/02/2022 OJCharles mutations not resolved by sequence MacIntyre A 1004 HSV1 Clinical isolate UL30 R1229I Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 11/02/2022 OJCharles KOS A 1005 HSV1 Clinical isolate UL30 L1234I Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 12/02/2022 OJCharles unkown co-mutations A 1006 HSV1 Clinical isolate UL30 A1235T Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 13/02/2022 OJCharles mutations not resolved by sequence MacIntyre A 1007 HSV1 UL30 D368A Resistant Resistant Impaired Mismatch Extension by a Herpes Simplex DNA Polymerase Mutant with an Editing Nuclease Defect https://www.sciencedirect.com/science/article/pii/S0021925819602449 doi.org/10.1074/jbc.273.37.24075 lab induced strain PCR DNA hybridization assay 15/02/2022 OJCharles A 1008 HSV1 Clinical isolate UL30 I529M Resistant Polymorphism Mutations in the DNA Polymerase and Thymidine Kinase Genes of Herpes Simplex Virus Clinical Isolates Resistant to Antiherpetic Drugs https://link.springer.com/article/10.1134/S0026893310030118 doi.org/10.1134/S0026893310030118 Isolated strain PRA 16/02/2022 OJCharles co-occurs with resistant M880T and unknown mutations L2 O 1009 HSV1 Clinical isolate UL30 K532T Resistant Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PCR DNA hybridization assay 17/02/2022 OJCharles Cannot be inferred O 1010 HSV1 Clinical isolate UL30 E545D 10 1.3 Mutations in the DNA Polymerase and Thymidine Kinase Genes of Herpes Simplex Virus Clinical Isolates Resistant to Antiherpetic Drugs https://link.springer.com/article/10.1134/S0026893310030118 doi.org/10.1134/S0026893310030118 Isolated strain PRA 18/02/2022 OJCharles co-occurs with unknwon mutations L2 O 1011 HSV1 UL30 Y557S Resistant Herpes Simplex Virus Type 1 DNA Polymerase: MUTATIONAL ANALYSIS OF THE 3?-5?-EXONUCLEASE DOMAIN https://www.sciencedirect.com/science/article/pii/S0021925818350592 doi.org/10.1074/jbc.271.46.29245 Marker transfer PCR DNA hybridization assay 19/02/2022 OJCharles A 1012 HSV1 Clinical isolate UL30 Q570R 3.7 0.2 Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients. https://journals.sagepub.com/doi/10.1177/135965350400900413 doi.org/10.1177/135965350400900413 Isolated strain yield reduction assay (ELVIRA) 20/02/2022 OJCharles A 1013 HSV1 UL30 V573M 0.5 0.25 Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-81-3-639#tab2 doi.org/10.1099/0022-1317-81-3-639 Lab induced strain PRA 21/02/2022 OJCharles A 1014 HSV1 Clinical isolate UL30 D581A Resistant Phenotypic and genotypic characterization of clinical isolates of herpes simplex virus resistant to aciclovir https://www.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.18880-0#tab2 doi.org/10.1099/vir.0.18880-0 Isolated strain TK functional kinetic assay 22/02/2022 OJCharles A 1015 HSV1 Clinical isolate UL30 L583V Resistant Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PCR DNA hybridization assay 23/02/2022 OJCharles Cannot be inferred O 1016 HSV1 SC16 UL30 E597D 10 8 Related functional domains in virus DNA polymerases https://www.ncbi.nlm.nih.gov/pmc/articles/PMC553373/pdf/emboj00241-0168.pdf doi.org/10.1002/j.1460-2075.1987.tb04735.x Lab induced strain PRA 24/02/2022 OJCharles A 1017 HSV1 TAS UL30 A605V 5 0.3 10 1.7 Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/ doi.org/10.1128/AAC.49.2.606-611.2005 Lab induced strain PRA 04/02/2021 OJCharles A 1018 HSV1 Clinical isolate UL30 Y608* Resistant Phenotypic and genotypic characterization of induced acyclovir-resistant clinical isolates of herpes simplex virus type 1 https://www.sciencedirect.com/science/article/pii/S0166354213002544 doi.org/10.1016/j.antiviral.2013.09.008 Isolated strain PRA 26/02/2022 OJCharles cannot see in paper O 1019 HSV1 KOS UL30 Q618H 9 Polymorphism 1.9 Polymorphism DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions https://journals.sagepub.com/doi/abs/10.1177/135965350701200502 doi.org/10.1177/135965350701200502 Lab induced strain Cytopathic effect 27/02/2022 OJCharles KOS A 1020 HSV1 Clinical isolate UL30 V621S Resistant Phenotypic and genotypic characterization of induced acyclovir-resistant clinical isolates of herpes simplex virus type 1 https://www.sciencedirect.com/science/article/pii/S0166354213002544 doi.org/10.1016/j.antiviral.2013.09.008 Isolated strain PRA 28/02/2022 OJCharles co-occuring resistant mutant O 1021 HSV1 Clinical isolate UL30 A657T Resistant Polymorphism Polymorphism Resistant Resistant Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2 https://pubmed.ncbi.nlm.nih.gov/22155911/ doi.org/10.3851/IMP1870 Isolated strain dye uptake assay 01/03/2022 OJCharles A 1022 HSV1 Clinical isolate UL30 D672N Resistant Polymorphism Resistant Resistant Resistant Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 02/03/2022 OJCharles A 1023 HSV1 KOS UL30 R700G 2 6 Polymorphism Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants https://www.sciencedirect.com/science/article/pii/S0166354297000545 doi.org/10.1016/S0166-3542(97)00054-5 Lab induced strain PRA 03/03/2022 OJCharles KOS A 1024 HSV1 UL30 R700M 1.4 Resistant Polymorphism 0.4 Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-81-3-639#tab2 doi.org/10.1099/0022-1317-81-3-639 Lab induced strain PRA 04/03/2022 OJCharles A 1025 HSV1 UL30 L702H Resistant Polymorphism Resistant Resistant Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain PRA 05/03/2022 OJCharles ref wrong E 1026 HSV1 Clinical isolate UL30 L702P 128 257 Mutations in the DNA Polymerase and Thymidine Kinase Genes of Herpes Simplex Virus Clinical Isolates Resistant to Antiherpetic Drugs https://link.springer.com/article/10.1134/S0026893310030118 doi.org/10.1134/S0026893310030118 Isolated strain PRA 06/03/2022 OJCharles co-occurs with unknwon mutations L2 O 1027 HSV1 KOS UL30 V714M 2.7 Polymorphism 3.8 Polymorphism DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions https://journals.sagepub.com/doi/abs/10.1177/135965350701200502 doi.org/10.1177/135965350701200502 Lab induced strain Cytopathic effect 07/03/2022 OJCharles KOS A 1028 HSV1 Clinical isolate UL30 V715G Resistant Polymorphism Resistant Resistant Bone Marrow Transplantation in a ChildWith Wiskott-Aldrich Syndrome Latently InfectedWith Acyclovir-Resistant (ACVr) Herpes SimplexVirus Type 1: Emergence of Foscarnet-ResistantVirus Originating From the ACVrVirus https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.10175 doi.org/10.1002/jmv.10175 Isolated strain PRA 08/03/2022 OJCharles TAS A 1029 HSV1 Clinical isolate UL30 F716L 1.8 2.9 2.9 Mutations in the DNA Polymerase and Thymidine Kinase Genes of Herpes Simplex Virus Clinical Isolates Resistant to Antiherpetic Drugs https://link.springer.com/article/10.1134/S0026893310030118 doi.org/10.1134/S0026893310030118 Isolated strain PRA 10/03/2022 OJCharles co-occurs with unknwon mutations L2 O 1030 HSV1 Clinical isolate UL30 F733C Resistant Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 15/03/2022 OJCharles co-occurs with large deletion O 1031 HSV1 Clinical isolate UL30 E771Q Resistant Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PCR DNA hybridization assay 16/03/2022 OJCharles A 1032 HSV1 KOS UL30 L774F 3.7 3.2 A Point Mutation within Conserved Region VI of Herpes Simplex Virus Type 1 DNA Polymerase Confers Altered Drug Sensitivity and Enhances Replication Fidelity https://www.ncbi.nlm.nih.gov/pmc/articles/PMC368862/ doi.org/10.1128/JVI.78.2.650-657.2004 Marker Transfer PRA 17/03/2022 OJCharles KOS A 1033 HSV1 Clinical isolate UL30 S775N Resistant Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 18/03/2022 OJCharles A 1034 HSV1 UL30 W781V 3 14 3 Contrasting Effects of W781V and W780V Mutations in Helix N of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Antiviral Drug Susceptibility https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442382/ doi.org/10.1128/JVI.03360-14 Marker Transfer PRA 21/03/2022 OJCharles A 1035 HSV1 KOS UL30 P797T Resistant Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition https://www.ncbi.nlm.nih.gov/pmc/articles/PMC282039/ doi.org/10.1073/pnas.85.18.6672 lab induced strain PRA 23/03/2022 OJCharles infer pol mutation phenotype using virus phenotype assay ignorant of tk genotype KOS O 1036 HSV1 Clinical isolate UL30 E798K Resistant Polymorphism Resistant Polymorphism Resistant Heterogeneity and Evolution of Thymidine Kinase and DNA Polymerase Mutants of Herpes Simplex Virus Type 1: Implications for Antiviral Therapy https://pubmed.ncbi.nlm.nih.gov/23315323/ doi.org/10.1093/infdis/jit019 Isolated strain PRA 24/03/2022 OJCharles co-occurs with resmut O 1037 HSV1 KOS UL30 L802F 7.4 Resistant Resistant Polymorphism DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions https://journals.sagepub.com/doi/abs/10.1177/135965350701200502 doi.org/10.1177/135965350701200502 Lab induced strain Cytopathic effect 25/03/2022 OJCharles KOS A 1038 HSV1 KOS UL30 V813M 5 4 3 Resistant Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants https://www.sciencedirect.com/science/article/pii/S0166354297000545 doi.org/10.1016/S0166-3542(97)00054-5 Lab induced strain PRA 26/03/2022 OJCharles KOS A 1039 HSV1 SC16 UL30 N815S 150 Polymorphism 0.4 Polymorphism Resistant Related functional domains in virus DNA polymerases https://www.ncbi.nlm.nih.gov/pmc/articles/PMC553373/pdf/emboj00241-0168.pdf doi.org/10.1002/j.1460-2075.1987.tb04735.x Lab induced strain PRA 27/03/2022 OJCharles redundant O 1040 HSV1 UL30 G841C Resistant Resistant Resistant Resistant Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain PRA 30/03/2022 OJCharles ref wrong E 1041 HSV1 SC16 UL30 G841S 29 2.6 Related functional domains in virus DNA polymerases https://www.ncbi.nlm.nih.gov/pmc/articles/PMC553373/pdf/emboj00241-0168.pdf doi.org/10.1002/j.1460-2075.1987.tb04735.x Lab induced strain PRA 31/03/2022 OJCharles A 1042 HSV1 KOS UL30 R842S 150 4 Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants https://www.sciencedirect.com/science/article/pii/S0166354297000545 doi.org/10.1016/S0166-3542(97)00054-5 Lab induced strain PRA 01/04/2022 OJCharles KOS A 1043 HSV1 Clinical isolate UL30 M880T 10 1.3 Mutations in the DNA Polymerase and Thymidine Kinase Genes of Herpes Simplex Virus Clinical Isolates Resistant to Antiherpetic Drugs https://link.springer.com/article/10.1134/S0026893310030118 doi.org/10.1134/S0026893310030118 Isolated strain PRA 02/04/2022 OJCharles co-occurs with unknwon mutations L2 O 1044 HSV1 UL30 S889A 10 225 Resistance to Antiviral Inhibitors Caused by the Mutation S889A in the Highly-Conserved 885-GDTDS Motif of the Herpes Simplex Virus Type 1 DNA Polymerase https://www.sciencedirect.com/science/article/pii/S004268228371439X doi.org/10.1006/viro.1993.1439 Marker transfer PCR DNA hybridization assay 03/04/2022 OJCharles A 1045 HSV1 UL30 F891Y Resistant Resistant Engineered Herpes Simplex Virus DNA Polymerase Point Mutants: the Most Highly Conserved Region Shared among oL-Like DNA Polymerases Is Involved in Substrate Recognition https://www.ncbi.nlm.nih.gov/pmc/articles/PMC248752/pdf/jvirol00067-0201.pdf doi.org/10.1128/JVI.64.12.5883-5890.1990 Marker Transfer PRA 05/04/2022 OJCharles A 1046 HSV1 UL30 V892M Resistant Resistant Engineered Herpes Simplex Virus DNA Polymerase Point Mutants: the Most Highly Conserved Region Shared among oL-Like DNA Polymerases Is Involved in Substrate Recognition https://www.ncbi.nlm.nih.gov/pmc/articles/PMC248752/pdf/jvirol00067-0201.pdf doi.org/10.1128/JVI.64.12.5883-5890.1990 Marker Transfer PRA 06/04/2022 OJCharles A 1047 HSV1 Clinical isolate UL30 G901V 25 Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 07/04/2022 OJCharles mutations not resolved by sequence MacIntyre A 1048 HSV1 UL30 I922N Polymorphism Resistant Differential Mutation Patterns in Thymidine Kinase and DNA Polymerase Genes of Herpes Simplex Virus Type 1 Clones Passaged in the Presence of Acyclovir or Penciclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC153316/ doi.org/10.1128/AAC.47.5.1707-1713.2003 Lab induced strain PRA 09/04/2022 OJCharles ref wrong E 1049 HSV1 TAS UL30 V958L Resistant Polymorphism Resistant Resistant Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/ doi.org/10.1128/AAC.49.2.606-611.2005 Lab induced strain PRA 04/02/2021 OJCharles A 1050 HSV1 UL30 R959H 3.4 Resistant Resistant Polymorphism DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions https://journals.sagepub.com/doi/abs/10.1177/135965350701200502 doi.org/10.1177/135965350701200502 Lab induced strain Cytopathic effect 12/04/2022 OJCharles A 1051 HSV1 KOS UL30 K960R 2.5 Resistant Polymorphism Polymorphism DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions https://journals.sagepub.com/doi/abs/10.1177/135965350701200502 doi.org/10.1177/135965350701200502 Lab induced strain Cytopathic effect 13/04/2022 OJCharles KOS A 1052 HSV1 KOS UL30 W998L 1.5 Resistant Polymorphism Polymorphism DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions https://journals.sagepub.com/doi/abs/10.1177/135965350701200502 doi.org/10.1177/135965350701200502 Lab induced strain Cytopathic effect 15/04/2022 OJCharles KOS A 1053 HSV1 Clinical isolate UL30 H1228D 3 Phenotypic and genotypic characterization of induced acyclovir-resistant clinical isolates of herpes simplex virus type 1 https://www.sciencedirect.com/science/article/pii/S0166354213002544 doi.org/10.1016/j.antiviral.2013.09.008 Isolated strain PRA 18/04/2022 OJCharles A 1054 HSV2 Clinical isolate UL30 A9T Polymorphism Polymorphism Resistance testing of clinical herpes simplex virus type 2 isolates collected over 4 decades https://www.sciencedirect.com/science/article/pii/S1438422115000776 doi.org/10.1016/j.ijmm.2015.08.014 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1055 HSV2 Clinical isolate UL30 A9T Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1056 HSV2 Clinical isolate UL30 G12R Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1057 HSV2 Clinical isolate UL30 P15S Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1058 HSV2 Clinical isolate UL30 P15R Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1059 HSV2 Clinical isolate UL30 Q34H Resistant Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 01/11/2020 OJCharles Y133F is polymorphic in subsequent studies A 1060 HSV2 Clinical isolate UL30 A36G Polymorphism Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1061 HSV2 Clinical isolate UL30 P37L Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1062 HSV2 Clinical isolate UL30 C40W Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 01/11/2020 OJCharles unkown co-mutations A 1063 HSV2 Clinical isolate UL30 R41H Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 01/11/2020 OJCharles Cannot be inferred O 1064 HSV2 Clinical isolate UL30 Q43R Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1065 HSV2 Clinical isolate UL30 H49Y Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1066 HSV2 Clinical isolate UL30 T53A Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1067 HSV2 Clinical isolate UL30 L60P Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1068 HSV2 Clinical isolate UL30 Q64R Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1069 HSV2 Clinical isolate UL30 R101W Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1070 HSV2 Clinical isolate UL30 L128S Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1071 HSV2 Clinical isolate UL30 E139K Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1072 HSV2 Clinical isolate UL30 T144P Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1073 HSV2 Clinical isolate UL30 I153T Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1074 HSV2 Clinical isolate UL30 T202M Polymorphism Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1075 HSV2 Clinical isolate UL30 R203Q Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 01/11/2020 OJCharles unkown co-mutations A 1076 HSV2 Clinical isolate UL30 L229M Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1077 HSV2 Clinical isolate UL30 A232T Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 01/11/2020 OJCharles Cannot be inferred O 1078 HSV2 Clinical isolate UL30 A251V Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1079 HSV2 Clinical isolate UL30 N286Y Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1080 HSV2 Clinical isolate UL30 I291V Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1081 HSV2 Clinical isolate UL30 A300T Polymorphism Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1082 HSV2 Clinical isolate UL30 G324E Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1083 HSV2 Clinical isolate UL30 F336L Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1084 HSV2 Clinical isolate UL30 T347M Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1085 HSV2 Clinical isolate UL30 Q507H Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1086 HSV2 Clinical isolate UL30 A547V Polymorphism Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1087 HSV2 Clinical isolate UL30 R628C Resistant Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles Only publshed with known resistance mutations, not given is any un-previously identified mutations in pol / tk. So this is problematic O 1088 HSV2 Clinical isolate UL30 G646S Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1089 HSV2 Clinical isolate UL30 D671N Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1090 HSV2 Clinical isolate UL30 D676G Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1091 HSV2 Clinical isolate UL30 D676N Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1092 HSV2 Clinical isolate UL30 del676-677 Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1093 HSV2 Clinical isolate UL30 del677-679 Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1094 HSV2 Clinical isolate UL30 E678G Polymorphism Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1095 HSV2 Clinical isolate UL30 G680R Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1096 HSV2 Clinical isolate UL30 G680D Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles mutations not resolved by sequence & unsure which sequences also / did not have a pol genotype O 1097 HSV2 Clinical isolate UL30 del681-682 Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1098 HSV2 Clinical isolate UL30 E682G Polymorphism Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1099 HSV2 Clinical isolate UL30 E682K Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1100 HSV2 Clinical isolate UL30 del682-683 Polymorphism Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1101 HSV2 Clinical isolate UL30 del683-686 Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1102 HSV2 Clinical isolate UL30 E686* Polymorphism Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1103 HSV2 Clinical isolate UL30 D708N Polymorphism Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1104 HSV2 Clinical isolate UL30 D716N Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1105 HSV2 Clinical isolate UL30 E746K Polymorphism Polymorphism Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2 https://pubmed.ncbi.nlm.nih.gov/22155911/ doi.org/10.3851/IMP1870 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1106 HSV2 Clinical isolate UL30 Q799R Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1107 HSV2 Clinical isolate UL30 T801P Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1108 HSV2 Clinical isolate UL30 E803K Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1109 HSV2 Clinical isolate UL30 A869D Polymorphism Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1110 HSV2 Clinical isolate UL30 A879V Polymorphism Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1111 HSV2 Clinical isolate UL30 P880H Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1112 HSV2 Clinical isolate UL30 T903M Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1113 HSV2 Clinical isolate UL30 A904G Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1114 HSV2 Clinical isolate UL30 A905E Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1115 HSV2 Clinical isolate UL30 M910I Polymorphism Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1116 HSV2 Clinical isolate UL30 K913M Polymorphism Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1117 HSV2 Clinical isolate UL30 T987S Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 01/11/2020 OJCharles unkown co-mutations A 1118 HSV2 Clinical isolate UL30 L995F Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 01/11/2020 OJCharles Cannot be inferred O 1119 HSV2 Clinical isolate UL30 A1000T Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1120 HSV2 Clinical isolate UL30 R1025H Polymorphism Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1121 HSV2 Clinical isolate UL30 I1026S Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 01/11/2020 OJCharles Cannot be inferred O 1122 HSV2 Clinical isolate UL30 A1083T Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1123 HSV2 Clinical isolate UL30 del1106-1111 Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1124 HSV2 Clinical isolate UL30 P1112* Polymorphism Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1125 HSV2 Clinical isolate UL30 A1114V Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1126 HSV2 Clinical isolate UL30 E1149G Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles problematic theres never data shown to prove this KOS O 1127 HSV2 Clinical isolate UL30 A1156T Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1128 HSV2 Clinical isolate UL30 A1209V Polymorphism Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1129 HSV2 Clinical isolate UL30 A1223V Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1130 HSV2 Clinical isolate UL30 R1230Q Polymorphism Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1131 HSV2 Clinical isolate UL23 A19V Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles Cannot be inferred O 1132 HSV2 Clinical isolate UL23 R26H Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1133 HSV2 Clinical isolate UL23 A27T Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles Cannot be inferred O 1134 HSV2 Clinical isolate UL23 S29A Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles Cannot be inferred O 1135 HSV2 UL23 G39E 1.2 Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Marker Transfer TK functional kinetic assay 01/11/2020 OJCharles A 1136 HSV2 Clinical isolate UL23 N78D Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1137 HSV2 Clinical isolate UL23 E96D Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1138 HSV2 Clinical isolate UL23 A119T Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1139 HSV2 Clinical isolate UL23 T131M Polymorphism Polymorphism Resistance testing of clinical herpes simplex virus type 2 isolates collected over 4 decades https://www.sciencedirect.com/science/article/pii/S1438422115000776#bib0120 doi.org/10.1016/j.ijmm.2015.08.014 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1140 HSV2 Clinical isolate UL23 A135P Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1141 HSV2 Clinical isolate UL23 D137E Polymorphism Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1142 HSV2 Clinical isolate UL23 L140F Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1143 HSV2 Clinical isolate UL23 G150D Polymorphism Polymorphism Resistance testing of clinical herpes simplex virus type 2 isolates collected over 4 decades https://www.sciencedirect.com/science/article/pii/S1438422115000776#bib0120 doi.org/10.1016/j.ijmm.2015.08.014 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1144 HSV2 Clinical isolate UL23 A157T Polymorphism Polymorphism Resistance testing of clinical herpes simplex virus type 2 isolates collected over 4 decades https://www.sciencedirect.com/science/article/pii/S1438422115000776#bib0120 doi.org/10.1016/j.ijmm.2015.08.014 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1145 HSV2 Clinical isolate UL23 T159I Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles Cannot be inferred O 1146 HSV2 Clinical isolate UL23 G201D Polymorphism Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1147 HSV2 Clinical isolate UL23 A215T Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1148 HSV2 Clinical isolate UL23 R220K Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1149 HSV2 Clinical isolate UL23 N245S Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles Cannot be inferred O 1150 HSV2 Clinical isolate UL23 R248W Polymorphism Polymorphism Resistance testing of clinical herpes simplex virus type 2 isolates collected over 4 decades https://www.sciencedirect.com/science/article/pii/S1438422115000776#bib0120 doi.org/10.1016/j.ijmm.2015.08.014 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1151 HSV2 Clinical isolate UL23 Q251R Polymorphism Polymorphism Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus http://pdfs.semanticscholar.org/273d/230d2dc0f09225c569b99871ac2aa4e3da70.pdf doi.org/10.3851/IMP1852 Isolated strain dye uptake assay 01/11/2020 OJCharles unkown co-mutations A 1152 HSV2 Clinical isolate UL23 R284S Polymorphism Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles Cannot be inferred O 1153 HSV2 Clinical isolate UL23 L342W Polymorphism Polymorphism Resistance testing of clinical herpes simplex virus type 2 isolates collected over 4 decades https://www.sciencedirect.com/science/article/pii/S1438422115000776#bib0120 doi.org/10.1016/j.ijmm.2015.08.014 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1154 HSV2 UL23 S32* 161 0.7 0.4 2.6 133 Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 01/11/2020 OJCharles A 1155 HSV2 Clinical isolate UL23 R34C Resistant Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles Cannot be inferred O 1156 HSV2 Clinical isolate UL23 R51W Resistant Journal of Medical Virology 73:60-64 (2004)Case ReportCharacterisation of Penciclovir Resistant AcyclovirSensitive Herpes Simplex Virus Type 2 IsolatedFrom an AIDS Patient https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.20061 doi.org/10.1002/jmv.20061 Isolated strain PRA 16/01/2021 OJCharles A 1157 HSV2 Clinical isolate UL23 Y53N Resistant Resistant Polymorphism Resistant Resistant Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 01/11/2020 OJCharles Cannot be inferred A 1158 HSV2 UL23 I54* 200 2.8 1.4 1.2 133.8 Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 01/11/2020 OJCharles A 1159 HSV2 UL23 I54* 150 1.7 0.7 3.1 115 Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 01/11/2020 OJCharles A 1160 HSV2 Clinical isolate UL23 G61W Resistant Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1161 HSV2 Clinical isolate UL23 K62N Resistant Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain PCR DNA hybridization assay 01/11/2020 OJCharles duplicate A2 O 1162 HSV2 UL23 S66P Resistant Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Marker Transfer TK functional kinetic assay 01/11/2020 OJCharles Hard to interpret as double mutant is sensetive O 1163 HSV2 UL23 A72S Resistant Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Marker Transfer TK functional kinetic assay 01/11/2020 OJCharles Hard to interpret as double mutant is sensetive O 1164 HSV2 Clinical isolate UL23 M86* Resistant Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1165 HSV2 Clinical isolate UL23 A94V Resistant Resistant Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles A 1166 HSV2 Clinical isolate UL23 L98* Resistant Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1167 HSV2 UL23 I101S 4 Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Marker Transfer TK functional kinetic assay 01/11/2020 OJCharles A 1168 HSV2 Clinical isolate UL23 Q105P Resistant Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses https://www.sciencedirect.com/science/article/pii/004268229190093Q doi.org/10.1016/0042-6822(91)90093-Q Isolated strain PRA 01/11/2020 OJCharles ignores potential pol mutants O 1169 HSV2 Clinical isolate UL23 T131P 10 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain PCR DNA hybridization assay 01/11/2020 OJCharles A2 A 1170 HSV2 Clinical isolate UL23 Y133F Resistant Resistant Polymorphism Resistant Resistant Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 01/11/2020 OJCharles Cannot be inferred A 1171 HSV2 Clinical isolate UL23 D137* Resistant Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1172 HSV2 Clinical isolate UL23 L158P Resistant Phenotypic and genotypic characterization of clinical isolates of herpes simplex virus resistant to aciclovir https://www.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.18880-0#tab2 doi.org/10.1099/vir.0.18880-0 Isolated strain TK functional kinetic assay 01/11/2020 OJCharles A 1173 HSV2 Clinical isolate UL23 R177W Resistant Polymorphism Recurrent Acyclovir-Resistant Genital Herpes in an Immunocompetent Patient https://www.nejm.org/doi/10.1056/NEJM199312093292405?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov doi.org/10.1056/NEJM199312093292405 Isolated strain PRA 01/11/2020 OJCharles co-occuring mutations have been subsequently characterised A 1174 HSV2 Clinical isolate UL23 S182D Resistant Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses https://www.sciencedirect.com/science/article/pii/004268229190093Q doi.org/10.1016/0042-6822(91)90093-Q Isolated strain PRA 01/11/2020 OJCharles ignores potential pol mutants O 1175 HSV2 Clinical isolate UL23 S182R Resistant Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses https://www.sciencedirect.com/science/article/pii/004268229190093Q doi.org/10.1016/0042-6822(91)90093-Q Isolated strain PRA 01/11/2020 OJCharles ignores potential pol mutants O 1176 HSV2 UL23 S182N Resistant Molecular analysis of a neurovirulent herpes simplex virus type 2 strain with reduced thymidine kinase activity https://link.springer.com/article/10.1007/BF01379080 doi.org/10.1007/BF01379080 Lab induced strain PRA 01/11/2020 OJCharles A 1177 HSV2 UL23 M183I 5 Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Marker Transfer TK functional kinetic assay 01/11/2020 OJCharles A 1178 HSV2 Clinical isolate UL23 M183* Resistant Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1179 HSV2 UL23 M183* Resistant Polymorphism Polymorphism Resistant Resistant Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 01/11/2020 OJCharles A 1180 HSV2 UL23 M183* 130 2.4 0.3 6.2 133 Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 01/11/2020 OJCharles A 1181 HSV2 Clinical isolate UL23 M183* Resistant Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1182 HSV2 UL23 M183* 500 0.7 11 81 1.2 Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 01/11/2020 OJCharles A 1183 HSV2 UL23 M183* 130 2.4 0.3 133 6.2 Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 01/11/2020 OJCharles A 1184 HSV2 Clinical isolate UL23 T184* Resistant Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1185 HSV2 Clinical isolate UL23 G201D Resistant Phenotypic and genotypic characterization of clinical isolates of herpes simplex virus resistant to aciclovir https://www.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.18880-0#tab2 doi.org/10.1099/vir.0.18880-0 Isolated strain TK functional kinetic assay 01/11/2020 OJCharles A 1186 HSV2 Clinical isolate UL23 R221C Resistant Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles A 1187 HSV2 Clinical isolate UL23 R221H Resistant Resistant Resistant Resistant Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 01/11/2020 OJCharles Cannot be inferred A 1188 HSV2 Clinical isolate UL23 Q222* Resistant Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1189 HSV2 Clinical isolate UL23 R223H Resistant Nucleotide sequence changes in thymidine kinase gene of herpes simplex virus type 2 clones from an isolate of a patient treated with acyclovir. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC174976/ doi.org/10.1128/aac.31.10.1483 Isolated strain PRA 01/11/2020 OJCharles A 1190 HSV2 UL23 D229* 500 0.4 0.3 133 1.2 Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 01/11/2020 OJCharles A 1191 HSV2 UL23 D229* 200 1.6 0.5 133 2 Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 01/11/2020 OJCharles A 1192 HSV2 Clinical isolate UL23 D229* Resistant Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1193 HSV2 Clinical isolate UL23 D229* Resistant Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1194 HSV2 Clinical isolate UL23 D229* Resistant Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1195 HSV2 Clinical isolate UL23 D229* Resistant Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain PCR DNA hybridization assay 01/11/2020 OJCharles A2 A 1196 HSV2 Clinical isolate UL23 D229* Resistant Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1197 HSV2 Clinical isolate UL23 D229* Resistant Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1198 HSV2 Clinical isolate UL23 Y239* Resistant Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles V239 or Y240? O 1199 HSV2 UL23 D259frameshift 200 1 0.8 133 1.2 Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 01/11/2020 OJCharles A 1200 HSV2 Clinical isolate UL23 R262* Resistant Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1201 HSV2 Clinical isolate UL23 L263* Resistant Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1202 HSV2 Clinical isolate UL23 L263* Resistant Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1203 HSV2 Clinical isolate UL23 R271V Resistant Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain PCR DNA hybridization assay 01/11/2020 OJCharles three mutations, 1 measure A2 O 1204 HSV2 Clinical isolate UL23 P272S Resistant Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain PCR DNA hybridization assay 01/11/2020 OJCharles three mutations, 1 measure A2 O 1205 HSV2 Clinical isolate UL23 D273R Resistant Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain PCR DNA hybridization assay 01/11/2020 OJCharles three mutations, 1 measure A2 O 1206 HSV2 Clinical isolate UL23 T288M Resistant Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain PCR DNA hybridization assay 01/11/2020 OJCharles A2 A 1207 HSV2 UL23 T288frameshift* 200 1 0.8 1.5 133 Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 01/11/2020 OJCharles A 1208 HSV2 UL23 I308frameshift 60 4.3 0.9 5.6 133 Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 01/11/2020 OJCharles A 1209 HSV2 UL23 V335frameshift 200 1.3 1.2 6.2 133 Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 01/11/2020 OJCharles A 1210 HSV2 Clinical isolate UL23 C336Y Resistant Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain PCR DNA hybridization assay 01/11/2020 OJCharles C is 337 G is 336 - followup A2 O 1211 HSV2 Clinical isolate UL23 M348* Resistant Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1212 HSV2 Clinical isolate UL23 M348* Resistant Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles A 1213 HSV2 UL23 M348* Resistant Genital Herpes Due to Acyclovir-SensitiveHerpes Simplex Virus Caused Secondary andRecurrent Herpetic Whitlows Due to ThymidineKinase-De?cient/Temperature-Sensitive Virus https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.20990 doi.org/10.1002/jmv.20990 Isolated strain PRA 01/11/2020 OJCharles A 1214 HSV2 Clinical isolate UL23 M348* Resistant Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1215 HSV2 Clinical isolate UL23 M348* Resistant Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles KOS A 1216 HSV2 UL23 M348* Resistant Resistant Resistant Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 01/11/2020 OJCharles A 1217 HSV2 Clinical isolate UL30 E250Q Resistant Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles O 1218 HSV2 Clinical isolate UL30 D307N Resistant Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles A 1219 HSV2 Clinical isolate UL30 E678G Resistant Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles Copies a susceptible mutant falsely as resistant from here https://aac.asm.org/content/aac/54/11/4833.full.pdf O 1220 HSV2 Clinical isolate UL30 G684* Resistant Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1221 HSV2 Clinical isolate UL30 A724T 0.8 3.1 3.4 Characterization of the DNA Polymerase and Thymidine Kinase Genes of Herpes Simplex Virus Isolates from AIDS Patients in whom Acyclovir and Foscarnet Therapy Sequentially Failed https://academic.oup.com/jid/article/180/2/487/881212 doi.org/10.1086/314900 Isolated strain PRA 01/11/2020 OJCharles Only pol conserved was sequenced A 1222 HSV2 Clinical isolate UL30 A724V Resistant Polymorphism Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals https://aac.asm.org/content/54/11/4833 doi.org/10.1128/AAC.00669-10 Isolated strain PRA 01/11/2020 OJCharles redundant KOS O 1223 HSV2 Clinical isolate UL30 S725G Resistant Novel mutations in the thymidine kinase and DNA polymerase genes of acyclovir and foscarnet resistant herpes simplex viruses infecting an immunocompromised patient https://www.sciencedirect.com/science/article/pii/S1386653202000057 doi.org/10.1016/S1386-6532(02)00005-7 Isolated strain PRA 01/11/2020 OJCharles redundant O 1224 HSV2 Clinical isolate UL30 S729N 2.4 1.4 5.9 Characterization of the DNA Polymerase and Thymidine Kinase Genes of Herpes Simplex Virus Isolates from AIDS Patients in whom Acyclovir and Foscarnet Therapy Sequentially Failed https://academic.oup.com/jid/article/180/2/487/881212 doi.org/10.1086/314900 Isolated strain PRA 01/11/2020 OJCharles Only pol conserved was sequenced A 1225 HSV2 Clinical isolate UL30 Q732R Resistant Resistant Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1226 HSV2 Clinical isolate UL30 L783M 0.8 1.9 8 Characterization of the DNA Polymerase and Thymidine Kinase Genes of Herpes Simplex Virus Isolates from AIDS Patients in whom Acyclovir and Foscarnet Therapy Sequentially Failed https://academic.oup.com/jid/article/180/2/487/881212 doi.org/10.1086/314900 Isolated strain PRA 01/11/2020 OJCharles Only pol conserved was sequenced A 1227 HSV2 Clinical isolate UL30 D785N 1.3 0.7 3.9 Characterization of the DNA Polymerase and Thymidine Kinase Genes of Herpes Simplex Virus Isolates from AIDS Patients in whom Acyclovir and Foscarnet Therapy Sequentially Failed https://academic.oup.com/jid/article/180/2/487/881212 doi.org/10.1086/314900 Isolated strain PRA 01/11/2020 OJCharles Only pol conserved was sequenced A 1228 HSV2 Clinical isolate UL30 Q829R Resistant Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles A 1229 HSV2 Clinical isolate UL30 L850I 0.8 0.3 9.2 Characterization of the DNA Polymerase and Thymidine Kinase Genes of Herpes Simplex Virus Isolates from AIDS Patients in whom Acyclovir and Foscarnet Therapy Sequentially Failed https://academic.oup.com/jid/article/180/2/487/881212 doi.org/10.1086/314900 Isolated strain PRA 01/11/2020 OJCharles Only pol conserved was sequenced A 1230 HSV2 Clinical isolate UL30 M910T Resistant Polymorphism Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Isolated strain dye uptake assay 01/11/2020 OJCharles A 1231 HSV2 Clinical isolate UL30 D912N Resistant Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 01/11/2020 OJCharles does not list all mutations so cant infer backward! O 1232 HSV2 Clinical isolate UL30 D912V Resistant Polymorphism Resistant Characterization of the DNA Polymerase and Thymidine Kinase Genes of Herpes Simplex Virus Isolates from AIDS Patients in whom Acyclovir and Foscarnet Therapy Sequentially Failed https://academic.oup.com/jid/article/180/2/487/881212 doi.org/10.1086/314900 Isolated strain PRA TK 28* 01/11/2020 OJCharles Only pol conserved was sequenced A 1233 HSV2 Clinical isolate UL30 A915V Resistant Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 01/11/2020 OJCharles co occurs with unknown mut O 1234 VZV HJO ORF36 L73I 1.3 0.7 2.7 1 0.9 Drug Resistance of Clinical Varicella-Zoster Virus Strains Confirmed by Recombinant Thymidine Kinase Expression and by Targeted Resistance Mutagenesis of a Cloned Wild-Type Isolate https://aac.asm.org/content/aac/59/5/2726.full.pdf doi.org/10.1128/AAC.05115-14 Recombinant BAC PRA 01/12/2020 OJCharles A 1235 VZV HJO ORF36 A163* 5.7 0.9 0.2 133 10 Drug Resistance of Clinical Varicella-Zoster Virus Strains Confirmed by Recombinant Thymidine Kinase Expression and by Targeted Resistance Mutagenesis of a Cloned Wild-Type Isolate https://aac.asm.org/content/aac/59/5/2726.full.pdf doi.org/10.1128/AAC.05115-14 Recombinant BAC PRA 01/12/2020 OJCharles A 1236 VZV HJO ORF36 W225R 5.7 2.1 1.5 133 10 Drug Resistance of Clinical Varicella-Zoster Virus Strains Confirmed by Recombinant Thymidine Kinase Expression and by Targeted Resistance Mutagenesis of a Cloned Wild-Type Isolate https://aac.asm.org/content/aac/59/5/2726.full.pdf doi.org/10.1128/AAC.05115-14 Recombinant BAC PRA 01/12/2020 OJCharles A 1237 VZV HJO ORF36 T256M 5.7 0.3 0.8 133 10 Drug Resistance of Clinical Varicella-Zoster Virus Strains Confirmed by Recombinant Thymidine Kinase Expression and by Targeted Resistance Mutagenesis of a Cloned Wild-Type Isolate https://aac.asm.org/content/aac/59/5/2726.full.pdf doi.org/10.1128/AAC.05115-14 Recombinant BAC PRA 01/12/2020 OJCharles A 1238 VZV HJO ORF36 Q303* 5.7 0.4 0.9 133 10 Drug Resistance of Clinical Varicella-Zoster Virus Strains Confirmed by Recombinant Thymidine Kinase Expression and by Targeted Resistance Mutagenesis of a Cloned Wild-Type Isolate https://aac.asm.org/content/aac/59/5/2726.full.pdf doi.org/10.1128/AAC.05115-14 Recombinant BAC PRA Pol A955T 01/12/2020 OJCharles A 1239 VZV HJO ORF36 N334* 5.7 0.8 0.6 133 10 Drug Resistance of Clinical Varicella-Zoster Virus Strains Confirmed by Recombinant Thymidine Kinase Expression and by Targeted Resistance Mutagenesis of a Cloned Wild-Type Isolate https://aac.asm.org/content/aac/59/5/2726.full.pdf doi.org/10.1128/AAC.05115-14 Recombinant BAC PRA 01/12/2020 OJCharles A 1240 VZV HJO ORF36 del7-74 5.7 1.3 0.7 133 10 Drug Resistance of Clinical Varicella-Zoster Virus Strains Confirmed by Recombinant Thymidine Kinase Expression and by Targeted Resistance Mutagenesis of a Cloned Wild-Type Isolate https://aac.asm.org/content/aac/59/5/2726.full.pdf doi.org/10.1128/AAC.05115-14 Recombinant BAC PRA 01/12/2020 OJCharles A 1241 VZV HJO ORF28 T237K 1.1 3.4 2.9 133 1.1 Drug Resistance of Clinical Varicella-Zoster Virus Strains Confirmed by Recombinant Thymidine Kinase Expression and by Targeted Resistance Mutagenesis of a Cloned Wild-Type Isolate https://aac.asm.org/content/aac/59/5/2726.full.pdf doi.org/10.1128/AAC.05115-14 Recombinant BAC PRA 01/12/2020 OJCharles A 1242 VZV HJO ORF28 A955T 0.9 0.6 0.8 133 0.8 Drug Resistance of Clinical Varicella-Zoster Virus Strains Confirmed by Recombinant Thymidine Kinase Expression and by Targeted Resistance Mutagenesis of a Cloned Wild-Type Isolate https://aac.asm.org/content/aac/59/5/2726.full.pdf doi.org/10.1128/AAC.05115-14 Recombinant BAC PRA 01/12/2020 OJCharles A 1243 VZV Clinical isolate ORF36 L332P 5.8 Clinical and Virologic Characterization of Acyclovir-Resistant Varicella-Zoster Viruses Isolated from 11 Patients with Acquired Immunodeficiency Syndrome https://academic.oup.com/cid/article/33/12/2061/365806 doi.org/10.1086/324503 Isolated strain PRA 01/12/2020 OJCharles Cha/Oka A 1244 VZV Clinical isolate ORF36 R183* 12 Clinical and Virologic Characterization of Acyclovir-Resistant Varicella-Zoster Viruses Isolated from 11 Patients with Acquired Immunodeficiency Syndrome https://academic.oup.com/cid/article/33/12/2061/365806 doi.org/10.1086/324503 Isolated strain PRA 01/12/2020 OJCharles Cha/Oka A 1245 VZV Clinical isolate ORF36 E192* 14 1 36 12 In Vitro-Selected Drug-Resistant Varicella-Zoster Virus Mutants in the Thymidine Kinase and DNA Polymerase Genes Yield Novel Phenotype-Genotype Associations and Highlight Differences between Antiherpesvirus Drugs https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302250/ doi.org/10.1128/JVI.06620-11 Isolated strain PRA 12/01/2020 OJCharles Oka A 1246 VZV Clinical isolate ORF36 T86A 12 1 38 15 In Vitro-Selected Drug-Resistant Varicella-Zoster Virus Mutants in the Thymidine Kinase and DNA Polymerase Genes Yield Novel Phenotype-Genotype Associations and Highlight Differences between Antiherpesvirus Drugs https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302250/ doi.org/10.1128/JVI.06620-11 Isolated strain PRA 12/01/2020 OJCharles Oka A 1247 VZV Clinical isolate ORF36 G24R 15 1 40 13 In Vitro-Selected Drug-Resistant Varicella-Zoster Virus Mutants in the Thymidine Kinase and DNA Polymerase Genes Yield Novel Phenotype-Genotype Associations and Highlight Differences between Antiherpesvirus Drugs https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302250/ doi.org/10.1128/JVI.06620-11 Isolated strain PRA 12/01/2020 OJCharles Oka A 1248 VZV Clinical isolate ORF28 K662E 4 8 2 4 In Vitro-Selected Drug-Resistant Varicella-Zoster Virus Mutants in the Thymidine Kinase and DNA Polymerase Genes Yield Novel Phenotype-Genotype Associations and Highlight Differences between Antiherpesvirus Drugs https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302250/ doi.org/10.1128/JVI.06620-11 Isolated strain PRA 12/01/2020 OJCharles Oka A 1249 VZV Clinical isolate ORF28 V666L 9 8 1 8 In Vitro-Selected Drug-Resistant Varicella-Zoster Virus Mutants in the Thymidine Kinase and DNA Polymerase Genes Yield Novel Phenotype-Genotype Associations and Highlight Differences between Antiherpesvirus Drugs https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302250/ doi.org/10.1128/JVI.06620-11 Isolated strain PRA 12/01/2020 OJCharles Oka A 1250 VZV Clinical isolate ORF28 L767S 12 5 1 10 In Vitro-Selected Drug-Resistant Varicella-Zoster Virus Mutants in the Thymidine Kinase and DNA Polymerase Genes Yield Novel Phenotype-Genotype Associations and Highlight Differences between Antiherpesvirus Drugs https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302250/ doi.org/10.1128/JVI.06620-11 Isolated strain PRA 12/01/2020 OJCharles Oka A 1251 VZV Clinical isolate ORF28 D668Y 4 1 1 2 In Vitro-Selected Drug-Resistant Varicella-Zoster Virus Mutants in the Thymidine Kinase and DNA Polymerase Genes Yield Novel Phenotype-Genotype Associations and Highlight Differences between Antiherpesvirus Drugs https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302250/ doi.org/10.1128/JVI.06620-11 Isolated strain PRA 12/01/2020 OJCharles Oka A 1252 VZV Clinical isolate ORF28 D668Y 10 4 1 1.4 In Vitro-Selected Drug-Resistant Varicella-Zoster Virus Mutants in the Thymidine Kinase and DNA Polymerase Genes Yield Novel Phenotype-Genotype Associations and Highlight Differences between Antiherpesvirus Drugs https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302250/ doi.org/10.1128/JVI.06620-11 Isolated strain PRA pol M808V 12/01/2020 OJCharles Oka A 1253 VZV Clinical isolate ORF36 G24E 36 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Varicella-Zoster Viruses Isolated from Persons with AIDS https://academic.oup.com/jid/article/170/1/68/863472 doi.org/10.1093/infdis/170.1.68 Isolated strain PRA 12/01/2020 OJCharles Oka A 1254 VZV Clinical isolate ORF36 C231* 17.5 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Varicella-Zoster Viruses Isolated from Persons with AIDS https://academic.oup.com/jid/article/170/1/68/863472 doi.org/10.1093/infdis/170.1.68 Isolated strain PRA 12/01/2020 OJCharles Oka A 1255 VZV Clinical isolate ORF36 E308Q 1.2 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Varicella-Zoster Viruses Isolated from Persons with AIDS https://academic.oup.com/jid/article/170/1/68/863472 doi.org/10.1093/infdis/170.1.68 Isolated strain PRA 12/01/2020 OJCharles Oka A 1256 VZV Clinical isolate ORF36 I38* 37 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Varicella-Zoster Viruses Isolated from Persons with AIDS https://academic.oup.com/jid/article/170/1/68/863472 doi.org/10.1093/infdis/170.1.68 Isolated strain PRA 12/01/2020 OJCharles Oka A 1257 VZV Clinical isolate ORF36 V194* 19 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Varicella-Zoster Viruses Isolated from Persons with AIDS https://academic.oup.com/jid/article/170/1/68/863472 doi.org/10.1093/infdis/170.1.68 Isolated strain PRA 12/01/2020 OJCharles Oka A 1258 VZV Clinical isolate ORF36 L298* 20 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Varicella-Zoster Viruses Isolated from Persons with AIDS https://academic.oup.com/jid/article/170/1/68/863472 doi.org/10.1093/infdis/170.1.68 Isolated strain PRA 12/01/2020 OJCharles Oka A 1259 VZV Clinical isolate ORF36 R54* 21.3 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Varicella-Zoster Viruses Isolated from Persons with AIDS https://academic.oup.com/jid/article/170/1/68/863472 doi.org/10.1093/infdis/170.1.68 Isolated strain PRA 12/01/2020 OJCharles Oka A 1260 VZV Clinical isolate ORF36 V171* 23.8 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Varicella-Zoster Viruses Isolated from Persons with AIDS https://academic.oup.com/jid/article/170/1/68/863472 doi.org/10.1093/infdis/170.1.68 Isolated strain PRA 12/01/2020 OJCharles Oka A 1261 VZV Clinical isolate ORF36 V333* 11.3 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Varicella-Zoster Viruses Isolated from Persons with AIDS https://academic.oup.com/jid/article/170/1/68/863472 doi.org/10.1093/infdis/170.1.68 Isolated strain PRA 12/01/2020 OJCharles Oka A 1262 VZV Clinical isolate ORF36 C138R 16 15 Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS https://www.ncbi.nlm.nih.gov/pmc/articles/PMC237457/ doi.org/10.1128/jvi.67.2.1024-1033.1993 Isolated strain PRA TK S242F 12/01/2020 OJCharles Oka A 1263 VZV Clinical isolate ORF36 R143G 16 15 Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS https://www.ncbi.nlm.nih.gov/pmc/articles/PMC237457/ doi.org/10.1128/jvi.67.2.1024-1033.1993 Isolated strain PRA 12/01/2020 OJCharles Oka A 1264 VZV Clinical isolate ORF36 D129N 8.7 15 Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS https://www.ncbi.nlm.nih.gov/pmc/articles/PMC237457/ doi.org/10.1128/jvi.67.2.1024-1033.1993 Isolated strain PRA 12/01/2020 OJCharles Oka A 1265 VZV Clinical isolate ORF36 K25R 16 15 Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS https://www.ncbi.nlm.nih.gov/pmc/articles/PMC237457/ doi.org/10.1128/jvi.67.2.1024-1033.1993 Isolated strain PRA 12/01/2020 OJCharles Oka A 1266 VZV Clinical isolate ORF36 R143K 16 1.5 Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS https://www.ncbi.nlm.nih.gov/pmc/articles/PMC237457/ doi.org/10.1128/jvi.67.2.1024-1033.1993 Isolated strain PRA 12/01/2020 OJCharles Oka A 1267 VZV Clinical isolate ORF36 E59G 10 11 Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS https://www.ncbi.nlm.nih.gov/pmc/articles/PMC237457/ doi.org/10.1128/jvi.67.2.1024-1033.1993 Isolated strain PRA 12/01/2020 OJCharles Oka A 1268 VZV Clinical isolate ORF36 E48G 26 4.8 42 1.2 61 Phenotypic and Genetic Characterization of Thymidine Kinase from Clinical Strains of Varicella-Zoster Virus Resistant to Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC89493/ doi.org/10.1128/aac.43.10.2412 Isolated strain TK functional kinetic assay 12/01/2020 OJCharles Oka A 1269 VZV Clinical isolate ORF36 R130Q 5 Mutant Varicella-Zoster Virus Thymidine Kinase: Correlation of Clinical Resistance and Enzyme Impairment https://www.ncbi.nlm.nih.gov/pmc/articles/PMC250677 doi.org/10.1128/jvi.65.12.6407-6413.1991 Isolated strain TK functional kinetic assay 12/01/2020 OJCharles Oka A 1270 VZV Clinical isolate ORF36 L154P 38 Molecular Analysis of the Pyrimidine Deoxyribonucleoside Kinase Gene of Wild-type and Acyclovir-resistant Strains of Varicella-Zoster Virus https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-69-10-2585#tab2 doi.org/10.1099/0022-1317-69-10-2585 Isolated strain PRA 12/01/2020 OJCharles Oka A 1271 VZV Clinical isolate ORF36 T256A 19 1.2 1 6.7 ACYCLOVIR-RESISTANT CHRONIC VERRUCOUS VACCINE STRAIN VARICELLA IN A PATIENT WITH NEUROBLASTOMA https://journals.lww.com/pidj/Fulltext/2008/10000/ACYCLOVIR_RESISTANT_CHRONIC_VERRUCOUS_VACCINE.24.aspx doi.org/10.1097/INF.0b013e318175d85c Isolated strain PRA 12/01/2020 OJCharles Oka A 1272 VZV Clinical isolate ORF36 S51L 1.5 2 0.7 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1273 VZV Clinical isolate ORF36 N119D 2 1.2 0.92 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1274 VZV Clinical isolate ORF36 V194A 1 1.2 0.5 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1275 VZV Clinical isolate ORF28 T39A 1 1.2 1.5 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1276 VZV Clinical isolate ORF28 M201I 1 0.8 1.1 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1277 VZV Clinical isolate ORF28 M201I 1.5 1.2 1.8 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1278 VZV Clinical isolate ORF28 G218D 1.6 1 1.9 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1279 VZV Clinical isolate ORF28 S386A 2 1 0.9 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1280 VZV Clinical isolate ORF28 S386A 2.6 1.2 1.5 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1281 VZV Clinical isolate ORF28 Q402P 1.1 1.2 1.9 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1282 VZV Clinical isolate ORF28 T417I 2 1.2 2.5 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1283 VZV Clinical isolate ORF28 G723R 1.1 1.2 1.5 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1284 VZV Clinical isolate ORF28 R753K 1.1 1.2 1.5 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1285 VZV Clinical isolate ORF28 V777I 0.7 1.2 1.4 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1286 VZV Clinical isolate ORF28 R950C 1.2 1.2 1.3 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1287 VZV Clinical isolate ORF28 T1066S 1.9 0.8 2 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1288 VZV Clinical isolate ORF28 R1076C 1.1 1.5 1.6 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1289 VZV Clinical isolate ORF28 C1185Y 2.9 1.8 2 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 12/01/2020 OJCharles Oka A 1290 VZV Clinical isolate ORF28 G186C Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Complementary assays for monitoring susceptibility of varicella-zoster virus resistance to antivirals https://www.sciencedirect.com/science/article/pii/S0166093416300787 doi.org/10.1016/j.jviromet.2016.03.006 Isolated strain PRA 12/01/2020 OJCharles Oka A 1291 VZV Clinical isolate ORF28 S863G Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Complementary assays for monitoring susceptibility of varicella-zoster virus resistance to antivirals https://www.sciencedirect.com/science/article/pii/S0166093416300787 doi.org/10.1016/j.jviromet.2016.03.006 Isolated strain PRA 12/01/2020 OJCharles Oka A 1292 VZV Clinical isolate ORF28 C1159R Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Complementary assays for monitoring susceptibility of varicella-zoster virus resistance to antivirals https://www.sciencedirect.com/science/article/pii/S0166093416300787 doi.org/10.1016/j.jviromet.2016.03.006 Isolated strain PRA 12/01/2020 OJCharles Oka A 1293 VZV Clinical isolate ORF28 I3L 0.9 Complementary assays for monitoring susceptibility of varicella-zoster virus resistance to antivirals https://www.sciencedirect.com/science/article/pii/S0166093416300787 doi.org/10.1016/j.jviromet.2016.03.006 Isolated strain PRA 12/01/2020 OJCharles Oka A 1294 VZV Clinical isolate ORF28 V638I 0.6 Complementary assays for monitoring susceptibility of varicella-zoster virus resistance to antivirals https://www.sciencedirect.com/science/article/pii/S0166093416300787 doi.org/10.1016/j.jviromet.2016.03.006 Isolated strain PRA 12/01/2020 OJCharles Oka A 1295 VZV Clinical isolate ORF36 R143G 14 Complementary assays for monitoring susceptibility of varicella-zoster virus resistance to antivirals https://www.sciencedirect.com/science/article/pii/S0166093416300787 doi.org/10.1016/j.jviromet.2016.03.006 Isolated strain PRA 12/01/2020 OJCharles Oka A 1296 HSV1 UL30 L802F 2.4 2.2 2.2 0.9 2.8 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1297 HSV1 UL30 Q618H 3.4 0.6 1 0.3 2.9 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1298 HSV1 UL30 A605V 6.1 1.6 6.7 0.2 1.2 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1299 HSV1 UL30 A719V 7 0.7 3.6 0.5 2.8 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1300 HSV1 UL30 A719T 5.4 1 2.1 1 1.4 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1301 HSV1 UL30 S724N 4.1 2.8 3.1 0.4 6.6 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1302 HSV1 UL30 S724N 8.6 2.6 4.9 0.2 2.3 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1303 HSV1 UL30 N815S 77.8 2.2 2.2 0.9 2.8 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1304 HSV1 UL30 T821M 3.3 1.5 2.6 1 2.9 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1305 HSV1 UL30 R959H 3.3 1.8 3.5 1 2.6 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1306 HSV2 UL30 K533E 3.8 1.4 4.2 2.5 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1307 HSV2 UL30 A606V 6.2 1.7 6.2 2.6 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1308 HSV2 UL30 C625R 3.3 1.4 4.4 3.4 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1309 HSV2 UL30 R628C 2 1.3 2.5 2.2 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1310 HSV2 UL30 R628C 2 1.2 2.4 1.8 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1311 HSV2 UL30 A724V 3.6 1 2.7 1.6 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1312 HSV2 UL30 S725G 2.7 0.7 4 1.7 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1313 HSV2 UL30 S729N 6.9 1.6 6.9 3.8 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1314 HSV2 UL30 I731F 2.9 2.3 6 1.7 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1315 HSV2 UL30 Q732R 3.8 1.8 4.1 2.7 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1316 HSV2 UL30 M789T 3.3 1.4 3.2 2.7 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1317 HSV2 UL30 M789K 3.4 1.6 3.3 2.7 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1318 HSV2 UL30 V818A 4.6 1.1 5.1 2.8 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1319 HSV2 UL30 N820S 68 1 0.2 5.9 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1320 HSV2 UL30 Y823C 3.4 1.3 2 1.6 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1321 HSV2 UL30 R847C 6.6 1.6 6.1 2.4 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1322 HSV2 UL30 F923L 7.5 1.4 4.7 3.2 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1323 HSV2 UL30 T934A 5 1.1 5.4 2.8 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1324 HSV2 UL30 R964H 4.9 1 4.8 1.2 The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase https://academic.oup.com/jid/article/217/5/790/4653578 doi.org/10.1093/infdis/jix605 Marker Transfer PRA 04/02/2021 OJCharles A 1325 HSV2 Clinical isolate UL23 G39E 25.6 0.66 100 Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2 https://pubmed.ncbi.nlm.nih.gov/22155911/ doi.org/10.3851/IMP1870 Isolated strain dye uptake assay 04/02/2021 OJCharles Ambigious O 1326 HSV2 Clinical isolate UL30 L60P Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 14/01/2021 OJCharles A 1327 HSV2 Clinical isolate UL30 G906A Polymorphism Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354203002122#TBL6 doi.org/10.1016/j.antiviral.2003.08.018 Isolated strain PRA 14/01/2021 OJCharles A 1328 HSV1 UL23 R41H 1 2.3 1 1.1 Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility https://www.nature.com/articles/srep29903 doi.org/10.1038/srep29903 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1329 HSV1 UL23 G61A 46 2.9 60 27 Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility https://www.nature.com/articles/srep29903 doi.org/10.1038/srep29903 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1330 HSV1 UL23 P84L 95 4.4 225 8.9 Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility https://www.nature.com/articles/srep29903 doi.org/10.1038/srep29903 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1331 HSV1 UL23 R106H 1 3.1 1 1 Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility https://www.nature.com/articles/srep29903 doi.org/10.1038/srep29903 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1332 HSV1 UL23 A118V 1 4.8 1 1 Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility https://www.nature.com/articles/srep29903 doi.org/10.1038/srep29903 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1333 HSV1 UL23 L139V 1 1.2 1 0.5 Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility https://www.nature.com/articles/srep29903 doi.org/10.1038/srep29903 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1334 HSV1 UL23 K219T 1 1.6 1 0.8 Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility https://www.nature.com/articles/srep29903 doi.org/10.1038/srep29903 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1335 HSV1 UL23 S276R 1 3.8 1 0.9 Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility https://www.nature.com/articles/srep29903 doi.org/10.1038/srep29903 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1336 HSV1 UL23 L298R 1 2.5 1 1.1 Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility https://www.nature.com/articles/srep29903 doi.org/10.1038/srep29903 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1337 HSV1 UL23 S345P 1 1.7 1 0.7 Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility https://www.nature.com/articles/srep29903 doi.org/10.1038/srep29903 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1338 HSV1 UL23 V238I 1 1.6 1 1 Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility https://www.nature.com/articles/srep29903 doi.org/10.1038/srep29903 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1339 HSV2 MS UL23 G25A 1.1 0.3 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC PRA 04/02/2021 OJCharles A 1340 HSV2 MS UL23 G39E 0.7 0.5 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC PRA 04/02/2021 OJCharles A 1341 HSV2 MS UL23 Y53N 13 6.8 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC PRA 04/02/2021 OJCharles A 1342 HSV2 MS UL23 T131M 1.5 1.2 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC PRA 04/02/2021 OJCharles A 1343 HSV2 MS UL23 Y133F 0.4 1.2 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC PRA 04/02/2021 OJCharles A 1344 HSV2 MS UL23 G150D 0.7 0.3 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC PRA 04/02/2021 OJCharles A 1345 HSV2 MS UL23 A157T 0.5 0.3 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC PRA 04/02/2021 OJCharles A 1346 HSV2 MS UL23 R221H 12.9 7.8 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC PRA 04/02/2021 OJCharles A 1347 HSV2 MS UL23 R248W 0.9 1.3 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC PRA 04/02/2021 OJCharles A 1348 HSV2 MS UL23 L342W 0.3 1.3 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC PRA 04/02/2021 OJCharles A 1349 HSV2 MS UL23 G25A 1.8 2.4 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1350 HSV2 MS UL23 G39E 1.8 2.4 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1351 HSV2 MS UL23 Y53N 24.1 7.8 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1352 HSV2 MS UL23 T131M 0.2 1.4 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1353 HSV2 MS UL23 Y133F 0.6 2.5 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1354 HSV2 MS UL23 G150D 0.6 2 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1355 HSV2 MS UL23 A157T 0.5 1.7 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1356 HSV2 MS UL23 R221H 24.1 4.7 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1357 HSV2 MS UL23 R248W 1.9 2.3 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1358 HSV2 MS UL23 L342W 0.6 2 Relevance of non-synonymous thymidine kinase mutations for antiviral resistance of recombinant herpes simplex virus type 2 strains https://www.sciencedirect.com/science/article/pii/S0166354217307490 doi.org/10.1016/j.antiviral.2018.02.004 Recombinant BAC dye uptake assay 04/02/2021 OJCharles A 1359 HSV1 HSV1-17 UL30 P561S 0.85 1.48 0.91 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1360 HSV1 HSV1-17 UL30 V573M 1.9 1.16 0.87 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1361 HSV1 HSV1-17 UL30 R700M 0.98 3.67 0.14 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1362 HSV1 HSV1-17 UL30 V715M 2.86 0.35 0.81 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1363 HSV1 HSV1-17 UL30 A719T 5.94 1.85 2.18 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1364 HSV1 HSV1-17 UL30 S724N 9.87 2.05 2.69 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1365 HSV1 HSV1-17 UL30 L778M 5.53 2.04 2.03 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1366 HSV1 HSV1-17 UL30 D780N 6.1 1.21 2.17 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1367 HSV1 HSV1-17 UL30 L782I 6.43 1.76 2.29 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1368 HSV1 HSV1-17 UL30 K805Q 0.64 1.82 0.34 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1369 HSV1 HSV1-17 UL30 T821M 6.25 2.11 1.48 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1370 HSV1 HSV1-17 UL30 L846I 1.52 1.26 0.7 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1371 HSV1 HSV1-17 UL30 F891C 34.99 1.74 3.91 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1372 HSV1 HSV1-17 UL30 D907V 3.78 1.59 2.27 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1373 HSV1 HSV1-17 UL30 P920S 1.05 0.65 0.73 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1374 HSV1 HSV1-17 UL30 Y941H 9.39 0.39 1.38 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1375 HSV1 HSV1-17 UL30 N961K 5.34 1.41 0.83 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1376 HSV1 HSV1-17 UL30 L1007M 1.84 1.22 0.59 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1377 HSV1 HSV1-17 UL30 I1028T 1.74 2.28 0.58 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1378 HSV1 HSV1-17 UL30 S724N 11.61 2.38 2.53 Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids https://www.ncbi.nlm.nih.gov/pmc/articles/PMC161916/ doi.org/10.1128/JVI.77.14.7820-7829.2003 Marker Transfer PRA 04/02/2021 OJCharles HSV1-17 A 1379 HSV2 Clinical isolate UL23 G59P 61 Highly Reliable Heterologous System for Evaluating Resistance of Clinical Herpes Simplex Virus Isolates to Nucleoside Analogues https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114104/ doi.org/10.1128/JVI.75.7.3105-3110.2001 Isolated strain PRA 04/02/2021 OJCharles A 1380 VZV Clinical isolate ORF36 S179N 1 1.4 0.7 1 Phenotypic and Genetic Characterization of Thymidine Kinase from Clinical Strains of Varicella-Zoster Virus Resistant to Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC89493/ doi.org/10.1128/aac.43.10.2412 Isolated strain TK functional kinetic assay 04/02/2021 OJCharles Oka A 1381 HSV1 UL23 R51W 10 Herpes Simplex Virus Thymidine Kinase Mutations Associated with Resistance to Acyclovir: a Site-Directed Mutagenesis Study https://aac.asm.org/content/aac/49/3/1055.full.pdf doi.org/10.1128/AAC.49.3.1055-1059.2005 Marker Transfer TK functional kinetic assay 04/02/2021 OJCharles inferred fc A 1382 HSV1 UL23 E83K 10 Herpes Simplex Virus Thymidine Kinase Mutations Associated with Resistance to Acyclovir: a Site-Directed Mutagenesis Study https://aac.asm.org/content/aac/49/3/1055.full.pdf doi.org/10.1128/AAC.49.3.1055-1059.2005 Marker Transfer TK functional kinetic assay 04/02/2021 OJCharles inferred fc A 1383 HSV1 UL23 A175V 10 Herpes Simplex Virus Thymidine Kinase Mutations Associated with Resistance to Acyclovir: a Site-Directed Mutagenesis Study https://aac.asm.org/content/aac/49/3/1055.full.pdf doi.org/10.1128/AAC.49.3.1055-1059.2005 Marker Transfer TK functional kinetic assay 04/02/2021 OJCharles inferred fc A 1384 HSV1 UL23 D77N Polymorphism Herpes Simplex Virus Thymidine Kinase Mutations Associated with Resistance to Acyclovir: a Site-Directed Mutagenesis Study https://aac.asm.org/content/aac/49/3/1055.full.pdf doi.org/10.1128/AAC.49.3.1055-1059.2005 Marker Transfer TK functional kinetic assay 04/02/2021 OJCharles A 1385 Adeno ad5 pol L883S trust Resistant Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir https://www.sciencedirect.com/science/article/pii/S0166354202000980 doi.org/10.1016/S0166-3542(02)00098-0 Isolated strain PRA 04/02/2021 OJCharles L741S originally A 1386 Adeno ad5 pol S1183R Resistant Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir https://www.sciencedirect.com/science/article/pii/S0166354202000980 doi.org/10.1016/S0166-3542(02)00098-0 Isolated strain PRA pol L883S 04/02/2021 OJCharles co-occuring uncharacterised mutations S1041R O 1387 Adeno ad5 pol F882I Resistant Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir https://www.sciencedirect.com/science/article/pii/S0166354202000980 doi.org/10.1016/S0166-3542(02)00098-0 Isolated strain PRA pol V180I 04/02/2021 OJCharles co-occuring uncharacterised mutations - oringally F740I O 1388 Adeno ad5 pol V180I Resistant Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir https://www.sciencedirect.com/science/article/pii/S0166354202000980 doi.org/10.1016/S0166-3542(02)00098-0 Isolated strain PRA pol F882I 04/02/2021 OJCharles co-occuring uncharacterised mutations - and cannot find homolog in the refseq O 1389 Adeno ad5 pol A501E trust 4.6 Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir https://www.sciencedirect.com/science/article/pii/S0166354202000980 doi.org/10.1016/S0166-3542(02)00098-0 Isolated strain PRA 04/02/2021 OJCharles originally A359E A 1390 Adeno ad5 pol L554F Resistant Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir https://www.sciencedirect.com/science/article/pii/S0166354202000980 doi.org/10.1016/S0166-3542(02)00098-0 Isolated strain PRA pol A501E,V817L 04/02/2021 OJCharles co-occuring uncharacterised mutations - cannot find refseq homolog O 1391 Adeno ad5 pol V817L Resistant Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir https://www.sciencedirect.com/science/article/pii/S0166354202000980 doi.org/10.1016/S0166-3542(02)00098-0 Isolated strain PRA pol A501E, L554F 04/02/2021 OJCharles co-occuring uncharacterised mutations O 1392 Adeno ad5 pol T87I 1.9 2.1 Cidofovir Diphosphate Inhibits Adenovirus 5 DNA Polymerase via both Nonobligate Chain Termination and Direct Inhibition, and Polymerase Mutations Confer Cidofovir Resistance on Intact Virus https://aac.asm.org/content/aac/63/1/e01925-18.full.pdf doi.org/10.1128/AAC.01925-18. Lab induced strain pol V303I 04/02/2021 OJCharles co-occuring uncharacterised mutations O 1393 Adeno ad5 pol M689V nucleotide generic 4 4 4 Selective Modification of Adenovirus Replication Can Be Achieved through Rational Mutagenesis of the Adenovirus Type 5 DNA Polymerase https://jvi.asm.org/content/jvi/86/19/10484.full.pdf doi.org/10.1128/JVI.00739-12 Marker Transfer TK functional kinetic assay 04/02/2021 OJCharles this is not resistance data O 1394 Adeno ad5 pol C687S nucleotide generic 4 4 4 Selective Modification of Adenovirus Replication Can Be Achieved through Rational Mutagenesis of the Adenovirus Type 5 DNA Polymerase https://jvi.asm.org/content/jvi/86/19/10484.full.pdf doi.org/10.1128/JVI.00739-12 Marker Transfer TK functional kinetic assay 04/02/2021 OJCharles this is not resistance data O 1395 Adeno ad5 pol R665K nucleotide generic 4 4 4 Selective Modification of Adenovirus Replication Can Be Achieved through Rational Mutagenesis of the Adenovirus Type 5 DNA Polymerase https://jvi.asm.org/content/jvi/86/19/10484.full.pdf doi.org/10.1128/JVI.00739-12 Marker Transfer TK functional kinetic assay 04/02/2021 OJCharles this is not resistance data O 1396 Adeno ad5 pol I664V nucleotide generic 2.5 2.5 2.5 Selective Modification of Adenovirus Replication Can Be Achieved through Rational Mutagenesis of the Adenovirus Type 5 DNA Polymerase https://jvi.asm.org/content/jvi/86/19/10484.full.pdf doi.org/10.1128/JVI.00739-12 Marker Transfer TK functional kinetic assay 04/02/2021 OJCharles this is not resistance data - Don’t trust this it was not repruceable between cell lines O 1397 Adeno ad5 pol I664M nucleotide generic 1.7 1.7 1.7 Selective Modification of Adenovirus Replication Can Be Achieved through Rational Mutagenesis of the Adenovirus Type 5 DNA Polymerase https://jvi.asm.org/content/jvi/86/19/10484.full.pdf doi.org/10.1128/JVI.00739-12 Marker Transfer TK functional kinetic assay 04/02/2021 OJCharles this is not resistance data O 1398 HSV1 UL23 E83K 37 71 Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1 https://www.sciencedirect.com/science/article/pii/S0166354206000313 doi.org/10.1016/j.antiviral.2006.01.010 Marker Transfer TK functional kinetic assay 29/01/2021 OJCharles A 1399 HSV1 UL23 A189V 48 6.8 Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1 https://www.sciencedirect.com/science/article/pii/S0166354206000313 doi.org/10.1016/j.antiviral.2006.01.010 Marker Transfer TK functional kinetic assay 29/01/2021 OJCharles A 1400 HSV1 UL23 R216C 37 21 Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1 https://www.sciencedirect.com/science/article/pii/S0166354206000313 doi.org/10.1016/j.antiviral.2006.01.010 Marker Transfer TK functional kinetic assay 29/01/2021 OJCharles A 1401 HSV1 UL23 R163H 42 10 Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1 https://www.sciencedirect.com/science/article/pii/S0166354206000313 doi.org/10.1016/j.antiviral.2006.01.010 Marker Transfer TK functional kinetic assay 29/01/2021 OJCharles A 1402 HSV1 Clinical isolate UL23 P57H 42 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain dye uptake assay 04/02/2021 OJCharles A2 A 1403 HSV1 Clinical isolate UL23 K62N 12 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain PCR DNA hybridization assay 04/02/2021 OJCharles A2 A 1404 HSV1 Clinical isolate UL23 K62N 21 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain dye uptake assay 04/02/2021 OJCharles A2 A 1405 HSV1 Clinical isolate UL23 K62N 34 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain dye uptake assay 04/02/2021 OJCharles A2 A 1406 HSV1 Clinical isolate UL23 T63I 11 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain dye uptake assay 04/02/2021 OJCharles A2 A 1407 HSV1 Clinical isolate UL23 D228* 36 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain dye uptake assay 04/02/2021 OJCharles A2 A 1408 HSV1 Clinical isolate UL23 D228* 24 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain PCR DNA hybridization assay 04/02/2021 OJCharles A2 A 1409 HSV2 Clinical isolate UL23 T131P 25 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain dye uptake assay 04/02/2021 OJCharles A2 A 1410 HSV1 Clinical isolate UL23 T201P 22 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain dye uptake assay 04/02/2021 OJCharles A2 A 1411 HSV1 Clinical isolate UL23 R216C 16 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain PCR DNA hybridization assay 04/02/2021 OJCharles A2 A 1412 HSV1 Clinical isolate UL23 R216C 27 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain dye uptake assay 04/02/2021 OJCharles A2 A 1413 HSV1 Clinical isolate UL23 R222C 7.1 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain PCR DNA hybridization assay 04/02/2021 OJCharles A2 A 1414 HSV1 Clinical isolate UL23 R222C 9.8 Phenotypic and Genotypic Characterization of Acyclovir-Resistant Herpes Simplex Viruses from Immunocompromised Patients https://academic.oup.com/jid/article/178/2/297/904713 doi.org/10.1086/515626 Isolated strain dye uptake assay 04/02/2021 OJCharles A2 A 1415 HSV1 Clinical isolate UL23 A156T Polymorphism Polymorphism Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 07/01/2021 OJCharles mutations not resolved by sequence MacIntyre A 1416 HSV1 Clinical isolate UL23 C336Y 14 Highly Reliable Heterologous System for Evaluating Resistance of Clinical Herpes Simplex Virus Isolates to Nucleoside Analogues https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114104/ doi.org/10.1128/JVI.75.7.3105-3110.2001 Isolated strain PRA 04/02/2021 OJCharles A 1417 HSV1 Clinical isolate UL23 R222C 25 Highly Reliable Heterologous System for Evaluating Resistance of Clinical Herpes Simplex Virus Isolates to Nucleoside Analogues https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114104/ doi.org/10.1128/JVI.75.7.3105-3110.2001 Isolated strain PRA 04/02/2021 OJCharles A 1418 HSV2 Clinical isolate UL23 T131P 21 Highly Reliable Heterologous System for Evaluating Resistance of Clinical Herpes Simplex Virus Isolates to Nucleoside Analogues https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114104/ doi.org/10.1128/JVI.75.7.3105-3110.2001 Isolated strain PRA 04/02/2021 OJCharles A 1419 HSV1 Clinical isolate UL23 R176Q 8.9 Highly Reliable Heterologous System for Evaluating Resistance of Clinical Herpes Simplex Virus Isolates to Nucleoside Analogues https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114104/ doi.org/10.1128/JVI.75.7.3105-3110.2001 Isolated strain PRA 04/02/2021 OJCharles A 1420 HSV1 Clinical isolate UL23 Y172C Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain indirect ELISA 04/02/2021 OJCharles A 1421 HSV1 Clinical isolate UL23 L315S Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain indirect ELISA 04/02/2021 OJCharles A 1422 HSV1 Clinical isolate UL23 A174P Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain indirect ELISA 04/02/2021 OJCharles A 1423 HSV1 Clinical isolate UL23 Y53C Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain indirect ELISA 04/02/2021 OJCharles A 1424 HSV1 Clinical isolate UL23 E83N Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain indirect ELISA 04/02/2021 OJCharles assumed typo in wt aa not position was Y83N A 1425 HSV1 Clinical isolate UL23 T245M Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain indirect ELISA 04/02/2021 OJCharles A 1426 HSV1 Clinical isolate UL23 L208H Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain indirect ELISA 04/02/2021 OJCharles A 1427 HSV1 Clinical isolate UL23 A156V Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain indirect ELISA 04/02/2021 OJCharles A 1428 HSV1 Clinical isolate UL23 V348I Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain indirect ELISA 04/02/2021 OJCharles A 1429 HSV1 Clinical isolate UL23 M121R Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain indirect ELISA 04/02/2021 OJCharles A 1430 HSV1 Clinical isolate UL23 G200C Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain indirect ELISA 04/02/2021 OJCharles A 1431 HSV1 Clinical isolate UL23 T103P Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain indirect ELISA 04/02/2021 OJCharles A 1432 HSV1 Clinical isolate UL23 T287M Resistant Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum assay https://www.sciencedirect.com/science/article/pii/S0166093412004351 doi.org/10.1016/j.jviromet.2012.12.001 Isolated strain indirect ELISA 04/02/2021 OJCharles A 1433 HSV1 AB047358 UL23 T65N 4.7 Association between sensitivity of viral thymidine kinase-associated acyclovir-resistant herpes simplex virus type 1 and virulence https://virologyj.biomedcentral.com/articles/10.1186/s12985-017-0728-2 doi.org/10.1186/s12985-017-0728-2 Marker Transfer PRA 04/02/2021 OJCharles A 1434 HSV1 AB047358 UL23 P84S 10 Association between sensitivity of viral thymidine kinase-associated acyclovir-resistant herpes simplex virus type 1 and virulence https://virologyj.biomedcentral.com/articles/10.1186/s12985-017-0728-2 doi.org/10.1186/s12985-017-0728-2 Marker Transfer PRA 04/02/2021 OJCharles A 1435 HSV1 AB047358 UL23 T245M 6.5 Association between sensitivity of viral thymidine kinase-associated acyclovir-resistant herpes simplex virus type 1 and virulence https://virologyj.biomedcentral.com/articles/10.1186/s12985-017-0728-2 doi.org/10.1186/s12985-017-0728-2 Marker Transfer PRA 04/02/2021 OJCharles A 1436 HSV1 AB047358 UL23 C336Y 4.7 Association between sensitivity of viral thymidine kinase-associated acyclovir-resistant herpes simplex virus type 1 and virulence https://virologyj.biomedcentral.com/articles/10.1186/s12985-017-0728-2 doi.org/10.1186/s12985-017-0728-2 Marker Transfer PRA 04/02/2021 OJCharles A 1437 HSV1 Clinical isolate UL23 H105P 131 0.8 Rapid susceptibility testing for herpes simplex virus type 1 using real-time PCR https://www.sciencedirect.com/science/article/pii/S1386653212003502 doi.org/10.1016/j.jcv.2012.09.004 Isolated strain PRA 04/02/2021 OJCharles A 1438 HSV1 Clinical isolate UL30 S724N 72 4 Rapid susceptibility testing for herpes simplex virus type 1 using real-time PCR https://www.sciencedirect.com/science/article/pii/S1386653212003502 doi.org/10.1016/j.jcv.2012.09.004 Isolated strain PRA 04/02/2021 OJCharles A 1439 HSV1 Clinical isolate UL23 N376H Polymorphism Acyclovir Susceptibility and Genetic Characteristics of Sequential Herpes Simplex Virus Type 1 Corneal Isolates from Patients with Recurrent Herpetic Keratitis https://academic.oup.com/jid/article/200/9/1402/851413 doi.org/10.1086/606028 Isolated strain PCR DNA hybridization assay 04/02/2021 OJCharles Only sequences TK, so any Pol mutations are unnacounted for KOS A 1440 HSV1 Clinical isolate UL23 L170P Resistant Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes https://www.sciencedirect.com/science/article/pii/S0166354214000898 doi.org/10.1016/j.antiviral.2014.03.015 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1441 HSV1 Clinical isolate UL23 R89Q Polymorphism Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients https://www.sciencedirect.com/science/article/pii/S1386653213001157 doi.org/10.1016/j.jcv.2013.03.014 Isolated strain TK functional kinetic assay 04/02/2021 OJCharles co-ocurs with 138vi and 322ml which are polymorphisms KOS A 1442 HSV1 Clinical isolate UL23 V138I Polymorphism Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients https://www.sciencedirect.com/science/article/pii/S1386653213001157 doi.org/10.1016/j.jcv.2013.03.014 Isolated strain TK functional kinetic assay 04/02/2021 OJCharles KOS A 1443 HSV1 Clinical isolate UL23 G240E Polymorphism Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients https://www.sciencedirect.com/science/article/pii/S1386653213001157 doi.org/10.1016/j.jcv.2013.03.014 Isolated strain TK functional kinetic assay 04/02/2021 OJCharles KOS A 1444 HSV1 Clinical isolate UL23 S345P Polymorphism Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients https://www.sciencedirect.com/science/article/pii/S1386653213001157 doi.org/10.1016/j.jcv.2013.03.014 Isolated strain TK functional kinetic assay 04/02/2021 OJCharles KOS A 1445 HSV1 Clinical isolate UL23 D162N Resistant Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients https://www.sciencedirect.com/science/article/pii/S1386653213001157 doi.org/10.1016/j.jcv.2013.03.014 Isolated strain TK functional kinetic assay 04/02/2021 OJCharles KOS A 1446 HSV1 Clinical isolate UL23 P173L Resistant Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients https://www.sciencedirect.com/science/article/pii/S1386653213001157 doi.org/10.1016/j.jcv.2013.03.014 Isolated strain TK functional kinetic assay 04/02/2021 OJCharles many co occuring mutations KOS O 1447 HSV1 Clinical isolate UL23 M182* Resistant Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients https://www.sciencedirect.com/science/article/pii/S1386653213001157 doi.org/10.1016/j.jcv.2013.03.014 Isolated strain TK functional kinetic assay 04/02/2021 OJCharles KOS A 1448 HSV1 Clinical isolate UL23 R216H Resistant Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients https://www.sciencedirect.com/science/article/pii/S1386653213001157 doi.org/10.1016/j.jcv.2013.03.014 Isolated strain TK functional kinetic assay 04/02/2021 OJCharles KOS A 1449 HSV1 Clinical isolate UL23 R220H Resistant Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients https://www.sciencedirect.com/science/article/pii/S1386653213001157 doi.org/10.1016/j.jcv.2013.03.014 Isolated strain TK functional kinetic assay 04/02/2021 OJCharles KOS A 1450 HSV1 UL30 Y818C 50 2.3 2.3 0.8 2.9 Characterization of DNA Polymerase-Associated Acyclovir-Resistant Herpes Simplex Virus Type 1: Mutations, Sensitivity to Antiviral Compounds, Neurovirulence, and In-Vivo Sensitivity to Treatment https://www.jstage.jst.go.jp/article/yoken/66/5/66_404/_pdf/-char/en doi.org/10.7883/yoken.66.404 Lab induced strain PRA 04/02/2021 OJCharles A 1451 HSV1 UL30 N815S 600 0.5 2.3 2.5 2.9 Characterization of DNA Polymerase-Associated Acyclovir-Resistant Herpes Simplex Virus Type 1: Mutations, Sensitivity to Antiviral Compounds, Neurovirulence, and In-Vivo Sensitivity to Treatment https://www.jstage.jst.go.jp/article/yoken/66/5/66_404/_pdf/-char/en doi.org/10.7883/yoken.66.404 Lab induced strain PRA 04/02/2021 OJCharles A 1452 HSV1 UL30 V817M 36 0.8 2.3 0.8 1.5 Characterization of DNA Polymerase-Associated Acyclovir-Resistant Herpes Simplex Virus Type 1: Mutations, Sensitivity to Antiviral Compounds, Neurovirulence, and In-Vivo Sensitivity to Treatment https://www.jstage.jst.go.jp/article/yoken/66/5/66_404/_pdf/-char/en doi.org/10.7883/yoken.66.404 Lab induced strain PRA 04/02/2021 OJCharles A 1453 HSV1 UL30 G841C 24 1 2.3 0.3 1.4 Characterization of DNA Polymerase-Associated Acyclovir-Resistant Herpes Simplex Virus Type 1: Mutations, Sensitivity to Antiviral Compounds, Neurovirulence, and In-Vivo Sensitivity to Treatment https://www.jstage.jst.go.jp/article/yoken/66/5/66_404/_pdf/-char/en doi.org/10.7883/yoken.66.404 Lab induced strain PRA 04/02/2021 OJCharles A 1454 HSV1 UL30 L702H 56 0.5 2.3 0.5 1.2 Characterization of DNA Polymerase-Associated Acyclovir-Resistant Herpes Simplex Virus Type 1: Mutations, Sensitivity to Antiviral Compounds, Neurovirulence, and In-Vivo Sensitivity to Treatment https://www.jstage.jst.go.jp/article/yoken/66/5/66_404/_pdf/-char/en doi.org/10.7883/yoken.66.404 Lab induced strain PRA 04/02/2021 OJCharles A 1455 HSV1 Clinical isolate UL23 P268T Polymorphism Genetic Characterization of Thymidine Kinase from Acyclovir-Resistant and -Susceptible Herpes Simplex Virus Type 1 Isolated from Bone Marrow Transplant Recipients https://academic.oup.com/jid/article/182/1/290/883239 doi.org/10.1086/315696 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1456 HSV1 Clinical isolate UL23 D286E Polymorphism Genetic Characterization of Thymidine Kinase from Acyclovir-Resistant and -Susceptible Herpes Simplex Virus Type 1 Isolated from Bone Marrow Transplant Recipients https://academic.oup.com/jid/article/182/1/290/883239 doi.org/10.1086/315696 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1457 HSV1 Clinical isolate UL23 N376H Polymorphism Genetic Characterization of Thymidine Kinase from Acyclovir-Resistant and -Susceptible Herpes Simplex Virus Type 1 Isolated from Bone Marrow Transplant Recipients https://academic.oup.com/jid/article/182/1/290/883239 doi.org/10.1086/315696 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1458 HSV1 Clinical isolate UL23 N376H Polymorphism Genetic Characterization of Thymidine Kinase from Acyclovir-Resistant and -Susceptible Herpes Simplex Virus Type 1 Isolated from Bone Marrow Transplant Recipients https://academic.oup.com/jid/article/182/1/290/883239 doi.org/10.1086/315696 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1459 HSV1 UL30 R881G 1.3 1 Resistance to Antiviral Inhibitors Caused by the Mutation S889A in the Highly-Conserved 885-GDTDS Motif of the Herpes Simplex Virus Type 1 DNA Polymerase https://www.sciencedirect.com/science/article/pii/S004268228371439X doi.org/10.1006/viro.1993.1439 Marker transfer PCR DNA hybridization assay 04/02/2021 OJCharles A 1460 HSV1 KOS UL23 R51W Resistant Polymorphism Polymorphism Resistant Characterization of Herpes Simplex Virus Type 1 Thymidine Kinase Mutants Selected under a Single Round of High-Dose Brivudin https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1082774/#r5 doi.org/10.1128/JVI.79.9.5863-5869.2005 Lab induced strain PRA 04/02/2021 OJCharles KOS A 1480 HSV1 Clinical isolate UL23 M130I 5 Phenotypic and genotypic characterization of induced acyclovir-resistant clinical isolates of herpes simplex virus type 1 https://www.sciencedirect.com/science/article/pii/S0166354213002544 doi.org/10.1016/j.antiviral.2013.09.008 Isolated strain PRA 04/02/2021 OJCharles A 1481 HSV1 TAS UL23 C336Y 120 0.2 Genotypic and phenotypic characterization of the thymidine kinase of ACV-resistant HSV-1 derived from an acyclovir-sensitive herpes simplex virus type 1 strain https://www.sciencedirect.com/science/article/pii/S0166354202001316 doi.org/10.1016/S0166-3542(02)00131-6 Lab induced strain PRA 04/02/2021 OJCharles A 1482 HSV1 UL23 T287M 500 1 0.3 1670 300 Characterization of Herpes Simplex Viruses Selected in Culture for Resistance to Penciclovir or Acyclovir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114085/ doi.org/10.1128/JVI.75.4.1761-1769.2001 Lab induced strain PRA 04/02/2021 OJCharles A 1483 HSV1 SC16 UL30 A719V 19 10 Related functional domains in virus DNA polymerases https://www.ncbi.nlm.nih.gov/pmc/articles/PMC553373/pdf/emboj00241-0168.pdf doi.org/10.1002/j.1460-2075.1987.tb04735.x Lab induced strain PRA 04/02/2021 OJCharles A 1484 HSV1 SC16 UL30 G355D Polymorphism Related functional domains in virus DNA polymerases https://www.ncbi.nlm.nih.gov/pmc/articles/PMC553373/pdf/emboj00241-0168.pdf doi.org/10.1002/j.1460-2075.1987.tb04735.x Lab induced strain PRA 04/02/2021 OJCharles Occurs only along with a co-resistant mutation O 1485 HSV1 Clinical isolate UL23 D162H Resistant Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization https://www.sciencedirect.com/science/article/pii/S1386653204001246 doi.org/10.1016/j.jcv.2004.04.002 Isolated strain yield reduction assay (ELVIRA) 04/02/2021 OJCharles A 1486 HSV1 UL23 R176Q 4.1 Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization https://www.sciencedirect.com/science/article/pii/S1386653204001246 doi.org/10.1016/j.jcv.2004.04.002 Isolated strain yield reduction assay (ELVIRA) 04/02/2021 OJCharles A 1487 HSV2 UL23 D229H 181 Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization https://www.sciencedirect.com/science/article/pii/S1386653204001246 doi.org/10.1016/j.jcv.2004.04.002 Isolated strain yield reduction assay (ELVIRA) 04/02/2021 OJCharles A 1488 HSV2 UL23 T288M 30 Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization https://www.sciencedirect.com/science/article/pii/S1386653204001246 doi.org/10.1016/j.jcv.2004.04.002 Isolated strain yield reduction assay (ELVIRA) 04/02/2021 OJCharles A 1489 HSV2 UL23 G56E Resistant Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization https://www.sciencedirect.com/science/article/pii/S1386653204001246 doi.org/10.1016/j.jcv.2004.04.002 Isolated strain yield reduction assay (ELVIRA) 04/02/2021 OJCharles A 1490 HSV1 UL23 R222H 20 Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization https://www.sciencedirect.com/science/article/pii/S1386653204001246 doi.org/10.1016/j.jcv.2004.04.002 Isolated strain yield reduction assay (ELVIRA) UL23 R363C 04/02/2021 OJCharles unknwon comut O 1491 HSV2 UL23 T202A 70 0.3 Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization https://www.sciencedirect.com/science/article/pii/S1386653204001246 doi.org/10.1016/j.jcv.2004.04.002 Isolated strain yield reduction assay (ELVIRA) 04/02/2021 OJCharles A 1492 HSV1 UL30 S724N 11 Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-81-3-639#tab2 doi.org/10.1099/0022-1317-81-3-639 Lab induced strain PRA 04/02/2021 OJCharles A 1493 HSV1 UL30 A136T Polymorphism Polymorphism Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-81-3-639#tab2 doi.org/10.1099/0022-1317-81-3-639 Lab induced strain PRA 04/02/2021 OJCharles R700M is poly in followup papers A 1494 HSV1 UL30 L1007M 3.2 Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-81-3-639#tab2 doi.org/10.1099/0022-1317-81-3-639 Lab induced strain PRA 04/02/2021 OJCharles A 1495 HSV1 UL30 I1028T 1.6 1.5 Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-81-3-639#tab2 doi.org/10.1099/0022-1317-81-3-639 Lab induced strain PRA 04/02/2021 OJCharles A 1496 HSV1 KOS UL30 A719V 4.2 2.3 DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions https://journals.sagepub.com/doi/abs/10.1177/135965350701200502 doi.org/10.1177/135965350701200502 Lab induced strain Cytopathic effect 04/02/2021 OJCharles KOS A 1497 HSV1 KOS UL30 S724N 6 4.7 DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions https://journals.sagepub.com/doi/abs/10.1177/135965350701200502 doi.org/10.1177/135965350701200502 Lab induced strain Cytopathic effect 04/02/2021 OJCharles KOS A 1498 HSV1 KOS UL30 T821M 4.7 2.9 DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions https://journals.sagepub.com/doi/abs/10.1177/135965350701200502 doi.org/10.1177/135965350701200502 Lab induced strain Cytopathic effect 04/02/2021 OJCharles KOS A 1499 HSV1 KOS UL30 L1007M 2 DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions https://journals.sagepub.com/doi/abs/10.1177/135965350701200502 doi.org/10.1177/135965350701200502 Lab induced strain Cytopathic effect 04/02/2021 OJCharles KOS A 1500 HSV1 KOS UL30 I1028T 1.5 DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions https://journals.sagepub.com/doi/abs/10.1177/135965350701200502 doi.org/10.1177/135965350701200502 Lab induced strain Cytopathic effect 04/02/2021 OJCharles KOS A 1501 HSV1 KOS UL30 A605V 4 10 Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants https://www.sciencedirect.com/science/article/pii/S0166354297000545 doi.org/10.1016/S0166-3542(97)00054-5 Lab induced strain PRA 04/02/2021 OJCharles KOS A 1502 HSV1 KOS UL30 S724N 8 6 Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants https://www.sciencedirect.com/science/article/pii/S0166354297000545 doi.org/10.1016/S0166-3542(97)00054-5 Lab induced strain PRA 04/02/2021 OJCharles KOS A 1503 HSV1 KOS UL30 F891C 10 10 Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants https://www.sciencedirect.com/science/article/pii/S0166354297000545 doi.org/10.1016/S0166-3542(97)00054-5 Lab induced strain PRA 04/02/2021 OJCharles KOS A 1504 HSV1 KOS UL30 N961K 4 Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants https://www.sciencedirect.com/science/article/pii/S0166354297000545 doi.org/10.1016/S0166-3542(97)00054-5 Lab induced strain PRA 04/02/2021 OJCharles KOS A 1505 HSV1 TAS UL30 N494S Polymorphism Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/ doi.org/10.1128/AAC.49.2.606-611.2005 Lab induced strain PRA 04/02/2021 OJCharles A 1506 HSV1 TAS UL30 L702I 1 0.1 3 1 Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/ doi.org/10.1128/AAC.49.2.606-611.2005 Lab induced strain PRA 04/02/2021 OJCharles A 1507 HSV1 TAS UL30 F716L 6 0.1 10 2.2 Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/ doi.org/10.1128/AAC.49.2.606-611.2005 Lab induced strain PRA 04/02/2021 OJCharles A 1508 HSV1 TAS UL30 A719V 5.5 0.3 8 2.5 Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/ doi.org/10.1128/AAC.49.2.606-611.2005 Lab induced strain PRA 04/02/2021 OJCharles A 1509 HSV1 TAS UL30 S724N 3 1 10 4 Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/ doi.org/10.1128/AAC.49.2.606-611.2005 Lab induced strain PRA 04/02/2021 OJCharles A 1510 HSV1 TAS UL30 L778M 2.6 1 5 2.5 Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/ doi.org/10.1128/AAC.49.2.606-611.2005 Lab induced strain PRA 04/02/2021 OJCharles A 1511 HSV1 TAS UL30 E798K 3 Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/ doi.org/10.1128/AAC.49.2.606-611.2005 Lab induced strain PRA 04/02/2021 OJCharles A 1512 HSV1 TAS UL30 A834S 2 Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/ doi.org/10.1128/AAC.49.2.606-611.2005 Lab induced strain PRA 04/02/2021 OJCharles A 1513 HSV1 TAS UL30 T839I 2.3 Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/ doi.org/10.1128/AAC.49.2.606-611.2005 Lab induced strain PRA 04/02/2021 OJCharles A 1514 HSV1 TAS UL30 A910V 4 Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/ doi.org/10.1128/AAC.49.2.606-611.2005 Lab induced strain PRA 04/02/2021 OJCharles A 1515 HSV1 TAS UL30 V958L 12 Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/ doi.org/10.1128/AAC.49.2.606-611.2005 Lab induced strain PRA 04/02/2021 OJCharles A 1516 HSV1 TAS UL30 R959H 4.6 Genotypic Characterization of the DNA Polymerase and Sensitivity to Antiviral Compounds of Foscarnet-Resistant Herpes Simplex Virus Type 1 (HSV-1) Derived from a Foscarnet-Sensitive HSV-1 Strain https://www.ncbi.nlm.nih.gov/pmc/articles/PMC547286/ doi.org/10.1128/AAC.49.2.606-611.2005 Lab induced strain PRA 04/02/2021 OJCharles A 1517 HSV1 UL23 Y53D Resistant Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Marker Transfer TK functional kinetic assay 04/02/2021 OJCharles A 1518 HSV1 UL23 L170P Resistant Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Marker Transfer TK functional kinetic assay 04/02/2021 OJCharles A 1519 HSV1 UL23 A207P Resistant Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity https://www.sciencedirect.com/science/article/pii/S0166354212002239#b0010 doi.org/10.1016/j.antiviral.2012.09.016 Marker Transfer TK functional kinetic assay 04/02/2021 OJCharles A 1520 HSV1 Clinical isolate UL23 Y172C 80 Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1521 HSV1 Clinical isolate UL30 S724N 5 Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4505214/ doi.org/10.1128/AAC.00977-15 Isolated strain PRA 04/02/2021 OJCharles MacIntyre A 1522 HSV1 Clinical isolate UL23 N23S Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 14/04/2021 OJCharles Mackityre A 1523 HSV1 Clinical isolate UL23 K36E Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 14/04/2021 OJCharles Mackityre A 1524 HSV1 Clinical isolate UL23 L42P Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 14/04/2021 OJCharles Mackityre A 1525 HSV1 Clinical isolate UL23 G251C Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 14/04/2021 OJCharles Mackityre A 1526 HSV1 Clinical isolate UL23 A265T Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 14/04/2021 OJCharles Mackityre A 1527 HSV1 Clinical isolate UL23 V267L Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 14/04/2021 OJCharles Mackityre A 1528 HSV1 Clinical isolate UL23 P268T Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 14/04/2021 OJCharles Mackityre A 1529 HSV1 Clinical isolate UL23 D286E Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 14/04/2021 OJCharles Mackityre A 1530 HSV1 Clinical isolate UL23 N376H Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 14/04/2021 OJCharles Mackityre A 1531 HSV1 Clinical isolate UL23 V348I Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 14/04/2021 OJCharles Mackityre A 1532 HSV1 Clinical isolate UL30 F248L Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 14/04/2021 OJCharles Mackityre A 1533 HSV1 Clinical isolate UL30 A1203T Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 14/04/2021 OJCharles Mackityre A 1534 HSV1 Clinical isolate UL30 R330A Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 14/04/2021 OJCharles Mackityre A 1535 HSV1 Clinical isolate UL23 I143V Resistant Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 04/02/2021 OJCharles only co-occurs with unknown R256W Mackityre O 1536 HSV1 Clinical isolate UL23 R256W Resistant Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 04/02/2021 OJCharles only co-occurs with unknown I143V Mackityre O 1537 HSV1 Clinical isolate UL23 Y172C Resistant Polymorphism Polymorphism Resistant Resistant Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 04/05/2021 OJCharles A 1538 HSV1 Clinical isolate UL23 A174P Resistant Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay UL30 D1103H 04/02/2021 OJCharles only co-occurs with unknown mutation O 1539 HSV1 Clinical isolate UL23 L315S Resistant Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1540 HSV1 Clinical isolate UL30 P1124H Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1541 HSV1 Clinical isolate UL30 T1208A Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1542 HSV1 Clinical isolate UL30 A566T Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 04/02/2021 OJCharles Cannot be inferred O 1543 HSV1 Clinical isolate UL30 D1103H Polymorphism Polymorphism Polymorphism Polymorphism Polymorphism Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus https://www.sciencedirect.com/science/article/pii/S0166354210003864 doi.org/10.1016/j.antiviral.2010.03.002 Isolated strain dye uptake assay 04/02/2021 OJCharles Cannot be inferred O 1544 HSV1 Clinical isolate UL23 R222C Resistant Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes https://www.sciencedirect.com/science/article/pii/S0166354214000898 doi.org/10.1016/j.antiviral.2014.03.015 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1545 HSV1 Clinical isolate UL23 G200D 25 Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes https://www.sciencedirect.com/science/article/pii/S0166354214000898 doi.org/10.1016/j.antiviral.2014.03.015 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1546 HSV1 UL23 P131S 20 Thymidine Kinase Mutations Conferring Acyclovir Resistance in Herpes Simplex Type 1 Recombinant Viruses https://aac.asm.org/content/aac/50/11/3889.full.pdf doi.org/10.1128/AAC.00889-06 Marker transfer PRA 04/02/2021 OJCharles A 1547 HSV1 UL23 C336Y 30 Thymidine Kinase Mutations Conferring Acyclovir Resistance in Herpes Simplex Type 1 Recombinant Viruses https://aac.asm.org/content/aac/50/11/3889.full.pdf doi.org/10.1128/AAC.00889-06 Marker transfer PRA 04/02/2021 OJCharles A 1548 HSV1 F UL23 Q125H 13.3 5.3 Acyclovir Sensitivity and Neurovirulence of Herpes Simplex Virus Type 1 with Amino Acid Substitutions in the Viral Thymidine Kinase Gene, Which Were Detected in the Patients with Intractable Herpes Simplex Encephalitis Previously Reported https://www.jstage.jst.go.jp/article/yoken/71/5/71_JJID.2018.176/_pdf/-char/en doi.org/10.7883/yoken.JJID.2018.176 Recombinant BAC PRA 04/02/2021 OJCharles F A 1549 HSV1 F UL23 R41H 0.8 Acyclovir Sensitivity and Neurovirulence of Herpes Simplex Virus Type 1 with Amino Acid Substitutions in the Viral Thymidine Kinase Gene, Which Were Detected in the Patients with Intractable Herpes Simplex Encephalitis Previously Reported https://www.jstage.jst.go.jp/article/yoken/71/5/71_JJID.2018.176/_pdf/-char/en doi.org/10.7883/yoken.JJID.2018.176 Recombinant BAC PRA 04/02/2021 OJCharles F A 1550 HSV1 F UL23 A156V 0.9 Acyclovir Sensitivity and Neurovirulence of Herpes Simplex Virus Type 1 with Amino Acid Substitutions in the Viral Thymidine Kinase Gene, Which Were Detected in the Patients with Intractable Herpes Simplex Encephalitis Previously Reported https://www.jstage.jst.go.jp/article/yoken/71/5/71_JJID.2018.176/_pdf/-char/en doi.org/10.7883/yoken.JJID.2018.176 Recombinant BAC PRA 04/02/2021 OJCharles F A 1551 HSV1 Clinical isolate UL23 A37V Polymorphism HSV susceptibility to acyclovir - genotypic and phenotypic characterization https://journals.sagepub.com/doi/10.3851/IMP3279 doi.org/10.3851/IMP3279 Isolated strain PRA 04/02/2021 OJCharles A 1552 HSV1 Clinical isolate UL23 H283N Polymorphism HSV susceptibility to acyclovir - genotypic and phenotypic characterization https://journals.sagepub.com/doi/10.3851/IMP3279 doi.org/10.3851/IMP3279 Isolated strain PRA 04/02/2021 OJCharles A 1553 HSV1 Clinical isolate UL30 G641R 1 Polymorphism UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1554 HSV1 Clinical isolate UL30 G645D 1 Polymorphism UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1555 HSV1 Clinical isolate UL30 E649G 1.3 Polymorphism UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1556 HSV1 Clinical isolate UL30 G679D 1 Polymorphism UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1557 HSV1 Clinical isolate UL30 R681L 1 Polymorphism UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1558 HSV1 Clinical isolate UL30 I966M 2.5 Polymorphism UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1559 HSV1 Clinical isolate UL23 E43A 1.3 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles methodology is not explicit, were these individually transferred, or simply the experimentalists feeling? O 1560 HSV1 Clinical isolate UL23 L50M 1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles methodology is not explicit, were these individually transferred, or simply the experimentalists feeling? O 1561 HSV1 Clinical isolate UL23 L68R 1.2 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles methodology is not explicit, were these individually transferred, or simply the experimentalists feeling? O 1562 HSV1 Clinical isolate UL23 E43A 1.3 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1563 HSV1 Clinical isolate UL23 L50M 1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1564 HSV1 Clinical isolate UL23 L68R 1.5 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1565 HSV1 Clinical isolate UL23 S74L 39 1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles co-occurs with known resmut or other unknown mutant O 1566 HSV1 Clinical isolate UL23 Q109K 1 1.6 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1567 HSV1 Clinical isolate UL23 A133V 1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1568 HSV1 Clinical isolate UL23 A136N 1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A is not the tk wt AA have emailed author O 1569 HSV1 Clinical isolate UL23 S150L 1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1570 HSV1 Clinical isolate UL23 P154S 84 1.1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles co-occurs with known resmut or other unknown mutant O 1571 HSV1 Clinical isolate UL23 L159R 56 1.4 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles co-occurs with known resmut or other unknown mutant O 1572 HSV1 Clinical isolate UL23 E225L 25 2.2 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles co-occurs with known resmut or other unknown mutant O 1573 HSV1 Clinical isolate UL23 L242P 18 1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1574 HSV1 Clinical isolate UL23 Y248H 53 0.85 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles co-occurs with known resmut or other unknown mutant O 1575 HSV1 Clinical isolate UL23 D258N 1.3 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1576 HSV1 Clinical isolate UL23 S263L 1.6 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1577 HSV1 Clinical isolate UL23 P280S 1.3 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1578 HSV1 Clinical isolate UL23 N301S 1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1579 HSV1 Clinical isolate UL23 A316S 1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1580 HSV1 Clinical isolate UL23 M322L 1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1581 HSV1 Clinical isolate UL23 I326V 1.3 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1582 HSV1 Clinical isolate UL23 D330A 1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles methodology is not explicit, were these individually transferred, or simply the experimentalists feeling? O 1583 HSV1 Clinical isolate UL23 D338H 1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1584 HSV1 Clinical isolate UL23 Q342H 1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1585 HSV1 Clinical isolate UL23 T344I 1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1586 HSV1 Clinical isolate UL23 Q349R 1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1587 HSV1 Clinical isolate UL23 V352L 1.9 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1588 HSV1 Clinical isolate UL23 R370W 1.9 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1589 HSV1 Clinical isolate UL23 E371D 1.9 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles A 1590 HSV1 Clinical isolate UL5 L49I 20 10 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles co-occurs with other unknown mutants O 1591 HSV1 Clinical isolate UL5 L138V 19 8.6 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles co-occurs with other unknown mutants O 1592 HSV1 Clinical isolate UL5 S173L 53 1.5 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles co-occurs with other unknown mutants O 1593 HSV1 Clinical isolate UL5 A280T 39 1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles co-occurs with other unknown mutants O 1594 HSV1 Clinical isolate UL5 A575V 39 1 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles co-occurs with other unknown mutants O 1595 HSV1 Clinical isolate UL5 V600A 19 8.6 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles co-occurs with other unknown mutants O 1596 HSV1 Clinical isolate UL5 A602T 19 8.6 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles methodology is not explicit, were these individually transferred, or simply the experimentalists feeling? O 1597 HSV1 Clinical isolate UL5 D862N 20 10 UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients https://www.sciencedirect.com/science/article/pii/S0166354219300452 doi.org/10.1016/j.antiviral.2019.05.012 Isolated strain dye uptake assay 04/02/2021 OJCharles co-occurs with other unknown mutants O 1598 HSV1 Clinical isolate UL23 L340R 14 Input of recombinant phenotyping for the characterization of a novel acyclovir-resistance mutation identified in a patient with recurrent herpetic keratitis https://www.sciencedirect.com/science/article/pii/S0166354219302700 doi.org/10.1016/j.antiviral.2019.06.007 Isolated strain PRA 04/02/2021 OJCharles KOS A 1599 HSV1 UL23 L340R 34 Input of recombinant phenotyping for the characterization of a novel acyclovir-resistance mutation identified in a patient with recurrent herpetic keratitis https://www.sciencedirect.com/science/article/pii/S0166354219302700 doi.org/10.1016/j.antiviral.2019.06.007 Recombinant BAC PRA 04/02/2021 OJCharles KOS A 1600 HSV1 UL23 R216H Resistant Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles A 1601 HSV1 UL23 L170P Resistant Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1602 HSV1 UL23 S181N Resistant Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1603 HSV1 UL23 Q15K Polymorphism Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1604 HSV1 UL23 R20C Polymorphism Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1605 HSV1 UL23 R32H Polymorphism Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1606 HSV1 UL23 E43A Polymorphism Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1607 HSV1 UL23 E43D Polymorphism Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1608 HSV1 UL23 G61E Resistant Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1609 HSV1 UL23 R89H Polymorphism Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1610 HSV1 UL23 A93V Resistant Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1611 HSV1 UL23 M121K Resistant Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1612 HSV1 UL23 A156V Polymorphism Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1613 HSV1 UL23 R163G Resistant Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1614 HSV1 UL23 del173 Resistant Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1615 HSV1 UL23 V238F Resistant Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1616 HSV1 UL23 N244H Polymorphism Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1617 HSV1 UL23 G264V Resistant Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1618 HSV1 UL23 P269S Polymorphism Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1619 HSV1 UL23 G271V Polymorphism Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1620 HSV1 UL23 S276N Polymorphism Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1621 HSV1 UL23 I326V Polymorphism Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1622 HSV1 UL23 N376* Resistant Stepwise characterization of non-synonymous mutations in the HSV-1 thymidine kinase gene by different functional assays https://www.sciencedirect.com/science/article/pii/S016609341730071X doi.org/10.1016/j.jviromet.2017.05.013 Lab induced strain TK functional kinetic assay 04/02/2021 OJCharles JQ352247.1 A 1623 HSV2 UL23 R220T Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 04/02/2021 OJCharles A 1624 HSV2 UL30 A1213T Polymorphism Surveillance of herpes simplex virus resistance to antivirals: A 4-year survey https://www.sciencedirect.com/science/article/pii/S0166354213002581#tblfn8 doi.org/10.1016/j.antiviral.2013.09.012 Isolated strain PRA 04/02/2021 OJCharles M1213 original have inferred type A 1625 HHV6b U38 654 4.2 118 1.2 Characterization of a cidofovir-resistant HHV-6 mutant obtained by in vitro selection https://www.sciencedirect.com/science/article/pii/S0166354207005001 doi.org/10.1016/j.antiviral.2007.12.004 Lab induced strain qPCR 04/02/2021 OJCharles http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=nucleotide&doptcmdl=genbank&term=AB021506 A 1626 HHV6b U38 A961V Resistant Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-82-11-2767 doi.org/10.1099/0022-1317-82-11-2767 Lab induced strain ELISA 04/02/2021 OJCharles cannot infer O 1627 HHV6b U69 M317V Resistant Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-82-11-2767 doi.org/10.1099/0022-1317-82-11-2767 Lab induced strain 04/02/2021 OJCharles cannot infer O 1628 HHV6b Z29 U69 M317V Resistant Mapping ganciclovir resistance in the human herpesvirus?6 U69 protein kinase https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.10510 doi.org/10.1002/jmv.10510 Marker transfer PRA 04/02/2021 OJCharles Z29 A 1629 HHV6b Z29 U69 L212I Polymorphism Mapping ganciclovir resistance in the human herpesvirus?6 U69 protein kinase https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.10510 doi.org/10.1002/jmv.10510 Marker transfer PRA 04/02/2021 OJCharles Z29 A 1630 HHV6b Z29 U69 C447G Resistant Mapping ganciclovir resistance in the human herpesvirus?6 U69 protein kinase https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.10510 doi.org/10.1002/jmv.10510 Marker transfer PRA 04/02/2021 OJCharles Z29 A 1631 HHV6b Z29 U69 C462Y Resistant Mapping ganciclovir resistance in the human herpesvirus?6 U69 protein kinase https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.10510 doi.org/10.1002/jmv.10510 Marker transfer PRA 04/02/2021 OJCharles Z29 A 1632 HHV6b Z29 U69 M317V Resistant Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography https://www.sciencedirect.com/science/article/pii/S0166093409003012 doi.org/10.1016/j.jviromet.2009.06.016 Marker transfer qPCR 04/02/2021 OJCharles Z29 A 1633 HHV6b Z29 U69 A446D Resistant Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography https://www.sciencedirect.com/science/article/pii/S0166093409003012 doi.org/10.1016/j.jviromet.2009.06.016 Marker transfer qPCR 04/02/2021 OJCharles Z29 A 1634 HHV6b Z29 U69 C447G Resistant Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography https://www.sciencedirect.com/science/article/pii/S0166093409003012 doi.org/10.1016/j.jviromet.2009.06.016 Marker transfer qPCR 04/02/2021 OJCharles Z29 A 1635 HHV6b Z29 U69 L449S Resistant Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography https://www.sciencedirect.com/science/article/pii/S0166093409003012 doi.org/10.1016/j.jviromet.2009.06.016 Marker transfer qPCR 04/02/2021 OJCharles Z29 A 1636 HHV6b Z29 U69 A462D Resistant Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography https://www.sciencedirect.com/science/article/pii/S0166093409003012 doi.org/10.1016/j.jviromet.2009.06.016 Marker transfer qPCR 04/02/2021 OJCharles Z29 A 1637 HHV6b Z29 U69 C462Y Resistant Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography https://www.sciencedirect.com/science/article/pii/S0166093409003012 doi.org/10.1016/j.jviromet.2009.06.016 Marker transfer qPCR 04/02/2021 OJCharles Z29 A 1638 HHV6b Z29 U69 L201I Polymorphism Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography https://www.sciencedirect.com/science/article/pii/S0166093409003012 doi.org/10.1016/j.jviromet.2009.06.016 Marker transfer qPCR 04/02/2021 OJCharles Z29 A 1639 HHV6b Z29 U69 L212I Polymorphism Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography https://www.sciencedirect.com/science/article/pii/S0166093409003012 doi.org/10.1016/j.jviromet.2009.06.016 Marker transfer qPCR 04/02/2021 OJCharles Z29 A 1640 HHV6b HST U38 R798I 4 213 1.2 Characterization of a cidofovir-resistant HHV-6 mutant obtained by in vitro selection https://www.sciencedirect.com/science/article/pii/S0166354207005001 doi.org/10.1016/j.antiviral.2007.12.004 Lab induced strain qPCR 04/02/2021 OJCharles HST A 1647 VZV Clinical isolate ORF36 Q90* Resistant Development of Resistance to Acyclovir during Chronic Infection with the Oka Vaccine Strain of Varicella-Zoster Virus, in an Immunosuppressed Child https://academic.oup.com/jid/article/188/7/954/820206 doi.org/10.1086/378502 Isolated strain TK functional kinetic assay 28/05/2021 OJCharles Resistant Phenotype not established this was effect on TK activity (which is hand in hand) but not directly a resistance measurement Oka A 1648 VZV Clinical isolate ORF36 L92P Resistant Analysis of mutations in the thymidine kinase genes of drug-resistant varicella-zoster virus populations using the polymerase chain reaction https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-72-3-623#tab2 doi.org/10.1099/0022-1317-72-3-623 TK functional kinetic assay 28/05/2021 OJCharles 9883 A 1649 VZV Clinical isolate ORF36 L92P Resistant Analysis of mutations in the thymidine kinase genes of drug-resistant varicella-zoster virus populations using the polymerase chain reaction https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-72-3-623#tab2 doi.org/10.1099/0022-1317-72-3-623 TK functional kinetic assay 28/05/2021 OJCharles 9883 A 1651 VZV Oka ORF36 A29T 1 Complementary assays for monitoring susceptibility of varicella-zoster virus resistance to antivirals https://www.sciencedirect.com/science/article/pii/S0166093416300787 doi.org/10.1016/j.jviromet.2016.03.006 Isolated strain PRA 18/11/2021 OJCharles Oka A 1652 VZV Clinical isolate ORF36 S288L Polymorphism Resistance testing of clinical varicella-zoster virus strains https://www.sciencedirect.com/science/article/pii/S0166354211002841 doi.org/10.1016/j.antiviral.2011.04.005 Isolated strain PRA 18/11/2021 OJCharles Oka A 1653 VZV Clinical isolate ORF36 K186R 1 1 1 1 Genetic polymorphism of thymidine kinase (TK) and DNA polymerase (pol) of clinical varicella-zoster virus (VZV) isolates collected over three decades https://www.sciencedirect.com/science/article/pii/S1386653217302433#tbl0005 doi.org/10.1016/j.jcv.2017.08.011 Isolated strain PRA 18/11/2021 OJCharles Co-occurs with D545Y , needs to be tested indep Oka O 1654 VZV Clinical isolate ORF36 A319V Polymorphism Molecular Analysis of the Pyrimidine Deoxyribonucleoside Kinase Gene of Wild-type and Acyclovir-resistant Strains of Varicella-Zoster Virus https://www.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-69-10-2585#tab2 doi.org/10.1099/0022-1317-69-10-2585 Isolated strain PRA 18/11/2021 OJCharles Oka A 1655 HCMV AD169 UL97 C592G 3.1 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing https://www.sciencedirect.com/science/article/pii/S0166354221001297 doi.org/10.1016/j.antiviral.2021.105139 Lab induced strain SEAP 21/12/2021 OJCharles AD169 A 1656 HCMV AD169 UL97 F342Y 5.9 4.2 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing https://www.sciencedirect.com/science/article/pii/S0166354221001297 doi.org/10.1016/j.antiviral.2021.105139 Lab induced strain SEAP 21/12/2021 OJCharles AD169 A 1657 HCMV AD169 UL97 Y335H 0.9 1 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing https://www.sciencedirect.com/science/article/pii/S0166354221001297 doi.org/10.1016/j.antiviral.2021.105139 Lab induced strain SEAP 21/12/2021 OJCharles AD169 A 1658 HCMV AD169 UL97 V345I 1.3 0.4 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing https://www.sciencedirect.com/science/article/pii/S0166354221001297 doi.org/10.1016/j.antiviral.2021.105139 Lab induced strain SEAP 21/12/2021 OJCharles AD169 A 1659 HCMV AD169 UL97 L348V 0.9 1.6 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing https://www.sciencedirect.com/science/article/pii/S0166354221001297 doi.org/10.1016/j.antiviral.2021.105139 Lab induced strain SEAP 21/12/2021 OJCharles AD169 A 1660 HCMV AD169 UL97 K359N 2.1 0.7 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing https://www.sciencedirect.com/science/article/pii/S0166354221001297 doi.org/10.1016/j.antiviral.2021.105139 Lab induced strain SEAP 21/12/2021 OJCharles AD169 A 1661 HCMV AD169 UL97 E362D 3.8 0.1 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing https://www.sciencedirect.com/science/article/pii/S0166354221001297 doi.org/10.1016/j.antiviral.2021.105139 Lab induced strain SEAP 21/12/2021 OJCharles AD169 A 1662 HCMV AD169 UL97 A378T 1 1.1 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing https://www.sciencedirect.com/science/article/pii/S0166354221001297 doi.org/10.1016/j.antiviral.2021.105139 Lab induced strain SEAP 21/12/2021 OJCharles AD169 A 1663 HCMV AD169 UL97 V388M 1.2 1.1 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing https://www.sciencedirect.com/science/article/pii/S0166354221001297 doi.org/10.1016/j.antiviral.2021.105139 Lab induced strain SEAP 21/12/2021 OJCharles AD169 A 1664 HCMV AD169 UL97 H415Y 1.1 0.6 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing https://www.sciencedirect.com/science/article/pii/S0166354221001297 doi.org/10.1016/j.antiviral.2021.105139 Lab induced strain SEAP 21/12/2021 OJCharles AD169 A 1665 HCMV AD169 UL97 A435V 1 0.6 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing https://www.sciencedirect.com/science/article/pii/S0166354221001297 doi.org/10.1016/j.antiviral.2021.105139 Lab induced strain SEAP 21/12/2021 OJCharles AD169 A 1666 HCMV AD169 UL97 C437Y 0.9 0.9 Ganciclovir and maribavir susceptibility phenotypes of cytomegalovirus UL97 ATP binding region mutations detected by expanded genotypic testing https://www.sciencedirect.com/science/article/pii/S0166354221001297 doi.org/10.1016/j.antiviral.2021.105139 Lab induced strain SEAP 21/12/2021 OJCharles AD169 A 1667 HCMV AD169 UL54 D301N 0.2 14 Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility https://www.sciencedirect.com/science/article/pii/S0166354221001716 doi.org/10.1016/j.antiviral.2021.105181 Recombinant BAC SEAP 21/12/2021 OJCharles AD169 A 1668 HCMV AD169 UL54 N408D 0.2 3.3 Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility https://www.sciencedirect.com/science/article/pii/S0166354221001716 doi.org/10.1016/j.antiviral.2021.105181 Recombinant BAC SEAP 21/12/2021 OJCharles AD169 A 1669 HCMV AD169 UL54 N408K 0.1 32 Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility https://www.sciencedirect.com/science/article/pii/S0166354221001716 doi.org/10.1016/j.antiviral.2021.105181 Recombinant BAC SEAP 21/12/2021 OJCharles AD169 A 1670 HCMV AD169 UL54 N410K 0.7 2.5 Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility https://www.sciencedirect.com/science/article/pii/S0166354221001716 doi.org/10.1016/j.antiviral.2021.105181 Recombinant BAC SEAP 21/12/2021 OJCharles AD169 A 1671 HCMV AD169 UL54 F412C 0.2 17 Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility https://www.sciencedirect.com/science/article/pii/S0166354221001716 doi.org/10.1016/j.antiviral.2021.105181 Recombinant BAC SEAP 21/12/2021 OJCharles AD169 A 1672 HCMV AD169 UL54 F412L 0.2 12 Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility https://www.sciencedirect.com/science/article/pii/S0166354221001716 doi.org/10.1016/j.antiviral.2021.105181 Recombinant BAC SEAP 21/12/2021 OJCharles AD169 A 1673 HCMV AD169 UL54 K513R 3.6 14 Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility https://www.sciencedirect.com/science/article/pii/S0166354221001716 doi.org/10.1016/j.antiviral.2021.105181 Recombinant BAC SEAP 21/12/2021 OJCharles AD169 A 1674 HCMV AD169 UL54 D515Y 0.6 2.2 Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility https://www.sciencedirect.com/science/article/pii/S0166354221001716 doi.org/10.1016/j.antiviral.2021.105181 Recombinant BAC SEAP 21/12/2021 OJCharles AD169 A 1675 HCMV AD169 UL54 L516P 0.2 5.3 Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility https://www.sciencedirect.com/science/article/pii/S0166354221001716 doi.org/10.1016/j.antiviral.2021.105181 Recombinant BAC SEAP 21/12/2021 OJCharles AD169 A 1676 HCMV AD169 UL54 P522S 0.2 4.4 Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility https://www.sciencedirect.com/science/article/pii/S0166354221001716 doi.org/10.1016/j.antiviral.2021.105181 Recombinant BAC SEAP 21/12/2021 OJCharles AD169 A 1677 HCMV AD169 UL54 L545W 0.3 6.4 Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility https://www.sciencedirect.com/science/article/pii/S0166354221001716 doi.org/10.1016/j.antiviral.2021.105181 Recombinant BAC SEAP 21/12/2021 OJCharles AD169 A 1678 HCMV AD169 UL54 Q578H 8.6 2.9 Resistant Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility https://www.sciencedirect.com/science/article/pii/S0166354221001716 doi.org/10.1016/j.antiviral.2021.105181 Recombinant BAC SEAP 21/12/2021 OJCharles AD169 A 1679 HCMV AD169 UL54 T700A 4.6 1.7 Resistant Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility https://www.sciencedirect.com/science/article/pii/S0166354221001716 doi.org/10.1016/j.antiviral.2021.105181 Recombinant BAC SEAP 21/12/2021 OJCharles AD169 A 1680 HCMV AD169 UL54 A809V 5.2 2 Resistant Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility https://www.sciencedirect.com/science/article/pii/S0166354221001716 doi.org/10.1016/j.antiviral.2021.105181 Recombinant BAC SEAP 21/12/2021 OJCharles AD169 A 1681 HCMV AD169 UL54 D981del2 0.8 3.3 Resistant Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility https://www.sciencedirect.com/science/article/pii/S0166354221001716 doi.org/10.1016/j.antiviral.2021.105181 Recombinant BAC SEAP 21/12/2021 OJCharles AD169 A 1682 HCMV AD169 UL54 A987G 0.4 7.7 Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility https://www.sciencedirect.com/science/article/pii/S0166354221001716 doi.org/10.1016/j.antiviral.2021.105181 Recombinant BAC SEAP 21/12/2021 OJCharles AD169 A 1683 HCMV AD169 UL54 A987V 1.6 0.9 Resistant Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility https://www.sciencedirect.com/science/article/pii/S0166354221001716 doi.org/10.1016/j.antiviral.2021.105181 Recombinant BAC SEAP 21/12/2021 OJCharles AD169 A 1684 HSV1 HSV1-17 UL30 L49I 1 1.6 0.6 Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes https://www.sciencedirect.com/science/article/pii/S016635422100156X doi.org/10.1016/j.antiviral.2021.105166 Recombinant BAC GFP fluorescence reduction assay 22/12/2021 OJCharles Could incorporate metabolic data too but reps are worse HSV1-17 A 1685 HSV1 HSV1-17 UL30 E70K 1.9 0.7 Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes https://www.sciencedirect.com/science/article/pii/S016635422100156X doi.org/10.1016/j.antiviral.2021.105166 Recombinant BAC GFP fluorescence reduction assay 22/12/2021 OJCharles HSV1-17 A 1686 HSV1 HSV1-17 UL30 L359I 1.4 1 0.8 Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes https://www.sciencedirect.com/science/article/pii/S016635422100156X doi.org/10.1016/j.antiviral.2021.105166 Recombinant BAC GFP fluorescence reduction assay 22/12/2021 OJCharles HSV1-17 A 1687 HSV1 HSV1-17 UL30 E421V 1.4 1 0.7 Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes https://www.sciencedirect.com/science/article/pii/S016635422100156X doi.org/10.1016/j.antiviral.2021.105166 Recombinant BAC GFP fluorescence reduction assay 22/12/2021 OJCharles HSV1-17 A 1688 HSV1 HSV1-17 UL30 P829S 1.5 1.2 0.7 Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes https://www.sciencedirect.com/science/article/pii/S016635422100156X doi.org/10.1016/j.antiviral.2021.105166 Recombinant BAC GFP fluorescence reduction assay 22/12/2021 OJCharles HSV1-17 A 1689 HSV1 HSV1-17 UL30 T1121M 0.8 1.6 1.1 Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes https://www.sciencedirect.com/science/article/pii/S016635422100156X doi.org/10.1016/j.antiviral.2021.105166 Recombinant BAC GFP fluorescence reduction assay 22/12/2021 OJCharles HSV1-17 A 1690 HSV1 HSV1-17 UL30 M1226I 1.5 1.5 Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes https://www.sciencedirect.com/science/article/pii/S016635422100156X doi.org/10.1016/j.antiviral.2021.105166 Recombinant BAC GFP fluorescence reduction assay 22/12/2021 OJCharles HSV1-17 A 1691 HSV1 HSV1-17 UL23 G61A 26 1.1 1 Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes https://www.sciencedirect.com/science/article/pii/S016635422100156X doi.org/10.1016/j.antiviral.2021.105166 Recombinant BAC GFP fluorescence reduction assay 22/12/2021 OJCharles HSV1-17 A 1692 HSV1 HSV1-17 UL30 S724N 22 4.1 11.2 Antiviral susceptibility of recombinant Herpes simplex virus 1 strains with specific polymerase amino acid changes https://www.sciencedirect.com/science/article/pii/S016635422100156X doi.org/10.1016/j.antiviral.2021.105166 Recombinant BAC GFP fluorescence reduction assay 22/12/2021 OJCharles HSV1-17 A 1693 HSV1 HSV1-17 UL30 Q618I 1.5 0.2 Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00390-21 Recombinant BAC PRA 22/12/2021 OJCharles HSV1-17 A 1694 HSV1 HSV1-17 UL30 I619K 2.1 2.5 Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00390-21 Recombinant BAC PRA 22/12/2021 OJCharles HSV1-17 A 1695 HSV1 HSV1-17 UL30 T623A 1.4 1 Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00390-21 Recombinant BAC PRA 22/12/2021 OJCharles HSV1-17 A 1696 HSV1 HSV1-17 UL30 L625I 2.4 1.6 Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00390-21 Recombinant BAC PRA 22/12/2021 OJCharles HSV1-17 A 1697 HSV1 HSV1-17 UL30 V694Q 1.3 1.7 Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00390-21 Recombinant BAC PRA 22/12/2021 OJCharles HSV1-17 A 1698 HSV1 HSV1-17 UL30 Q697P 1.5 1.3 Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00390-21 Recombinant BAC PRA 22/12/2021 OJCharles HSV1-17 A 1699 HSV1 HSV1-17 UL30 P712Y 3.7 0.6 Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00390-21 Recombinant BAC PRA 22/12/2021 OJCharles HSV1-17 A 1700 HSV1 HSV1-17 UL30 A719T 3.5 2 Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00390-21 Recombinant BAC PRA 22/12/2021 OJCharles HSV1-17 A 1701 HCMV AD169 UL54 I580K 2.1 1.1 Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00390-21 Recombinant BAC GLuc reporter assay 22/12/2021 OJCharles AD169 A 1702 HCMV AD169 UL54 T584A 1 1 Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00390-21 Recombinant BAC GLuc reporter assay 22/12/2021 OJCharles AD169 A 1703 HCMV AD169 UL54 L586I 0.6 1 Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00390-21 Recombinant BAC GLuc reporter assay 22/12/2021 OJCharles AD169 A 1704 HCMV AD169 UL54 V694Q 0.5 1.6 Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00390-21 Recombinant BAC GLuc reporter assay 22/12/2021 OJCharles AD169 A 1705 HCMV AD169 UL54 Q697P 0.7 3.8 Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00390-21 Recombinant BAC GLuc reporter assay 22/12/2021 OJCharles AD169 A 1706 HCMV AD169 UL54 A719T 2.4 2.5 Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet https://journals.asm.org/doi/10.1128/AAC.00390-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00390-21 Recombinant BAC GLuc reporter assay 22/12/2021 OJCharles AD169 A 1707 HSV1 VR-3 UL5 K356N 1 1 261 Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00494-21 Recombinant BAC PRA 22/12/2021 OJCharles VR-3 A 1708 HSV1 VR-3 UL5 G352C 1 1 25 Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00494-21 Recombinant BAC PRA 22/12/2021 OJCharles VR-3 A 1709 HSV1 VR-3 UL5 G352V 1 1 3 Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00494-21 Recombinant BAC PRA 22/12/2021 OJCharles VR-3 A 1710 HSV1 VR-3 UL5 M355T 1 1 6 Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00494-21 Recombinant BAC PRA 22/12/2021 OJCharles VR-3 A 1711 HSV1 VR-3 UL5 E34K 1 1 1.5 Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00494-21 Recombinant BAC PRA 22/12/2021 OJCharles VR-3 A 1712 HSV1 VR-3 UL5 I341S 1 1 1.5 Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00494-21 Recombinant BAC PRA 22/12/2021 OJCharles VR-3 A 1713 HSV1 VR-3 UL5 C477D 1 1 1.5 Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00494-21 Recombinant BAC PRA 22/12/2021 OJCharles VR-3 A 1714 HSV1 VR-3 UL52 F360V 1 1 158 Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00494-21 Recombinant BAC PRA 22/12/2021 OJCharles VR-3 A 1715 HSV1 VR-3 UL52 F360C 1 1 25 Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00494-21 Recombinant BAC PRA 22/12/2021 OJCharles VR-3 A 1716 HSV1 VR-3 UL52 N902T 1 1 6 Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00494-21 Recombinant BAC PRA 22/12/2021 OJCharles VR-3 A 1717 HSV1 VR-3 UL52 Y222C 1 1 1.5 Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00494-21 Recombinant BAC PRA 22/12/2021 OJCharles VR-3 A 1718 HSV1 VR-3 UL52 F294L 1 1 1.5 Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00494-21 Recombinant BAC PRA 22/12/2021 OJCharles VR-3 A 1719 HSV1 VR-3 UL52 S364G 1 1 1 Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00494-21 Recombinant BAC PRA 22/12/2021 OJCharles VR-3 A 1720 HSV2 UW-268 UL5 K355N 2800 Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00494-21 Lab induced strain PRA 22/12/2021 OJCharles VR-3 A 1721 HSV2 UW-268 UL5 G351R 2196 Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00494-21 Lab induced strain PRA 22/12/2021 OJCharles UW-268 A 1722 HSV2 UW-268 UL5 K355E 8 Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00494-21 Lab induced strain PRA 22/12/2021 OJCharles UW-268 A 1723 HSV2 UW-268 UL5 I340V 2.1 Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus https://journals.asm.org/doi/10.1128/AAC.00494-21?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed doi.org/10.1128/AAC.00494-21 Lab induced strain PRA 22/12/2021 OJCharles UW-268 A 1724 HCMV Toledo UL54 T700A 0.9 0.7 7.6 Analysis of Novel Drug-Resistant Human Cytomegalovirus DNA Polymerase Mutations Reveals the Role of a DNA-Binding Loop in Phosphonoformic Acid Resistance https://www.frontiersin.org/articles/10.3389/fmicb.2022.771978/full doi.org/10.3389/fmicb.2022.771978 Recombinant BAC PRA 04/03/2022 OJCharles Toledo A 1725 HCMV Toledo UL54 H600L 11.1 4.9 5.2 Analysis of Novel Drug-Resistant Human Cytomegalovirus DNA Polymerase Mutations Reveals the Role of a DNA-Binding Loop in Phosphonoformic Acid Resistance https://www.frontiersin.org/articles/10.3389/fmicb.2022.771978/full doi.org/10.3389/fmicb.2022.771978 Recombinant BAC PRA 04/03/2022 OJCharles Toledo A 1726 HCMV Toledo UL54 E756G 1 1.8 8.8 Analysis of Novel Drug-Resistant Human Cytomegalovirus DNA Polymerase Mutations Reveals the Role of a DNA-Binding Loop in Phosphonoformic Acid Resistance https://www.frontiersin.org/articles/10.3389/fmicb.2022.771978/full doi.org/10.3389/fmicb.2022.771978 Recombinant BAC PRA 04/03/2022 OJCharles Toledo A 1727 HCMV Toledo UL54 H600L 1.4 0.7 37 Analysis of Novel Drug-Resistant Human Cytomegalovirus DNA Polymerase Mutations Reveals the Role of a DNA-Binding Loop in Phosphonoformic Acid Resistance https://www.frontiersin.org/articles/10.3389/fmicb.2022.771978/full doi.org/10.3389/fmicb.2022.771978 Recombinant BAC PRA UL54 T700A 04/03/2022 OJCharles Toledo A 1729 Adeno ad5 pol V303I 1.9 2.1 Cidofovir Diphosphate Inhibits Adenovirus 5 DNA Polymerase via both Nonobligate Chain Termination and Direct Inhibition, and Polymerase Mutations Confer Cidofovir Resistance on Intact Virus https://aac.asm.org/content/aac/63/1/e01925-18.full.pdf doi.org/10.1128/AAC.01925-18 Lab induced strain Functional enzyme kinetic assay pol T87I 04/02/2022 OJCharles co-occuring uncharacterised mutations O 1730 HCMV AD169 UL97 C480F 17.5 0.84 10 Phenotype and Genotype Study of Novel C480F Maribavir-Ganciclovir Cross-Resistance Mutation Detected in Hematopoietic Stem Cell and Solid Organ Transplant Recipients https://academic.oup.com/jid/article/224/6/1024/6105173 doi.org/10.1093/infdis/jiab029 Recombinant BAC GFP fluorescence reduction assay 05/08/2023 OJCharles AD169 A 1731 HSV1 F UL23 T63A 10 Drug resistance of herpes simplex virus type 1Structural considerations at the molecular level of the thymidine kinase https://febs.onlinelibrary.wiley.com/doi/abs/10.1046/j.1432-1327.1998.2550472.x?sid=nlm%3Apubmed doi.org/10.1046/j.1432-1327.1998.2550472.x Marker transfer TK functional kinetic assay 17/05/2022 OJCharles fold change guessed, no tk activity F A 1732 HSV1 F UL23 T63S 5 Drug resistance of herpes simplex virus type 1Structural considerations at the molecular level of the thymidine kinase https://febs.onlinelibrary.wiley.com/doi/abs/10.1046/j.1432-1327.1998.2550472.x?sid=nlm%3Apubmed doi.org/10.1046/j.1432-1327.1998.2550472.x Marker transfer TK functional kinetic assay 17/05/2022 OJCharles F A 1733 HCMV AD169 UL56 R246C 0.6 1.8 0.9 0.8 0.5 Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045154/ doi.org/10.1128/spectrum.00191-22 Recombinant BAC GFP fluorescence reduction assay 09/10/2022 OJCharles AD169 A 1734 HCMV AD169 UL51 D12E 1.4 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure https://www.sciencedirect.com/science/article/pii/S0166354222001309 doi.org/10.1016/j.antiviral.2022.105361 Recombinant BAC GFP fluorescence reduction assay 09/10/2022 OJCharles AD169 A 1735 HCMV AD169 UL51 A95V 13.8 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure https://www.sciencedirect.com/science/article/pii/S0166354222001309 doi.org/10.1016/j.antiviral.2022.105361 Recombinant BAC GFP fluorescence reduction assay 09/10/2022 OJCharles AD169 A 1736 HCMV AD169 UL51 V113L 1.5 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure https://www.sciencedirect.com/science/article/pii/S0166354222001309 doi.org/10.1016/j.antiviral.2022.105361 Recombinant BAC GFP fluorescence reduction assay 09/10/2022 OJCharles AD169 A 1737 HCMV AD169 UL51 A95V 128 First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure https://www.sciencedirect.com/science/article/pii/S0166354222001309 doi.org/10.1016/j.antiviral.2022.105361 Recombinant BAC GFP fluorescence reduction assay UL56 L257I 09/10/2022 OJCharles AD169 A 1738 HCMV AD169 UL56 V231L 8.8 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4 doi.org/10.1016/j.antiviral.2022.105422 Recombinant BAC SEAP 09/10/2022 OJCharles AD169 A 1739 HCMV AD169 UL56 Q234R 2 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4 doi.org/10.1016/j.antiviral.2022.105422 Recombinant BAC SEAP 09/10/2022 OJCharles AD169 A 1740 HCMV AD169 UL56 L243P 1 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4 doi.org/10.1016/j.antiviral.2022.105422 Recombinant BAC SEAP 09/10/2022 OJCharles AD169 A 1741 HCMV AD169 UL56 S262C 1 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4 doi.org/10.1016/j.antiviral.2022.105422 Recombinant BAC SEAP 09/10/2022 OJCharles AD169 A 1742 HCMV AD169 UL56 L328I 1.4 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4 doi.org/10.1016/j.antiviral.2022.105422 Recombinant BAC SEAP 09/10/2022 OJCharles AD169 A 1743 HCMV AD169 UL56 H335Y 0.8 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4 doi.org/10.1016/j.antiviral.2022.105422 Recombinant BAC SEAP 09/10/2022 OJCharles AD169 A 1744 HCMV AD169 UL56 E339G 1.2 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4 doi.org/10.1016/j.antiviral.2022.105422 Recombinant BAC SEAP 09/10/2022 OJCharles AD169 A 1745 HCMV AD169 UL56 K350R 1 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4 doi.org/10.1016/j.antiviral.2022.105422 Recombinant BAC SEAP 09/10/2022 OJCharles AD169 A 1746 HCMV AD169 UL56 V363I 3.7 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4 doi.org/10.1016/j.antiviral.2022.105422 Recombinant BAC SEAP 09/10/2022 OJCharles AD169 A 1747 HCMV AD169 UL56 N368I 1.3 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4 doi.org/10.1016/j.antiviral.2022.105422 Recombinant BAC SEAP 09/10/2022 OJCharles AD169 A 1748 HCMV AD169 UL56 R369K 4.9 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4 doi.org/10.1016/j.antiviral.2022.105422 Recombinant BAC SEAP 09/10/2022 OJCharles AD169 A 1749 HCMV AD169 UL56 T399I 0.8 Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing https://www.sciencedirect.com/science/article/pii/S0166354222001917#bib4 doi.org/10.1016/j.antiviral.2022.105422 Recombinant BAC SEAP 09/10/2022 OJCharles AD169 A 1750 HCMV AD169 UL54 G441S Polymorphism Polymorphism Polymorphism Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection https://academic.oup.com/jid/article-abstract/226/9/1528/6672993 doi.org/10.1093/infdis/jiac349 Isolated strain PRA 05/08/2023 OJCharles AD169 A 1751 HCMV AD169 UL54 A543V Resistant Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection https://academic.oup.com/jid/article-abstract/226/9/1528/6672993 doi.org/10.1093/infdis/jiac349 Isolated strain PRA UL54 M460I 05/08/2023 OJCharles co-occurs with M460I which causes GCVr and has not been tested against CDV but given GCVr it is more likely it causes CDVr and A543V is therefore hard to determine AD169 O 1752 HCMV AD169 UL54 F460S Polymorphism Polymorphism Polymorphism Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection https://academic.oup.com/jid/article-abstract/226/9/1528/6672993 doi.org/10.1093/infdis/jiac349 Isolated strain PRA 05/08/2023 OJCharles AD169 A 1753 HCMV AD169 UL54 R512C Polymorphism Polymorphism Polymorphism Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection https://academic.oup.com/jid/article-abstract/226/9/1528/6672993 doi.org/10.1093/infdis/jiac349 Isolated strain PRA 05/08/2023 OJCharles AD169 A 1754 HCMV AD169 UL54 A928T Resistant Resistant Resistant Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection https://academic.oup.com/jid/article-abstract/226/9/1528/6672993 doi.org/10.1093/infdis/jiac349 Isolated strain PRA 05/08/2023 OJCharles no other mutations noted AD169 A 1755 HCMV AD169 UL56 F345L 1.42 1.67 1 1 Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection https://academic.oup.com/jid/article-abstract/226/9/1528/6672993 doi.org/10.1093/infdis/jiac349 Isolated strain PRA 05/08/2023 OJCharles AD169 A 1756 HCMV AD169 UL56 P800L 0.23 0.13 1 1.1 Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection https://academic.oup.com/jid/article-abstract/226/9/1528/6672993 doi.org/10.1093/infdis/jiac349 Isolated strain PRA 05/08/2023 OJCharles AD169 A 1757 HSV1 KOS UL30 Q727R Resistant Resistant A Herpes Simplex Virus 1 DNA Polymerase Multidrug Resistance Mutation Identified in a Patient With Immunodeficiency and Confirmed by Gene Editing https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiad184/7177683?redirectedFrom=fulltext doi.org/10.1093/infdis/jiad184 Marker transfer Cytopathic effect 05/08/2023 OJCharles KOS A 1758 HSV1 Clinical isolate UL30 R264C 1.9 0.6 1.2 0.7 1.2 2 A Herpes Simplex Virus 1 DNA Polymerase Multidrug Resistance Mutation Identified in a Patient With Immunodeficiency and Confirmed by Gene Editing https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiad184/7177683?redirectedFrom=fulltext doi.org/10.1093/infdis/jiad184 Isolated strain Cytopathic effect 05/08/2023 OJCharles lost ref KOS P 1759 HSV1 Clinical isolate UL30 T245M 199 297 1.2 0.9 545 467 A Herpes Simplex Virus 1 DNA Polymerase Multidrug Resistance Mutation Identified in a Patient With Immunodeficiency and Confirmed by Gene Editing https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiad184/7177683?redirectedFrom=fulltext doi.org/10.1093/infdis/jiad184 Isolated strain Cytopathic effect 05/08/2023 OJCharles lost ref KOS O 1760 HCMV AD169 UL56 V231L 5.6 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1761 HCMV AD169 UL56 L241P 173 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1762 HCMV AD169 UL56 R369M 16 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1763 HCMV AD169 UL89 D344E 1.6 A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance https://www.sciencedirect.com/science/article/pii/S0166354217306393 doi.org/10.1016/j.antiviral.2017.10.019 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1764 HCMV AD169 UL56 V231L 8.1 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf doi.org/10.1128/AAC.00922-18 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1765 HCMV AD169 UL56 V236M 49 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf doi.org/10.1128/AAC.00922-18 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1766 HCMV AD169 UL56 L257F 14 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf doi.org/10.1128/AAC.00922-18 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1767 HCMV AD169 UL56 C325Y 8800 New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir https://aac.asm.org/content/aac/62/9/e00922-18.full.pdf doi.org/10.1128/AAC.00922-18 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1768 HCMV AD169 UL27 R448P 1.5 Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo https://www.sciencedirect.com/science/article/pii/S0166354212001283 doi.org/10.1016/j.antiviral.2012.05.013 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1769 HCMV AD169 UL27 D534Y 1.4 Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo https://www.sciencedirect.com/science/article/pii/S0166354212001283 doi.org/10.1016/j.antiviral.2012.05.013 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1770 HCMV AD169 UL97 I324V 0.6 Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo https://www.sciencedirect.com/science/article/pii/S0166354212001283 doi.org/10.1016/j.antiviral.2012.05.013 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1771 HCMV AD169 UL97 S334G 1.1 Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo https://www.sciencedirect.com/science/article/pii/S0166354212001283 doi.org/10.1016/j.antiviral.2012.05.013 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1772 HCMV AD169 UL27 R233S 2 Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo https://www.sciencedirect.com/science/article/pii/S0166354212001283 doi.org/10.1016/j.antiviral.2012.05.013 Recombinant BAC SEAP UL97 S334G 07/08/2023 OJCharles AD169 A 1773 HCMV AD169 UL97 L337M 7.2 Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo https://www.sciencedirect.com/science/article/pii/S0166354212001283 doi.org/10.1016/j.antiviral.2012.05.013 Recombinant BAC SEAP UL27 R233S 07/08/2023 OJCharles AD169 A 1774 HCMV AD169 UL97 V353A 12 Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo https://www.sciencedirect.com/science/article/pii/S0166354212001283 doi.org/10.1016/j.antiviral.2012.05.013 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1775 HCMV AD169 UL97 S386L 0.9 Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo https://www.sciencedirect.com/science/article/pii/S0166354212001283 doi.org/10.1016/j.antiviral.2012.05.013 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1776 HCMV Clinical isolate UL97 M460V 6 1 Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action https://journals.asm.org/doi/full/10.1128/aac.46.8.2365-2372.2002 doi.org/10.1128/aac.46.8.2365-2372.2002 Isolated strain PCR DNA hybridization assay 07/08/2023 OJCharles AD169 A 1777 HCMV Clinical isolate UL97 H520E 5.2 1.6 Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action https://journals.asm.org/doi/full/10.1128/aac.46.8.2365-2372.2002 doi.org/10.1128/aac.46.8.2365-2372.2002 Isolated strain PCR DNA hybridization assay 07/08/2023 OJCharles AD169 A 1778 HCMV Clinical isolate UL97 A594V 6 Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action https://journals.asm.org/doi/full/10.1128/aac.46.8.2365-2372.2002 doi.org/10.1128/aac.46.8.2365-2372.2002 Isolated strain PCR DNA hybridization assay 07/08/2023 OJCharles AD169 A 1779 HCMV Clinical isolate UL54 T700A 2.2 0.8 Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action https://journals.asm.org/doi/full/10.1128/aac.46.8.2365-2372.2002 doi.org/10.1128/aac.46.8.2365-2372.2002 Isolated strain PCR DNA hybridization assay 07/08/2023 OJCharles AD169 A 1780 HCMV Clinical isolate UL97 L397R 1 34 Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action https://journals.asm.org/doi/full/10.1128/aac.46.8.2365-2372.2002 doi.org/10.1128/aac.46.8.2365-2372.2002 Isolated strain PCR DNA hybridization assay 07/08/2023 OJCharles AD169 A 1781 HCMV AD169 UL27 V353A 16 Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under Maribavir https://aac.asm.org/content/53/1/81 doi.org/10.1128/AAC.01177-08 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1782 HCMV AD169 UL97 V353A 1.7 15 Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant https://jvi.asm.org/content/82/1/246.short doi.org/10.1128/JVI.01787-07 Marker transfer SEAP 07/08/2023 OJCharles AD169 A 1783 HCMV AD169 UL97 H587Y 1 1 Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II Mutant https://jvi.asm.org/content/82/1/246.short doi.org/10.1128/JVI.01787-07 Marker transfer SEAP 07/08/2023 OJCharles AD169 A 1784 HCMV AD169 UL27 R233S 4.7 Mutations in the Human Cytomegalovirus UL27 Gene That Confer Resistance to Maribavir https://journals.asm.org/doi/full/10.1128/jvi.78.13.7124-7130.2004 doi.org/10.1128/jvi.78.13.7124-7130.2004 Marker Transfer PRA 07/08/2023 OJCharles AD169 A 1785 HCMV AD169 UL27 W362R 2 Mutations in the Human Cytomegalovirus UL27 Gene That Confer Resistance to Maribavir https://journals.asm.org/doi/full/10.1128/jvi.78.13.7124-7130.2004 doi.org/10.1128/jvi.78.13.7124-7130.2004 Marker Transfer PRA 07/08/2023 OJCharles AD169 A 1786 HCMV AD169 UL97 M460V 7 0.3 Cytomegalovirus UL97 Kinase Mutations That Confer Maribavir Resistance https://academic.oup.com/jid/article-lookup/doi/10.1086/518514 doi.org/10.1086/518514 Marker Transfer SEAP 07/08/2023 OJCharles AD169 A 1787 HCMV AD169 UL97 V353A 10 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf doi.org/10.1128/AAC.00511-13 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1788 HCMV AD169 UL97 M460I 11 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf doi.org/10.1128/AAC.00511-13 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1789 HCMV AD169 UL97 C592G 2.7 Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance https://aac.asm.org/content/aac/57/7/3375.full.pdf doi.org/10.1128/AAC.00511-13 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1790 HCMV AD169 UL97 A594V 8.3 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1791 HCMV AD169 UL97 C603R 8.3 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1792 HCMV AD169 UL97 V665I 1.1 Recombinant Phenotyping of Cytomegalovirus UL97 Kinase Sequence Variants for Ganciclovir Resistance https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876423/ doi.org/10.1128/AAC.00186-10 Recombinant BAC SEAP 07/08/2023 OJCharles AD169 A 1793 HCMV AD169 UL97 K355M 25 13 Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions https://journals.asm.org/doi/full/10.1128/aac.01726-13 doi.org/10.1128/aac.01726-13 Recombinant BAC PRA 07/08/2023 OJCharles AD169 A 1794 HCMV Towne UL97 C592G 2.5 Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir https://academic.oup.com/jid/article/185/2/162/2191141 doi.org/10.1086/338362 Marker Transfer PRA 07/08/2023 OJCharles Towne A 1795 HCMV Towne UL97 L634Q 1.1 Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir https://academic.oup.com/jid/article/185/2/162/2191141 doi.org/10.1086/338362 Marker Transfer PRA 07/08/2023 OJCharles Towne A 1796 HCMV Towne UL97 C607F 1.6 Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir https://academic.oup.com/jid/article/185/2/162/2191141 doi.org/10.1086/338362 Marker Transfer PRA 07/08/2023 OJCharles Towne A 1797 HCMV AD169 UL97 L595S 4.9 Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir https://academic.oup.com/jid/article/185/2/162/2191141 doi.org/10.1086/338362 Marker Transfer PRA 07/08/2023 OJCharles AD169 A 1798 HCMV AD169 UL97 C592G 2.6 Cytomegalovirus UL97 Phosphotransferase Mutations That Affect Susceptibility to Ganciclovir https://academic.oup.com/jid/article/185/2/162/2191141 doi.org/10.1086/338362 Marker Transfer PRA 07/08/2023 OJCharles AD169 A 1799 HCMV Clinical Isolate UL97 L595F 1 0.4 1.5 High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes https://academic.oup.com/jid/article/176/1/69/901024 doi.org/10.1086/514041 Isolated strain PRA 07/08/2023 OJCharles A 1800 HCMV Clinical Isolate UL97 A594V 1.7 1.7 1.1 High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes https://academic.oup.com/jid/article/176/1/69/901024 doi.org/10.1086/514041 Isolated strain PRA 07/08/2023 OJCharles A 1801 HCMV Clinical Isolate UL97 M460V 1.7 1.2 0.9 High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes https://academic.oup.com/jid/article/176/1/69/901024 doi.org/10.1086/514041 Isolated strain PRA 07/08/2023 OJCharles A 1802 HCMV Clinical Isolate UL97 M460I 2.2 1 0.6 High-Level Resistance of Cytomegalovirus to Ganciclovir Is Associated with Alterations in Both the UL97 and DNA Polymerase Genes https://academic.oup.com/jid/article/176/1/69/901024 doi.org/10.1086/514041 Isolated strain PRA 07/08/2023 OJCharles A 1803 HCMV Clinical Isolate UL97 L595S 4 1 1 Analysis and Characterization of Antiviral Drug–Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients https://academic.oup.com/jid/article/186/6/760/2191110 doi.org/10.1086/342844 Isolated strain PRA 07/08/2023 OJCharles A 1804 HCMV Clinical Isolate UL97 H520Q 3.2 0.5 1.5 Analysis and Characterization of Antiviral Drug–Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients https://academic.oup.com/jid/article/186/6/760/2191110 doi.org/10.1086/342844 Isolated strain PRA 07/08/2023 OJCharles A 1805 HCMV Clinical Isolate UL97 A594P 2.6 2.5 0.7 Analysis and Characterization of Antiviral Drug–Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients https://academic.oup.com/jid/article/186/6/760/2191110 doi.org/10.1086/342844 Isolated strain PRA 07/08/2023 OJCharles A 1806 HCMV Clinical Isolate UL54 F412S 2.3 16 1 Analysis and Characterization of Antiviral Drug–Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients https://academic.oup.com/jid/article/186/6/760/2191110 doi.org/10.1086/342844 Isolated strain PRA 07/08/2023 OJCharles A 1807 HCMV Clinical Isolate UL97 A594V 1.8 Analysis and Characterization of Antiviral Drug–Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients https://academic.oup.com/jid/article/186/6/760/2191110 doi.org/10.1086/342844 Isolated strain PRA 07/08/2023 OJCharles large discrepencies between reps O 1808 HCMV Clinical Isolate UL97 C607Y 4 Analysis and Characterization of Antiviral Drug–Resistant Cytomegalovirus Isolates from Solid Organ Transplant Recipients https://academic.oup.com/jid/article/186/6/760/2191110 doi.org/10.1086/342844 Isolated strain PRA 07/08/2023 OJCharles A 1809 HCMV UL97 L595F 7 Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma https://www.jci.org/articles/view/117648 doi.org/10.1172/jci117648 Isolated strain PRA 14/08/2023 OJCharles A 1810 HCMV UL97 T659I 4 Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma https://www.jci.org/articles/view/117648 doi.org/10.1172/jci117648 Isolated strain PRA 14/08/2023 OJCharles A 1811 HCMV UL54 V715M 1 5.5 Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS https://journals.asm.org/doi/10.1128/JVI.70.3.1390-1395.1996 doi.org/10.1128/jvi.70.3.1390-1395.1996 Marker Transfer PRA 14/08/2023 OJCharles AD169 A 1812 HCMV AD169 UL54 N495K 1 2.5 5.6 Rapid determination of antiviral drug susceptibility of human cytomegalovirus by real-time PCR https://www.sciencedirect.com/science/article/pii/S0166354208004221 doi.org/10.1016/j.antiviral.2008.09.009 Marker Transfer PRA 14/08/2023 OJCharles AD169 A 1813 HCMV AD169 UL54 L545S 8 10 Rapid determination of antiviral drug susceptibility of human cytomegalovirus by real-time PCR https://www.sciencedirect.com/science/article/pii/S0166354208004221 doi.org/10.1016/j.antiviral.2008.09.009 Marker Transfer PRA 14/08/2023 OJCharles AD169 A 1814 HCMV UL97 A594V 10 Antiviral Susceptibilities and Analysis of UL97 and DNA Polymerase Sequences of Clinical Cytomegalovirus Isolates from Immunocompromised Patients https://academic.oup.com/jid/article/175/5/1087/853432 doi.org/10.1086/516446 Isolated strain PRA 14/08/2023 OJCharles A 1815 HCMV UL97 A594T 5 Antiviral Susceptibilities and Analysis of UL97 and DNA Polymerase Sequences of Clinical Cytomegalovirus Isolates from Immunocompromised Patients https://academic.oup.com/jid/article/175/5/1087/853432 doi.org/10.1086/516446 Isolated strain PRA 14/08/2023 OJCharles A 1816 HCMV UL97 C603W Resistant Polymorphism Polymorphism Drug-resistant cytomegalovirus in transplant recipients: a French cohort study https://academic.oup.com/jac/article/65/12/2628/755060#13268428 doi.org/10.1093/jac/dkq368 Isolated strain PCR DNA hybridization assa 14/08/2023 OJCharles AD169 A 1817 HCMV UL54 A834P Resistant Resistant Resistant Drug-resistant cytomegalovirus in transplant recipients: a French cohort study https://academic.oup.com/jac/article/65/12/2628/755060#13268428 doi.org/10.1093/jac/dkq368 Isolated strain PCR DNA hybridization assa 14/08/2023 OJCharles AD169 A 1818 HCMV UL97 M460V 8.2 Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients www.sciencedirect.com/science/article/pii/S1386653206004161 doi.org/10.1016/j.jcv.2006.11.005 Marker Transfer SEAP 14/08/2023 OJCharles AD169 A 1819 HCMV UL54 D413A 6.5 10 0.8 Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients www.sciencedirect.com/science/article/pii/S1386653206004161 doi.org/10.1016/j.jcv.2006.11.005 Marker Transfer SEAP 14/08/2023 OJCharles AD169 A 1820 HCMV Towne UL54 D588N 3.8 2.7 3.2 How Evolution of Mutations Conferring Drug Resistance Affects Viral Dynamics and Clinical Outcomes of Cytomegalovirus-Infected Hematopoietic Cell Transplant Recipients https://www.ncbi.nlm.nih.gov/pmc/articles/PMC540138/ doi.org/10.1128/JCM.43.1.208-213.2005 Marker Transfer PRA 14/08/2023 OJCharles Towne A 1821 HCMV UL97 C592F 4 0.8 1.8 1.6 Aciclovir Selects for Ganciclovir-Cross-Resistance ofHuman Cytomegalovirus In Vitro That is Only in PartExplained by Known Mutations in the UL97 Protein https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.2003 doi.org/10.1002/jmv.2003 Lab derived mutant PRA 14/08/2023 OJCharles A 1822 HCMV UL97 K599M 1.5 1.6 1 3.8 Aciclovir Selects for Ganciclovir-Cross-Resistance ofHuman Cytomegalovirus In Vitro That is Only in PartExplained by Known Mutations in the UL97 Protein https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.2003 doi.org/10.1002/jmv.2003 Lab derived mutant PRA 14/08/2023 OJCharles Reported as L599M compared to AD169 which has K599 and L600. Assuming the correct mutation is K599M A 1823 HCMV UL54 F412C 3.6 10 2.5 Evolution of Mutations Conferring Multidrug Resistance during Prophylaxis and Therapy for Cytomegalovirus Disease https://academic.oup.com/jid/article/176/3/786/872103 doi.org/10.1086/517302 Lab derived mutant PRA 14/08/2023 OJCharles AD169 A 1824 HCMV UL54 L802M 3.6 1.8 11 Evolution of Mutations Conferring Multidrug Resistance during Prophylaxis and Therapy for Cytomegalovirus Disease https://academic.oup.com/jid/article/176/3/786/872103 doi.org/10.1086/517302 Lab derived mutant PRA 14/08/2023 OJCharles AD169 A 1825 HCMV AD169 UL97 D605E 0.6 GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E https://www.sciencedirect.com/science/article/pii/S0166354201002029 doi.org/10.1016/S0166-3542(01)00202-9 Marker Transfer PRA 14/08/2023 OJCharles AD169 A 1826 HCMV AD169 UL97 A594P 4.6 GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E https://www.sciencedirect.com/science/article/pii/S0166354201002029 doi.org/10.1016/S0166-3542(01)00202-9 Marker Transfer PRA 14/08/2023 OJCharles AD169 A 1827 HCMV AD169 UL97 A594P 3.8 GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E https://www.sciencedirect.com/science/article/pii/S0166354201002029 doi.org/10.1016/S0166-3542(01)00202-9 Marker Transfer PRA UL97 D605E 14/08/2023 OJCharles AD169 A 1828 HCMV TB40 UL97 M460V 5.9 Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay https://www.sciencedirect.com/science/article/abs/pii/S1386653215002759 doi.org/10.1016/j.jcv.2015.06.090 Recombinant BAC PRA 14/08/2023 OJCharles TB40 A 1829 HCMV TB40 UL97 I610T 2.6 Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay https://www.sciencedirect.com/science/article/abs/pii/S1386653215002759 doi.org/10.1016/j.jcv.2015.06.090 Recombinant BAC PRA 14/08/2023 OJCharles TB40 A 1830 HCMV TB40 UL97 E596D 1.3 Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay https://www.sciencedirect.com/science/article/abs/pii/S1386653215002759 doi.org/10.1016/j.jcv.2015.06.090 Recombinant BAC PRA 14/08/2023 OJCharles TB40 A 1831 HCMV TB40 UL54 D515E 2.4 1.6 1.1 Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay https://www.sciencedirect.com/science/article/abs/pii/S1386653215002759 doi.org/10.1016/j.jcv.2015.06.090 Recombinant BAC PRA 14/08/2023 OJCharles TB40 A 1832 HCMV TB40 UL54 I521T 2.1 4.9 1 Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay https://www.sciencedirect.com/science/article/abs/pii/S1386653215002759 doi.org/10.1016/j.jcv.2015.06.090 Recombinant BAC PRA 14/08/2023 OJCharles TB40 A 1833 HCMV TB40 UL54 L516M 1.3 1.1 1.2 Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation https://www.sciencedirect.com/science/article/abs/pii/S0166354213002866 doi.org/10.1016/j.antiviral.2013.09.026 Recombinant BAC PRA 14/08/2023 OJCharles TB40 A 1834 HCMV Clinical isolate UL97 M460V 15.5 Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation https://www.sciencedirect.com/science/article/abs/pii/S0166354213002866 doi.org/10.1016/j.antiviral.2013.09.026 Isolated strain PRA 14/08/2023 OJCharles TB40 A 1835 HCMV Clinical isolate UL97 M615V 1.1 Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis https://www.sciencedirect.com/science/article/abs/pii/S1386653210000181 doi.org/10.1016/j.jcv.2010.01.009 Recombinant BAC PRA 14/08/2023 OJCharles A 1836 HCMV UL97 C603R 3.6 Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis https://www.sciencedirect.com/science/article/abs/pii/S1386653210000181 doi.org/10.1016/j.jcv.2010.01.009 Recombinant BAC PRA 14/08/2023 OJCharles A 1837 HCMV AD169 UL97 C592G 3 Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene https://journals.asm.org/doi/10.1128/JCM.00391-17 doi.org/10.1128/jcm.00391-17 Recombinant BAC SEAP 14/08/2023 OJCharles AD169 A 1838 HCMV AD169 UL97 A594V 6.5 Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene https://journals.asm.org/doi/10.1128/JCM.00391-17 doi.org/10.1128/jcm.00391-17 Recombinant BAC SEAP 14/08/2023 OJCharles AD169 A 1839 HCMV AD169 UL97 A591V 3.8 Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene https://journals.asm.org/doi/10.1128/JCM.00391-17 doi.org/10.1128/jcm.00391-17 Recombinant BAC SEAP 14/08/2023 OJCharles AD169 A 1840 HCMV AD169 UL97 K599E 1.2 Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene https://journals.asm.org/doi/10.1128/JCM.00391-17 doi.org/10.1128/jcm.00391-17 Recombinant BAC SEAP 14/08/2023 OJCharles AD169 A 1841 HCMV AD169 UL97 T601M 1 Differentiated Levels of Ganciclovir Resistance Conferred by Mutations at Codons 591 to 603 of the Cytomegalovirus UL97 Kinase Gene https://journals.asm.org/doi/10.1128/JCM.00391-17 doi.org/10.1128/jcm.00391-17 Recombinant BAC SEAP 14/08/2023 OJCharles AD169 A 1842 HCMV AD169 UL54 L897S 1 1 0.9 Phenotyping of Cytomegalovirus Drug Resistance Mutations by Using Recombinant Viruses Incorporating a Reporter Gene https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168698/ doi.org/10.1128/AAC.49.7.2710-2715.2005 Lab derived mutant SEAP 15/08/2023 OJCharles you can draw this as we know UL97H587Y has no impact A 1843 HCMV AD169 UL97 M460V 9 Phenotyping of Cytomegalovirus Drug Resistance Mutations by Using Recombinant Viruses Incorporating a Reporter Gene https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168698/ doi.org/10.1128/AAC.49.7.2710-2715.2005 Lab derived mutant SEAP 15/08/2023 OJCharles A 1844 HCMV AD169 UL97 C592G 3 1.4 1 Phenotyping of Cytomegalovirus Drug Resistance Mutations by Using Recombinant Viruses Incorporating a Reporter Gene https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168698/ doi.org/10.1128/AAC.49.7.2710-2715.2005 Lab derived mutant SEAP 15/08/2023 OJCharles A 1845 HCMV AD169 UL97 A594V 9 Phenotyping of Cytomegalovirus Drug Resistance Mutations by Using Recombinant Viruses Incorporating a Reporter Gene https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168698/ doi.org/10.1128/AAC.49.7.2710-2715.2005 Lab derived mutant SEAP 15/08/2023 OJCharles A 1846 HCMV AD169 UL54 N408H 2 3.3 1.1 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334 doi.org/10.1093/infdis/jiad293 Recombinant BAC SEAP 29/11/2023 OJCharles A 1847 HCMV AD169 UL54 L501F 2.6 3.8 1.3 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334 doi.org/10.1093/infdis/jiad293 Recombinant BAC SEAP 29/11/2023 OJCharles AD169 A 1848 HCMV AD169 UL54 T503A 3.1 3.7 1.5 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334 doi.org/10.1093/infdis/jiad293 Recombinant BAC SEAP 29/11/2023 OJCharles AD169 A 1849 HCMV AD169 UL54 K513Q 6.6 18 1 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334 doi.org/10.1093/infdis/jiad293 Recombinant BAC SEAP 29/11/2023 OJCharles AD169 A 1850 HCMV AD169 UL54 P522T 2.1 2 1.4 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334 doi.org/10.1093/infdis/jiad293 Recombinant BAC SEAP 29/11/2023 OJCharles AD169 A 1851 HCMV AD169 UL54 L545F 4 11 1.2 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334 doi.org/10.1093/infdis/jiad293 Recombinant BAC SEAP 29/11/2023 OJCharles AD169 A 1852 HCMV AD169 UL54 C590F 1.6 1.6 2.3 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334 doi.org/10.1093/infdis/jiad293 Recombinant BAC SEAP 29/11/2023 OJCharles AD169 A 1853 HCMV AD169 UL97 A594P 8.1 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334 doi.org/10.1093/infdis/jiad293 Recombinant BAC SEAP 29/11/2023 OJCharles AD169 A 1854 HCMV AD169 UL97 E596Q 2.7 Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad293/7233334 doi.org/10.1093/infdis/jiad293 Recombinant BAC SEAP 29/11/2023 OJCharles AD169 A 1855 HSV2 Clinical isolate UL30 L783M 2.7 7.6 Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.2195 doi.org/10.1002/jmv.2195 Isolated strain PRA 01/12/2023 OJCharles A 1856 HSV2 Clinical isolate UL30 A724T 1 3.1 Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.2195 doi.org/10.1002/jmv.2195 Isolated strain PRA 01/12/2023 OJCharles A 1857 HSV2 Clinical isolate UL30 S729N 1.6 3.2 Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.2195 doi.org/10.1002/jmv.2195 Isolated strain PRA 01/12/2023 OJCharles A 1858 HSV2 Clinical isolate UL30 D785N 0.3 3.9 Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.2195 doi.org/10.1002/jmv.2195 Isolated strain PRA 01/12/2023 OJCharles A 1859 HSV2 Clinical isolate UL30 L850I 0.3 9.2 Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.2195 doi.org/10.1002/jmv.2195 Isolated strain PRA 01/12/2023 OJCharles A 1860 HSV1 PDK UL52 A899T 43 A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target https://academic.oup.com/jac/article/61/5/1044/847175 doi.org/10.1093/jac/dkn057 Lab derived mutant PRA 01/12/2023 OJCharles PDK A 1861 HSV1 PDK UL52 A899T 2500 A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target https://academic.oup.com/jac/article/61/5/1044/847175 doi.org/10.1093/jac/dkn057 Lab derived mutant PRA UL5 K356T 01/12/2023 OJCharles PDK A 1862 HSV1 PDK UL52 A899T 100 A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target https://academic.oup.com/jac/article/61/5/1044/847175 doi.org/10.1093/jac/dkn057 Lab derived mutant PRA 01/12/2023 OJCharles PDK A 1863 HSV1 SC16 UL5 K356Q 100 A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target https://academic.oup.com/jac/article/61/5/1044/847175 doi.org/10.1093/jac/dkn057 Lab derived mutant PRA 01/12/2023 OJCharles SC16 A 1864 HSV1 SC16 UL5 G352R 3333 A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target https://academic.oup.com/jac/article/61/5/1044/847175 doi.org/10.1093/jac/dkn057 Lab derived mutant PRA 01/12/2023 OJCharles SC16 A 1865 HSV1 SC16 UL5 K356T 100 A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target https://academic.oup.com/jac/article/61/5/1044/847175 doi.org/10.1093/jac/dkn057 Lab derived mutant PRA 01/12/2023 OJCharles SC16 A 1866 HSV1 SC16 UL5 K356T 124 A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target https://academic.oup.com/jac/article/61/5/1044/847175 doi.org/10.1093/jac/dkn057 Lab derived mutant PRA 01/12/2023 OJCharles SC16 A 1867 HSV1 SC16 UL5 M355T 15 High Frequency of Spontaneous Helicaseprimase Inhibitor (BAY 57–1293) Drug-Resistant Variants in Certain Laboratory Isolates of HSV-1 https://journals.sagepub.com/doi/10.1177/095632020701800102 doi.org/10.1177/095632020701800102 Lab derived mutant PRA 01/12/2023 OJCharles my concern with this paper is that they do not cover other important genes eg BAY-Pr1 is 50fold resistance with no ul5 mutations discard all? A 1868 HSV1 SC16 UL5 K356T 125 High Frequency of Spontaneous Helicaseprimase Inhibitor (BAY 57–1293) Drug-Resistant Variants in Certain Laboratory Isolates of HSV-1 https://journals.sagepub.com/doi/10.1177/095632020701800102 doi.org/10.1177/095632020701800102 Lab derived mutant PRA 01/12/2023 OJCharles my concern with this paper is that they do not cover other important genes eg BAY-Pr1 is 50fold resistance with no ul5 mutations discard all? A 1869 HSV1 SC16 UL5 G352R 4000 High Frequency of Spontaneous Helicaseprimase Inhibitor (BAY 57–1293) Drug-Resistant Variants in Certain Laboratory Isolates of HSV-1 https://journals.sagepub.com/doi/10.1177/095632020701800102 doi.org/10.1177/095632020701800102 Lab derived mutant PRA 01/12/2023 OJCharles my concern with this paper is that they do not cover other important genes eg BAY-Pr1 is 50fold resistance with no ul5 mutations discard all? A 1870 HSV1 PDK UL5 A199T 50 High Frequency of Spontaneous Helicaseprimase Inhibitor (BAY 57–1293) Drug-Resistant Variants in Certain Laboratory Isolates of HSV-1 https://journals.sagepub.com/doi/10.1177/095632020701800102 doi.org/10.1177/095632020701800102 Lab derived mutant PRA 01/12/2023 OJCharles my concern with this paper is that they do not cover other important genes eg BAY-Pr1 is 50fold resistance with no ul5 mutations discard all? A 1871 HSV1 PDK UL5 K356T 2000 High Frequency of Spontaneous Helicaseprimase Inhibitor (BAY 57–1293) Drug-Resistant Variants in Certain Laboratory Isolates of HSV-1 https://journals.sagepub.com/doi/10.1177/095632020701800102 doi.org/10.1177/095632020701800102 Lab derived mutant PRA 01/12/2023 OJCharles my concern with this paper is that they do not cover other important genes eg BAY-Pr1 is 50fold resistance with no ul5 mutations discard all? A 1872 HSV2 Clinical isolate UL5 H334R Polymorphism No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy https://academic.oup.com/jid/article/214/2/258/2572113 doi.org/10.1093/infdis/jiw129 Isolated strain PRA 01/12/2023 OJCharles Bry A 1873 HSV1 UL5 N342K 40 Antiviral drug resistance and helicase–primase inhibitors of herpes simplex virus https://www.sciencedirect.com/science/article/abs/pii/S1368764610000609 doi.org/10.1016/j.drup.2010.11.002 Lab derived mutant PRA 01/12/2023 OJCharles A 1874 HSV1 UL5 G352V 400 Antiviral drug resistance and helicase–primase inhibitors of herpes simplex virus https://www.sciencedirect.com/science/article/abs/pii/S1368764610000609 doi.org/10.1016/j.drup.2010.11.002 Lab derived mutant PRA 01/12/2023 OJCharles A 1875 HSV1 UL5 G352R 3000 Antiviral drug resistance and helicase–primase inhibitors of herpes simplex virus https://www.sciencedirect.com/science/article/abs/pii/S1368764610000609 doi.org/10.1016/j.drup.2010.11.002 Lab derived mutant PRA 01/12/2023 OJCharles A 1876 HSV1 UL5 M355T 5 Antiviral drug resistance and helicase–primase inhibitors of herpes simplex virus https://www.sciencedirect.com/science/article/abs/pii/S1368764610000609 doi.org/10.1016/j.drup.2010.11.002 Lab derived mutant PRA 01/12/2023 OJCharles A 1877 HSV1 UL5 K356N 5000 Antiviral drug resistance and helicase–primase inhibitors of herpes simplex virus https://www.sciencedirect.com/science/article/abs/pii/S1368764610000609 doi.org/10.1016/j.drup.2010.11.002 Lab derived mutant PRA 01/12/2023 OJCharles A 1878 HSV1 UL5 K356Q 150 Antiviral drug resistance and helicase–primase inhibitors of herpes simplex virus https://www.sciencedirect.com/science/article/abs/pii/S1368764610000609 doi.org/10.1016/j.drup.2010.11.002 Lab derived mutant PRA 01/12/2023 OJCharles A 1879 HSV2 UL23 A190V 8 Genotypic testing improves detection of antiviral resistance in human herpes simplex virus https://www.sciencedirect.com/science/article/pii/S1386653223001774 doi.org/10.1016/j.jcv.2023.105554 Isolated strain PRA 01/12/2023 OJCharles A 1880 HSV2 UL30 T1200A 1 Genotypic testing improves detection of antiviral resistance in human herpes simplex virus https://www.sciencedirect.com/science/article/pii/S1386653223001774 doi.org/10.1016/j.jcv.2023.105554 Isolated strain PRA 01/12/2023 OJCharles A 1881 HSV1 KOS UL30 Y941H 10 Resistant A Point Mutation within a Distinct Conserved Region of the Herpes Simplex Virus DNA Polymerase Gene Confers Drug Resistance https://journals.asm.org/doi/10.1128/jvi.66.3.1774-1776.1992 doi.org/10.1128/jvi.66.3.1774-1776.1992 Marker Transfer PRA 01/12/2023 OJCharles KOS A 1882 HSV1 Clinical isolate UL30 L216I 1 1 1 Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients https://academic.oup.com/jid/article/215/6/865/2973094 doi.org/10.1093/infdis/jix042 Isolated strain PRA 01/12/2023 OJCharles TAS A 1883 HSV1 Clinical isolate UL30 I890M 1 3.5 5.7 Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients https://academic.oup.com/jid/article/215/6/865/2973094 doi.org/10.1093/infdis/jix042 Isolated strain PRA 01/12/2023 OJCharles TAS A 1884 HSV1 Clinical isolate UL23 L327R 4.2 10 0.6 Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients https://academic.oup.com/jid/article/215/6/865/2973094 doi.org/10.1093/infdis/jix042 Isolated strain PRA 01/12/2023 OJCharles TAS A 1885 HSV1 Clinical isolate UL30 R700G 0.1 0.8 1.2 Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients https://academic.oup.com/jid/article/215/6/865/2973094 doi.org/10.1093/infdis/jix042 Isolated strain PRA 01/12/2023 OJCharles many herpesdrgnovel mutations in strain but good repeated evidence mutations together are natural polymorphims TAS A 1886 HSV1 Clinical isolate UL30 A748V 0.1 0.8 1.2 Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients https://academic.oup.com/jid/article/215/6/865/2973094 doi.org/10.1093/infdis/jix042 Isolated strain PRA 01/12/2023 OJCharles many herpesdrgnovel mutations in strain but good repeated evidence mutations together are natural polymorphims TAS A 1887 HSV1 Clinical isolate UL30 K908Q 0.1 0.8 1.2 Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients https://academic.oup.com/jid/article/215/6/865/2973094 doi.org/10.1093/infdis/jix042 Isolated strain PRA 01/12/2023 OJCharles many herpesdrgnovel mutations in strain but good repeated evidence mutations together are natural polymorphims TAS A 1888 HSV1 Clinical isolate UL30 A605V 0.1 3.1 3.5 Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients https://academic.oup.com/jid/article/215/6/865/2973094 doi.org/10.1093/infdis/jix042 Isolated strain PRA 01/12/2023 OJCharles TAS A 1889 HSV1 Clinical isolate UL23 G279D 0.8 Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients https://academic.oup.com/jid/article/215/6/865/2973094 doi.org/10.1093/infdis/jix042 Isolated strain PRA 01/12/2023 OJCharles TAS A 1890 HSV1 Clinical isolate UL23 G56D 10 4.7 1.7 Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients https://academic.oup.com/jid/article/215/6/865/2973094 doi.org/10.1093/infdis/jix042 Isolated strain PRA 01/12/2023 OJCharles TAS A 1891 HSV1 Clinical isolate UL30 V278A 0.1 0.3 0.3 Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients https://academic.oup.com/jid/article/215/6/865/2973094 doi.org/10.1093/infdis/jix042 Isolated strain PRA 01/12/2023 OJCharles many herpesdrgnovel mutations in strain but good repeated evidence mutations together are natural polymorphims TAS A 1892 HSV1 Clinical isolate UL30 A1131T 0.1 0.3 0.3 Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients https://academic.oup.com/jid/article/215/6/865/2973094 doi.org/10.1093/infdis/jix042 Isolated strain PRA 01/12/2023 OJCharles many herpesdrgnovel mutations in strain but good repeated evidence mutations together are natural polymorphims TAS A 1893 HSV1 Clinical isolate UL23 G200D 49 47 0.7 Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients https://academic.oup.com/jid/article/215/6/865/2973094 doi.org/10.1093/infdis/jix042 Isolated strain PRA 01/12/2023 OJCharles TAS A 1894 HSV1 Clinical isolate UL30 D672N 0.3 0.5 1.3 Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients https://academic.oup.com/jid/article/215/6/865/2973094 doi.org/10.1093/infdis/jix042 Isolated strain PRA 01/12/2023 OJCharles many herpesdrgnovel mutations in strain but good repeated evidence mutations together are natural polymorphims TAS A 1895 HSV1 Clinical isolate UL23 L32P 0.3 0.5 1.3 Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients https://academic.oup.com/jid/article/215/6/865/2973094 doi.org/10.1093/infdis/jix042 Isolated strain PRA 01/12/2023 OJCharles this mutations makes no sense perhaps P31L but unsure ALSO many herpesdrgnovel mutations in strain but good repeated evidence mutations together are natural polymorphims TAS O 1896 HSV1 Clinical isolate UL23 R89Q Polymorphism Polymorphism Polymorphism Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients https://academic.oup.com/jid/article/215/6/865/2973094 doi.org/10.1093/infdis/jix042 Isolated strain PRA 01/12/2023 OJCharles many herpesdrgnovel mutations in strain but good repeated evidence mutations together are natural polymorphims TAS A 1897 HSV1 Clinical isolate UL30 S724N 0.3 3.9 5 Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients https://academic.oup.com/jid/article/215/6/865/2973094 doi.org/10.1093/infdis/jix042 Isolated strain PRA 01/12/2023 OJCharles TAS A 1898 HSV1 Clinical isolate UL30 " A719V" 0.5 2.8 1.3 Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients https://academic.oup.com/jid/article/215/6/865/2973094 doi.org/10.1093/infdis/jix042 Isolated strain PRA 01/12/2023 OJCharles TAS A 1899 HSV1 Clinical isolate UL23 N23S Polymorphism Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7 doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7 Isolated strain PRA 01/12/2023 OJCharles Strain 17 A 1900 HSV1 Clinical isolate UL23 K36E Polymorphism Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7 doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7 Isolated strain PRA 01/12/2023 OJCharles Strain 17 A 1901 HSV1 Clinical isolate UL23 L42P Polymorphism Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7 doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7 Isolated strain PRA 01/12/2023 OJCharles Strain 17 A 1902 HSV1 Clinical isolate UL23 R89Q Polymorphism Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7 doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7 Isolated strain PRA 01/12/2023 OJCharles Strain 17 A 1903 HSV1 Clinical isolate UL23 G240E Polymorphism Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7 doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7 Isolated strain PRA 01/12/2023 OJCharles Strain 17 A 1904 HSV1 Clinical isolate UL23 A265T Polymorphism Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7 doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7 Isolated strain PRA 01/12/2023 OJCharles Strain 17 A 1905 HSV1 Clinical isolate UL23 V267L Polymorphism Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7 doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7 Isolated strain PRA 01/12/2023 OJCharles Strain 17 A 1906 HSV1 Clinical isolate UL23 P268T Polymorphism Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7 doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7 Isolated strain PRA 01/12/2023 OJCharles Strain 17 A 1907 HSV1 Clinical isolate UL23 R281Q Polymorphism Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7 doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7 Isolated strain PRA 01/12/2023 OJCharles Strain 17 A 1908 HSV1 Clinical isolate UL23 D286E Polymorphism Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7 doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7 Isolated strain PRA 01/12/2023 OJCharles Strain 17 A 1909 HSV1 Clinical isolate UL23 P355Q Polymorphism Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7 doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7 Isolated strain PRA 01/12/2023 OJCharles Strain 17 A 1910 HSV1 Clinical isolate UL23 N376P Polymorphism Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: Analysis of clinical isolates from herpetic keratitis patients and laboratory strains https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199810%2956%3A2%3C151%3A%3AAID-JMV9%3E3.0.CO%3B2-7 doi.org/10.1002/(SICI)1096-9071(199810)56:2<151::AID-JMV9>3.0.CO;2-7 Isolated strain PRA 01/12/2023 OJCharles Strain 17 A 1911 HSV1 Clinical isolate UL23 N23S 1 Acyclovir-resistant HSV-1 isolates among immunocompromised patients in southern Taiwan: Low prevalence and novel mutations https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28985 doi.org/10.1002/jmv.28985 Isolated strain PRA 01/12/2023 OJCharles reported as S23N KOS A 1912 HSV1 Clinical isolate UL30 E226D 1 Acyclovir-resistant HSV-1 isolates among immunocompromised patients in southern Taiwan: Low prevalence and novel mutations https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28985 doi.org/10.1002/jmv.28985 Isolated strain PRA 01/12/2023 OJCharles KOS A 1913 HSV1 Clinical isolate UL30 A566T 1 Acyclovir-resistant HSV-1 isolates among immunocompromised patients in southern Taiwan: Low prevalence and novel mutations https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28985 doi.org/10.1002/jmv.28985 Isolated strain PRA 01/12/2023 OJCharles reported as T566A KOS A 1914 HSV1 Clinical isolate UL30 E676D 1 Acyclovir-resistant HSV-1 isolates among immunocompromised patients in southern Taiwan: Low prevalence and novel mutations https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28985 doi.org/10.1002/jmv.28985 Isolated strain PRA 01/12/2023 OJCharles KOS A 1915 HSV1 Clinical isolate UL23 Y248D 4 Acyclovir-resistant HSV-1 isolates among immunocompromised patients in southern Taiwan: Low prevalence and novel mutations https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28985 doi.org/10.1002/jmv.28985 Isolated strain PRA 01/12/2023 OJCharles KOS A 1916 HSV1 Clinical isolate UL23 K36E 1 Acyclovir-resistant HSV-1 isolates among immunocompromised patients in southern Taiwan: Low prevalence and novel mutations https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28985 doi.org/10.1002/jmv.28985 Isolated strain PRA 01/12/2023 OJCharles KOS A 1917 HSV1 Clinical isolate UL30 R227H 1 Acyclovir-resistant HSV-1 isolates among immunocompromised patients in southern Taiwan: Low prevalence and novel mutations https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28985 doi.org/10.1002/jmv.28985 Isolated strain PRA 01/12/2023 OJCharles KOS A 1918 HSV1 Clinical isolate UL30 A351D 1 Acyclovir-resistant HSV-1 isolates among immunocompromised patients in southern Taiwan: Low prevalence and novel mutations https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.28985 doi.org/10.1002/jmv.28985 Isolated strain PRA 01/12/2023 OJCharles KOS A 1919 HSV1 M13 UL23 G56V 100 Site-directed mutagenesis of a nucleotide-binding domain in HSV-1 thymidine kinase: Effects on catalytic activity https://www.sciencedirect.com/science/article/abs/pii/004268228890308X doi.org/10.1016/0042-6822(88)90308-X Marker Transfer TK functional kinetic assay 01/12/2023 OJCharles A 1920 HSV1 M13 UL23 G59V 100 Site-directed mutagenesis of a nucleotide-binding domain in HSV-1 thymidine kinase: Effects on catalytic activity https://www.sciencedirect.com/science/article/abs/pii/004268228890308X doi.org/10.1016/0042-6822(88)90308-X Marker Transfer TK functional kinetic assay 01/12/2023 OJCharles A 1921 HSV1 M13 UL23 G61V 100 Site-directed mutagenesis of a nucleotide-binding domain in HSV-1 thymidine kinase: Effects on catalytic activity https://www.sciencedirect.com/science/article/abs/pii/004268228890308X doi.org/10.1016/0042-6822(88)90308-X Marker Transfer TK functional kinetic assay 01/12/2023 OJCharles A 1922 HSV1 M13 UL23 K62I 100 Site-directed mutagenesis of a nucleotide-binding domain in HSV-1 thymidine kinase: Effects on catalytic activity https://www.sciencedirect.com/science/article/abs/pii/004268228890308X doi.org/10.1016/0042-6822(88)90308-X Marker Transfer TK functional kinetic assay 01/12/2023 OJCharles A 1923 HSV1 M13 UL23 T63S 0.8 Site-directed mutagenesis of a nucleotide-binding domain in HSV-1 thymidine kinase: Effects on catalytic activity https://www.sciencedirect.com/science/article/abs/pii/004268228890308X doi.org/10.1016/0042-6822(88)90308-X Marker Transfer TK functional kinetic assay 01/12/2023 OJCharles A 1924 HSV1 M13 UL23 T63A 100 Site-directed mutagenesis of a nucleotide-binding domain in HSV-1 thymidine kinase: Effects on catalytic activity https://www.sciencedirect.com/science/article/abs/pii/004268228890308X doi.org/10.1016/0042-6822(88)90308-X Marker Transfer TK functional kinetic assay 01/12/2023 OJCharles A 1925 HSV1 Clinical isolate UL23 R176Q 200 Herpes Simplex Virus Isolates from an Immunocompromised Patient who Failed to Respond to Acyclovir Treatment Express Thymidine Kinase with Altered Substrate Specificity https://journals.sagepub.com/doi/10.1177/095632029100200504 doi.org/10.1177/095632029100200504 Isolated strain PRA 01/12/2023 OJCharles polymerase was not sequenced SC16 A 1926 HSV2 Clinical isolate UL23 A27T Polymorphism Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20061 doi.org/10.1002/jmv.20061 Isolated strain PRA 01/12/2023 OJCharles 333 A 1927 HSV2 Clinical isolate UL23 S29A Polymorphism Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20061 doi.org/10.1002/jmv.20061 Isolated strain PRA 01/12/2023 OJCharles 333 A 1928 HSV2 Clinical isolate UL23 R51W Resistant Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20061 doi.org/10.1002/jmv.20061 Isolated strain PRA 01/12/2023 OJCharles 333 A 1929 HSV2 Clinical isolate UL23 N78D Polymorphism Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20061 doi.org/10.1002/jmv.20061 Isolated strain PRA 01/12/2023 OJCharles 333 A 1930 HSV2 Clinical isolate UL23 L140F Polymorphism Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20061 doi.org/10.1002/jmv.20061 Isolated strain PRA 01/12/2023 OJCharles 333 A 1931 HSV1 Clinical isolate UL23 G21V Polymorphism Non-cytopathic herpes simplex virus type-1 isolated from acyclovir-treated patients with recurrent infections https://www.nature.com/articles/s41598-022-05188-w doi.org/10.1038/s41598-022-05188-w Isolated strain PRA 01/12/2023 OJCharles A 1932 HSV1 Clinical isolate UL23 D162N 64 Non-cytopathic herpes simplex virus type-1 isolated from acyclovir-treated patients with recurrent infections https://www.nature.com/articles/s41598-022-05188-w doi.org/10.1038/s41598-022-05188-w Isolated strain PRA 01/12/2023 OJCharles A 1933 HSV1 HM3PP UL23 R212K Resistant Non-cytopathic herpes simplex virus type-1 isolated from acyclovir-treated patients with recurrent infections https://www.nature.com/articles/s41598-022-05188-w doi.org/10.1038/s41598-022-05188-w Recombinant BAC PRA 01/12/2023 OJCharles HM3PP A 1934 HSV1 HM3PP UL23 E225K Resistant Non-cytopathic herpes simplex virus type-1 isolated from acyclovir-treated patients with recurrent infections https://www.nature.com/articles/s41598-022-05188-w doi.org/10.1038/s41598-022-05188-w Recombinant BAC PRA 01/12/2023 OJCharles HM3PP A 1935 HSV1 UL30 S724N 17 4.3 Sequential switching of DNA polymerase and thymidine kinase-mediated HSV-1 drug resistance in an immunocompromised child https://journals.sagepub.com/doi/10.1177/135965350400900107 doi.org/10.1177/135965350400900107 Isolated strain PRA 01/12/2023 OJCharles KOS A 1936 HSV1 UL23 R163H 12 1.1 Sequential switching of DNA polymerase and thymidine kinase-mediated HSV-1 drug resistance in an immunocompromised child https://journals.sagepub.com/doi/10.1177/135965350400900107 doi.org/10.1177/135965350400900107 Isolated strain PRA 01/12/2023 OJCharles KOS A 1937 HSV1 Strain17 UL30 V715G 4.6 3.4 Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases https://www.sciencedirect.com/science/article/abs/pii/S016635422100036X doi.org/10.1016/j.antiviral.2021.105046 Recombinant BAC PRA 01/12/2023 OJCharles Strain17 A 1938 HSV1 Strain17 UL30 V715M 3.4 1.5 Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases https://www.sciencedirect.com/science/article/abs/pii/S016635422100036X doi.org/10.1016/j.antiviral.2021.105046 Recombinant BAC PRA 01/12/2023 OJCharles Strain17 A 1939 HSV1 Strain17 UL30 V715S 9.2 5.6 Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases https://www.sciencedirect.com/science/article/abs/pii/S016635422100036X doi.org/10.1016/j.antiviral.2021.105046 Recombinant BAC PRA 01/12/2023 OJCharles Strain17 A 1940 HCMV AD169 UL54 V715M 1.2 3.7 Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases https://www.sciencedirect.com/science/article/abs/pii/S016635422100036X doi.org/10.1016/j.antiviral.2021.105046 Recombinant BAC PRA 01/12/2023 OJCharles AD169 A 1941 HCMV AD169 UL54 V715S 2.9 2.8 Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases https://www.sciencedirect.com/science/article/abs/pii/S016635422100036X doi.org/10.1016/j.antiviral.2021.105046 Recombinant BAC PRA 01/12/2023 OJCharles AD169 A 1942 HSV1 UL30 N522S Polymorphism Polymorphism Genotypic testing improves detection of antiviral resistance in human herpes simplex virus https://www.sciencedirect.com/science/article/pii/S1386653223001774 doi.org/10.1016/j.jcv.2023.105554 Isolated strain PRA 02/06/2024 OJCharles HSV1-A A 1943 HSV1 UL30 A566T Polymorphism Polymorphism Genotypic testing improves detection of antiviral resistance in human herpes simplex virus https://www.sciencedirect.com/science/article/pii/S1386653223001774 doi.org/10.1016/j.jcv.2023.105554 Isolated strain PRA 02/06/2024 OJCharles HSV1-A A 1944 HSV1 UL30 P1124H Polymorphism Polymorphism Genotypic testing improves detection of antiviral resistance in human herpes simplex virus https://www.sciencedirect.com/science/article/pii/S1386653223001774 doi.org/10.1016/j.jcv.2023.105554 Isolated strain PRA 02/06/2024 OJCharles HSV1-A A 1945 HSV1 UL30 A1203T Polymorphism Polymorphism Genotypic testing improves detection of antiviral resistance in human herpes simplex virus https://www.sciencedirect.com/science/article/pii/S1386653223001774 doi.org/10.1016/j.jcv.2023.105554 Isolated strain PRA 02/06/2024 OJCharles HSV1-A A 1946 HSV1 UL30 T821M 4 Genotypic testing improves detection of antiviral resistance in human herpes simplex virus https://www.sciencedirect.com/science/article/pii/S1386653223001774 doi.org/10.1016/j.jcv.2023.105554 Isolated strain PRA 02/06/2024 OJCharles HSV1-A A 1947 HSV1 UL30 A719V 13 Genotypic testing improves detection of antiviral resistance in human herpes simplex virus https://www.sciencedirect.com/science/article/pii/S1386653223001774 doi.org/10.1016/j.jcv.2023.105554 Isolated strain PRA 02/06/2024 OJCharles HSV1-A A 1948 HSV2 UL30 T934A 20 2.7 Genotypic testing improves detection of antiviral resistance in human herpes simplex virus https://www.sciencedirect.com/science/article/pii/S1386653223001774 doi.org/10.1016/j.jcv.2023.105554 Isolated strain PRA 02/06/2024 OJCharles HSV2-G1 A 1949 HSV2 UL30 R628C 2 Genotypic testing improves detection of antiviral resistance in human herpes simplex virus https://www.sciencedirect.com/science/article/pii/S1386653223001774 doi.org/10.1016/j.jcv.2023.105554 Isolated strain PRA 02/06/2024 OJCharles HSV2-G1 A 1950 HSV2 UL30 S729N 2.8 Genotypic testing improves detection of antiviral resistance in human herpes simplex virus https://www.sciencedirect.com/science/article/pii/S1386653223001774 doi.org/10.1016/j.jcv.2023.105554 Isolated strain PRA 02/06/2024 OJCharles HSV2-G1 A 1951 HSV1 UL23 E257K 3 Genotypic testing improves detection of antiviral resistance in human herpes simplex virus https://www.sciencedirect.com/science/article/pii/S1386653223001774 doi.org/10.1016/j.jcv.2023.105554 Isolated strain PRA 02/06/2024 OJCharles HSV2-G1 A 1952 HCMV AD169 UL56 V231L 8.1 Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation https://www.sciencedirect.com/science/article/abs/pii/S016635422400144X doi.org/10.1016/j.antiviral.2024.105935 Recombinant BAC SEAP 31/10/2024 OJCharles AD169 A 1953 HCMV AD169 UL56 S229Y 2 Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation https://www.sciencedirect.com/science/article/abs/pii/S016635422400144X doi.org/10.1016/j.antiviral.2024.105935 Recombinant BAC SEAP 31/10/2024 OJCharles AD169 A 1954 HCMV AD169 UL56 M329I 0.77 Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation https://www.sciencedirect.com/science/article/abs/pii/S016635422400144X doi.org/10.1016/j.antiviral.2024.105935 Recombinant BAC SEAP 31/10/2024 OJCharles AD169 A 1955 HCMV AD169 UL97 G343A 8.5 126 Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiae469/7762822 doi.org/10.1093/infdis/jiae469 Recombinant BAC SEAP 31/10/2024 OJCharles AD169 A 1956 HCMV AD169 UL97 C592G 3.2 Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiae469/7762822 doi.org/10.1093/infdis/jiae469 Recombinant BAC SEAP 31/10/2024 OJCharles AD169 A 1957 HCMV AD169 UL97 H411Y 17 Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiae469/7762822 doi.org/10.1093/infdis/jiae469 Recombinant BAC SEAP 31/10/2024 OJCharles AD169 A 1958 HCMV AD169 UL97 G343A 7.9 272 Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiae469/7762822 doi.org/10.1093/infdis/jiae469 Recombinant BAC SEAP UL97 H411Y 31/10/2024 OJCharles AD169 A 1959 HSV1 Clinical isolate UL23 F289S Successful treatment of acyclovir‐resistant herpes simplex virus infection with amenamevir in a patient who received umbilical cord blood transplantation for T‐cell prolymphocytic leukemia https://pmc.ncbi.nlm.nih.gov/articles/PMC11182414/#jha2899-supitem-0003 doi.org/10.1002/jha2.899 31/10/2024 OJCharles They did perform a phenotypic assay but it lacks basic detail. Also it is not clear if the mutation or the virus was resistance the wording is too loose. O 1960 HSV1 Clinical isolate UL23 A192V Resistant Role of Genotypic Analysis of the Thymidine Kinase Gene of Herpes Simplex Virus for Determination of Neurovirulence and Resistance to Acyclovir https://journals.asm.org/doi/10.1128/jcm.37.10.3171-3174.1999 doi.org/10.1128/jcm.37.10.3171-3174.1999 PRA 11/08/2025 OJCharles Cannot link a mutation to a clear effect O 1961 HSV2 Clinical isolate UL23 L139F Resistant Role of Genotypic Analysis of the Thymidine Kinase Gene of Herpes Simplex Virus for Determination of Neurovirulence and Resistance to Acyclovir https://journals.asm.org/doi/10.1128/jcm.37.10.3171-3174.1999 doi.org/10.1128/jcm.37.10.3171-3174.1999 PRA 11/08/2025 OJCharles Cannot link a mutation to a clear effect O 1962 HHV6b HST U69 L201I 1 Human herpesvirus 6 ganciclovir-resistant strain with amino acid substitutions associated with the death of an allogeneic stem cell transplant recipient https://www.sciencedirect.com/science/article/abs/pii/S1386653208003260 doi.org/10.1016/j.jcv.2008.09.002 Marker Transfer PCR DNA hybridization assay 11/08/2025 OJCharles HST A 1963 HHV6b HST U69 L212I 1 Human herpesvirus 6 ganciclovir-resistant strain with amino acid substitutions associated with the death of an allogeneic stem cell transplant recipient https://www.sciencedirect.com/science/article/abs/pii/S1386653208003260 doi.org/10.1016/j.jcv.2008.09.002 Marker Transfer PCR DNA hybridization assay 11/08/2025 OJCharles HST A 1964 HCMV AD169 UL97 V466G 2.9 1.2 1 0.5 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA 11/08/2025 OJCharles AD169 A 1965 HCMV AD169 UL97 C603R 3.5 1.4 1.5 1.3 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA 11/08/2025 OJCharles AD169 A 1966 HCMV AD169 UL54 N408D 2.1 3 1.1 1.4 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA 11/08/2025 OJCharles AD169 A 1967 HCMV AD169 UL54 K500N 2.9 5.8 1.2 0.5 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA 11/08/2025 OJCharles AD169 A 1968 HCMV AD169 UL54 C539R 2.2 5 0.5 1.1 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA 11/08/2025 OJCharles AD169 A 1969 HCMV AD169 UL54 L545S 2 5.1 1.3 0.4 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA 11/08/2025 OJCharles AD169 A 1970 HCMV AD169 UL54 T552N 1.9 1.4 4.8 1.7 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA 11/08/2025 OJCharles AD169 A 1971 HCMV AD169 UL54 Q578L 2.6 1.9 3.2 0.9 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA 11/08/2025 OJCharles AD169 A 1972 HCMV AD169 UL54 S585A 1.2 1.7 3.6 1 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA 11/08/2025 OJCharles AD169 A 1973 HCMV AD169 UL54 V787L 2 1.8 2.9 1.4 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA 11/08/2025 OJCharles AD169 A 1974 HCMV AD169 UL54 L802M 2.1 1.6 3.6 0.7 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA 11/08/2025 OJCharles AD169 A 1975 HCMV AD169 UL54 V812L 2.2 3.5 1.1 1.9 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA 11/08/2025 OJCharles AD169 A 1976 HCMV AD169 UL54 T821I 2.7 1.5 2.9 1.1 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA 11/08/2025 OJCharles AD169 A 1977 HCMV AD169 UL54 P829S 3.7 1.2 0.9 0.5 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA 11/08/2025 OJCharles AD169 A 1978 HCMV AD169 UL54 L957F 2.1 1.7 1.8 1.4 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA 11/08/2025 OJCharles AD169 A 1979 HCMV AD169 UL54 N408D 2.4 1.8 2.9 1.9 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA UL54 T552N 11/08/2025 OJCharles AD169 A 1980 HCMV AD169 UL54 K500N 2.3 2.8 2.8 0.7 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA UL54 S585A 11/08/2025 OJCharles AD169 A 1981 HCMV AD169 UL54 N408D 2.3 2.3 3.5 0.9 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA UL54 L957F 11/08/2025 OJCharles AD169 A 1982 HCMV AD169 UL54 L545S 3.2 4.1 1.8 1.8 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC PRA UL54 P829S 11/08/2025 OJCharles AD169 A 1983 HCMV AD169 UL56 V236M 1.4 1.2 0.6 20 1.1 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC GLuc 11/08/2025 OJCharles AD169 A 1984 HCMV AD169 UL56 C325F 1.2 1.2 0.6 4337 1.2 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC GLuc 11/08/2025 OJCharles AD169 A 1985 HCMV AD169 UL97 L337M 1.3 0.5 0.9 1 2.7 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC GLuc 11/08/2025 OJCharles AD169 A 1986 HCMV AD169 UL97 F342S 16.5 0.8 1 1 35 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC GLuc 11/08/2025 OJCharles AD169 A 1987 HCMV AD169 UL97 L397R 1.4 0.9 1 1.1 121 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC GLuc 11/08/2025 OJCharles AD169 A 1988 HCMV AD169 UL97 T409M 0.9 0.8 1.1 1.2 83 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC GLuc 11/08/2025 OJCharles AD169 A 1989 HCMV AD169 UL97 H411Y 0.4 0.6 0.4 1.2 20 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC GLuc 11/08/2025 OJCharles AD169 A 1990 HCMV AD169 UL97 P521L 46 0.7 1.9 1 94 In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973 doi.org/10.1016/j.antiviral.2022.105328 Recombinant BAC GLuc 11/08/2025 OJCharles AD169 A 1991 HCMV AD169 UL54 E756K 1.9 3 3.9 Novel Method Based on “En Passant” Mutagenesis Coupled with a Gaussia Luciferase Reporter Assay for Studying the Combined Effects of Human Cytomegalovirus Mutations https://journals.asm.org/doi/10.1128/jcm.01275-13 doi.org/10.1128/jcm.01275-13 Recombinant BAC GLuc 11/08/2025 OJCharles AD169 A 1992 HCMV AD169 UL97 A594V 8.2 Novel Method Based on “En Passant” Mutagenesis Coupled with a Gaussia Luciferase Reporter Assay for Studying the Combined Effects of Human Cytomegalovirus Mutations https://journals.asm.org/doi/10.1128/jcm.01275-13 doi.org/10.1128/jcm.01275-13 Recombinant BAC GLuc 11/08/2025 OJCharles AD169 A 1993 HCMV AD169 UL97 A594V 10.8 2 4.1 Novel Method Based on “En Passant” Mutagenesis Coupled with a Gaussia Luciferase Reporter Assay for Studying the Combined Effects of Human Cytomegalovirus Mutations https://journals.asm.org/doi/10.1128/jcm.01275-13 doi.org/10.1128/jcm.01275-13 Recombinant BAC GLuc UL54 E756K 11/08/2025 OJCharles AD169 A 1994 HCMV AD169 UL97 H587Y 1.2 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 1995 HCMV AD169 UL97 C592G 3.2 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 1996 HCMV AD169 UL97 C603W 8.3 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 1997 HCMV AD169 UL54 P522S 2.4 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 1998 HCMV AD169 UL54 A987G 6.2 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 1999 HCMV AD169 UL97 A440V 1.2 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 2000 HCMV AD169 UL97 A442G 12 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 2001 HCMV AD169 UL54 E315D 0.9 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 2002 HCMV AD169 UL54 F357L 1.2 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 2003 HCMV AD169 UL54 V377A 1.2 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 2004 HCMV AD169 UL54 P448S 1.2 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 2005 HCMV AD169 UL54 R512H 1.4 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 2006 HCMV AD169 UL54 C524R 1.2 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 2007 HCMV AD169 UL54 E530G 1.3 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 2008 HCMV AD169 UL54 D576G 1.3 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 2009 HCMV AD169 UL54 A635T 1.5 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 2010 HCMV AD169 UL54 P648S 1.2 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 2011 HCMV AD169 UL54 S649P 1.2 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 2012 HCMV AD169 UL54 V694I 1 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 2013 HCMV AD169 UL54 I837V 0.8 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 2014 HCMV AD169 UL54 L897P 0.9 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 2015 HCMV AD169 UL54 G993D 1.1 Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis https://journals.lww.com/transplantjournal/abstract/2010/12270/recombinant_phenotyping_of_cytomegalovirus.27 doi.org/10.1097/TP.0b013e3181fdd9d2 Recombinant BAC SEAP 11/08/2025 OJCharles AD169 A 2016 HCMV AD169 UL97 M460V 4.5 Analysis Of The Ul97 Phosphotransferase Coding Sequence In Clinical Cytomegalovirus Isolates And Identification Of Mutations Conferring Ganciclovir Resistance https://academic.oup.com/jid/article-abstract/171/3/576/821679 doi.org/10.1093/infdis/171.3.576 Marker Transfer PCR DNA hybridization assay 11/08/2025 OJCharles Other mutations present but not characterised AD169 O 2017 HCMV AD169 UL97 A594V 11 Analysis Of The Ul97 Phosphotransferase Coding Sequence In Clinical Cytomegalovirus Isolates And Identification Of Mutations Conferring Ganciclovir Resistance https://academic.oup.com/jid/article-abstract/171/3/576/821679 doi.org/10.1093/infdis/171.3.576 Marker Transfer PCR DNA hybridization assay 11/08/2025 OJCharles Other mutations present but not characterised AD169 O 2018 HCMV AD169 UL97 L595S 13 Analysis Of The Ul97 Phosphotransferase Coding Sequence In Clinical Cytomegalovirus Isolates And Identification Of Mutations Conferring Ganciclovir Resistance https://academic.oup.com/jid/article-abstract/171/3/576/821679 doi.org/10.1093/infdis/171.3.576 Marker Transfer PCR DNA hybridization assay 11/08/2025 OJCharles Other mutations present but not characterised AD169 O 2019 HCMV Clinical isolate UL97 M460V 10 Ganciclovir resistance mutations in UL97 and UL54 genes of Human cytomegalovirus isolates resistant to ganciclovir https://pubmed.ncbi.nlm.nih.gov/15230476/ Isolated strain PRA 14/08/2025 OJCharles High variation in "WT" reps - take absolute fold changes as a rough ballpark Clinical isolate A 2020 HCMV Clinical isolate UL97 A594T 2.7 Ganciclovir resistance mutations in UL97 and UL54 genes of Human cytomegalovirus isolates resistant to ganciclovir https://pubmed.ncbi.nlm.nih.gov/15230476/ Isolated strain PRA 14/08/2025 OJCharles High variation in "WT" reps - take absolute fold changes as a rough ballpark Clinical isolate A 2021 HCMV Clinical isolate UL97 A594T 3.1 Ganciclovir resistance mutations in UL97 and UL54 genes of Human cytomegalovirus isolates resistant to ganciclovir https://pubmed.ncbi.nlm.nih.gov/15230476/ Isolated strain PRA UL54 P522S 14/08/2025 OJCharles High variation in "WT" reps - take absolute fold changes as a rough ballpark Clinical isolate A 2022 HCMV Clinical isolate UL97 C603W 2 Ganciclovir resistance mutations in UL97 and UL54 genes of Human cytomegalovirus isolates resistant to ganciclovir https://pubmed.ncbi.nlm.nih.gov/15230476/ Isolated strain PRA 14/08/2025 OJCharles High variation in "WT" reps - take absolute fold changes as a rough ballpark Clinical isolate A 2023 HSV1 Clinical isolate UL23 A189V 70 81 1.1 0.9 13 20 0.3 Heterogeneity and viral replication fitness of HSV-1 clinical isolates with mutations in the thymidine kinase and DNA polymerase https://academic.oup.com/jac/article/77/11/3153/6691801 doi.org/10.1093/jac/dkac297 Isolated strain Cytopathic effect 14/08/2025 OJCharles paper includes tripple mutants - add later KOS A 2024 HSV1 Clinical isolate UL23 A189V 44 89 1.5 3.3 2 20 0.3 Heterogeneity and viral replication fitness of HSV-1 clinical isolates with mutations in the thymidine kinase and DNA polymerase https://academic.oup.com/jac/article/77/11/3153/6691801 doi.org/10.1093/jac/dkac297 Isolated strain Cytopathic effect UL30 L778M 14/08/2025 OJCharles paper includes tripple mutants - add later KOS A 2025 HSV1 Clinical isolate UL23 T183P 1.4 1.3 3.6 0.4 1.4 0.3 Heterogeneity and viral replication fitness of HSV-1 clinical isolates with mutations in the thymidine kinase and DNA polymerase https://academic.oup.com/jac/article/77/11/3153/6691801 doi.org/10.1093/jac/dkac297 Isolated strain Cytopathic effect UL30 L778M 14/08/2025 OJCharles paper includes tripple mutants - add later KOS A 2026 HSV1 Clinical isolate UL23 A189V 29 86 2.2 7.1 15 0.3 Heterogeneity and viral replication fitness of HSV-1 clinical isolates with mutations in the thymidine kinase and DNA polymerase https://academic.oup.com/jac/article/77/11/3153/6691801 doi.org/10.1093/jac/dkac297 Isolated strain Cytopathic effect UL30 L802F 14/08/2025 OJCharles paper includes tripple mutants - add later KOS A 2027 HSV1 Clinical isolate UL23 T183P 0.9 1.1 2.5 0.8 1.3 0.3 Heterogeneity and viral replication fitness of HSV-1 clinical isolates with mutations in the thymidine kinase and DNA polymerase https://academic.oup.com/jac/article/77/11/3153/6691801 doi.org/10.1093/jac/dkac297 Isolated strain Cytopathic effect UL30 L802F 14/08/2025 OJCharles paper includes tripple mutants - add later KOS A 2028 HCMV Towne UL54 D981del2 7 4 4 A Deletion Mutation in Region V of the Cytomegalovirus DNA Polymerase Sequence Confers Multidrug Resistance https://academic.oup.com/jid/article-abstract/182/6/1765/916204 doi.org/10.1086/317618 Marker Transfer PRA 14/08/2025 OJCharles Towne A 2029 VZV Clinical isolate ORF28 Q298K 1 Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199909%2959%3A1%3C84%3A%3AAID-JMV14%3E3.0.CO%3B2-N doi.org/10.1002/(SICI)1096-9071(199909)59:1<84::AID-JMV14>3.0.CO;2-N Isolated strain Cytopathic effect 14/08/2025 OJCharles Challenging to assign any pol mutation to a phenotype as clearly tk is dominating resistance for example see vrABD OKA A 2030 VZV Clinical isolate ORF28 S863G 1 Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199909%2959%3A1%3C84%3A%3AAID-JMV14%3E3.0.CO%3B2-N doi.org/10.1002/(SICI)1096-9071(199909)59:1<84::AID-JMV14>3.0.CO;2-N Isolated strain Cytopathic effect 14/08/2025 OJCharles OKA A 2031 VZV Clinical isolate ORF28 L1095M 1 Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype https://onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291096-9071%28199909%2959%3A1%3C84%3A%3AAID-JMV14%3E3.0.CO%3B2-N doi.org/10.1002/(SICI)1096-9071(199909)59:1<84::AID-JMV14>3.0.CO;2-N Isolated strain Cytopathic effect 14/08/2025 OJCharles OKA A 2032 HCMV MMT UL97 D605E 0.5 Single and multiple mutations in the human cytomegalovirus UL97 gene and their relationship to the enzymatic activity of UL97 kinase for ganciclovir phosphorylation https://www.sciencedirect.com/science/article/abs/pii/S0166354209004239 10.1016/j.antiviral.2009.08.005 Marker Transfer TK functional kinetic assay 18/08/2025 OJCharles Kinetic slowdown factors from this paper correlate very well with resistance fold changes from others - assuming 1:1 correlation MMT A 2033 HCMV MMT UL97 M460V 8.3 Single and multiple mutations in the human cytomegalovirus UL97 gene and their relationship to the enzymatic activity of UL97 kinase for ganciclovir phosphorylation https://www.sciencedirect.com/science/article/abs/pii/S0166354209004239 10.1016/j.antiviral.2009.08.005 Marker Transfer TK functional kinetic assay 18/08/2025 OJCharles Kinetic slowdown factors from this paper correlate very well with resistance fold changes from others - assuming 1:1 correlation MMT A 2034 HCMV MMT UL97 M460V 14 Single and multiple mutations in the human cytomegalovirus UL97 gene and their relationship to the enzymatic activity of UL97 kinase for ganciclovir phosphorylation https://www.sciencedirect.com/science/article/abs/pii/S0166354209004239 10.1016/j.antiviral.2009.08.005 Marker Transfer TK functional kinetic assay UL97 A594P 18/08/2025 OJCharles Kinetic slowdown factors from this paper correlate very well with resistance fold changes from others - assuming 1:1 correlation MMT A 2035 HCMV MMT UL97 A594P 3.2 Single and multiple mutations in the human cytomegalovirus UL97 gene and their relationship to the enzymatic activity of UL97 kinase for ganciclovir phosphorylation https://www.sciencedirect.com/science/article/abs/pii/S0166354209004239 10.1016/j.antiviral.2009.08.005 Marker Transfer TK functional kinetic assay 18/08/2025 OJCharles Kinetic slowdown factors from this paper correlate very well with resistance fold changes from others - assuming 1:1 correlation MMT A 2036 HCMV MMT UL97 A594P 4 Single and multiple mutations in the human cytomegalovirus UL97 gene and their relationship to the enzymatic activity of UL97 kinase for ganciclovir phosphorylation https://www.sciencedirect.com/science/article/abs/pii/S0166354209004239 10.1016/j.antiviral.2009.08.005 Marker Transfer TK functional kinetic assay UL97 D605E 18/08/2025 OJCharles Kinetic slowdown factors from this paper correlate very well with resistance fold changes from others - assuming 1:1 correlation MMT A 2037 HHV6b HST U38 H507Y 0.9 1.1 7.9 Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet https://journals.sagepub.com/doi/abs/10.1177/135965350701200608 doi.org/10.1177/135965350701200608 Lab induced strain PCR DNA hybridization assay 18/08/2025 OJCharles HST A 2038 HHV6b HST U38 H507Y 2.6 2.6 2.6 Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet https://journals.sagepub.com/doi/abs/10.1177/135965350701200608 doi.org/10.1177/135965350701200608 Marker Transfer Functional enzyme kinetic assay 18/08/2025 OJCharles HST A 2039 HHV6b HST U38 A961V 0.7 0.7 0.7 Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet https://journals.sagepub.com/doi/abs/10.1177/135965350701200608 doi.org/10.1177/135965350701200608 Marker Transfer Functional enzyme kinetic assay 18/08/2025 OJCharles HST A 2040 HHV6b HST U38 F292S 6 6 6 Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet https://journals.sagepub.com/doi/abs/10.1177/135965350701200608 doi.org/10.1177/135965350701200608 Marker Transfer Functional enzyme kinetic assay 18/08/2025 OJCharles HST A 2041 HHV6b HST U38 T435R 1.7 1.7 1.7 Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet https://journals.sagepub.com/doi/abs/10.1177/135965350701200608 doi.org/10.1177/135965350701200608 Marker Transfer Functional enzyme kinetic assay 18/08/2025 OJCharles HST A 2042 HHV6b HST U38 C525S 3.4 3.4 3.4 Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet https://journals.sagepub.com/doi/abs/10.1177/135965350701200608 doi.org/10.1177/135965350701200608 Marker Transfer Functional enzyme kinetic assay 18/08/2025 OJCharles HST A 2043 HHV6b HST U38 T435R 9 9 9 Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet https://journals.sagepub.com/doi/abs/10.1177/135965350701200608 doi.org/10.1177/135965350701200608 Marker Transfer Functional enzyme kinetic assay U38 C525S 18/08/2025 OJCharles HST A 2044 HCMV AD169 UL97 L397R 2.6 2 1.3 171 Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet https://www.sciencedirect.com/science/article/abs/pii/S1386653206002538 doi.org/10.1016/j.jcv.2006.07.010 Recombinant BAC SEAP 18/08/2025 OJCharles AD169 A 2045 HCMV AD169 UL97 M460V 8.2 0.4 Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet https://www.sciencedirect.com/science/article/abs/pii/S1386653206002538 doi.org/10.1016/j.jcv.2006.07.010 Recombinant BAC SEAP 18/08/2025 OJCharles AD169 A 2046 HCMV AD169 UL97 A594V 10.4 2.2 Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet https://www.sciencedirect.com/science/article/abs/pii/S1386653206002538 doi.org/10.1016/j.jcv.2006.07.010 Recombinant BAC SEAP 18/08/2025 OJCharles AD169 A 2047 HCMV AD169 UL97 C592G 3.9 1.4 Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet https://www.sciencedirect.com/science/article/abs/pii/S1386653206002538 doi.org/10.1016/j.jcv.2006.07.010 Recombinant BAC SEAP 18/08/2025 OJCharles AD169 A 2048 HCMV AD169 UL97 L595S 8.6 1.8 Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet https://www.sciencedirect.com/science/article/abs/pii/S1386653206002538 doi.org/10.1016/j.jcv.2006.07.010 Recombinant BAC SEAP 18/08/2025 OJCharles AD169 A 2049 HCMV AD169 UL54 A809V 2.1 1.8 4 0.4 Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet https://www.sciencedirect.com/science/article/abs/pii/S1386653206002538 doi.org/10.1016/j.jcv.2006.07.010 Recombinant BAC SEAP 18/08/2025 OJCharles AD169 A 2050 HCMV AD169 UL54 del981-982 4.6 3.3 2.5 0.6 Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet https://www.sciencedirect.com/science/article/abs/pii/S1386653206002538 doi.org/10.1016/j.jcv.2006.07.010 Recombinant BAC SEAP 18/08/2025 OJCharles AD169 A 2051 HCMV AD169 UL54 N408K 6.5 20 0.8 0.5 Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet https://www.sciencedirect.com/science/article/abs/pii/S1386653206002538 doi.org/10.1016/j.jcv.2006.07.010 Recombinant BAC SEAP 18/08/2025 OJCharles AD169 A 2052 HCMV Towne UL54 S291P 1.7 Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet https://www.sciencedirect.com/science/article/abs/pii/S0166093405000236 doi.org/10.1016/j.jviromet.2005.01.005 Marker Transfer Functional enzyme kinetic assay 18/08/2025 OJCharles Towne A 2053 HCMV Towne UL54 K415R 1.5 Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet https://www.sciencedirect.com/science/article/abs/pii/S0166093405000236 doi.org/10.1016/j.jviromet.2005.01.005 Marker Transfer Functional enzyme kinetic assay 18/08/2025 OJCharles Towne A 2054 HCMV Towne UL54 V715M 65 Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet https://www.sciencedirect.com/science/article/abs/pii/S0166093405000236 doi.org/10.1016/j.jviromet.2005.01.005 Marker Transfer Functional enzyme kinetic assay 18/08/2025 OJCharles Towne A 2055 HCMV Towne UL54 E756K 31 Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet https://www.sciencedirect.com/science/article/abs/pii/S0166093405000236 doi.org/10.1016/j.jviromet.2005.01.005 Marker Transfer Functional enzyme kinetic assay 18/08/2025 OJCharles Towne A 2056 HCMV Towne UL54 N495K 5 Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet https://www.sciencedirect.com/science/article/abs/pii/S0166093405000236 doi.org/10.1016/j.jviromet.2005.01.005 Marker Transfer Functional enzyme kinetic assay 18/08/2025 OJCharles Towne A 2057 VZV Clinical isolate ORF36 Q303* 6 1.8 Acyclovir-resistant Varicella-Zoster virus: Phenotypic and genetic characterization https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1096-9071(199807)55:3%3C250::AID-JMV12%3E3.0.CO;2-K doi.org/10.1002/(SICI)1096-9071(199807)55:3<250::AID-JMV12>3.0.CO;2-K Isolated strain PRA 18/08/2025 OJCharles OKA A 2058 VZV Clinical isolate ORF36 Tdel26 65 Selection and Characterization of Varicella-Zoster Virus Variants Resistant to (R)-9-[4-Hydroxy-2-(Hydroxymethy)Butyl]Guanine https://journals.asm.org/doi/10.1128/aac.45.6.1629-1636.2001?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed doi.org/10.1128/aac.45.6.1629-1636.2001 Lab induced strain PRA 18/08/2025 OJCharles VZV-32 A 2059 VZV Clinical isolate ORF36 E269del 20 Selection and Characterization of Varicella-Zoster Virus Variants Resistant to (R)-9-[4-Hydroxy-2-(Hydroxymethy)Butyl]Guanine https://journals.asm.org/doi/10.1128/aac.45.6.1629-1636.2001?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed doi.org/10.1128/aac.45.6.1629-1636.2001 Lab induced strain PRA 18/08/2025 OJCharles VZV-32 A 2060 VZV Clinical isolate ORF36 N479I 80 Phenotypic and genetic characterization of varicella-zoster virus mutants resistant to acyclovir, brivudine and/or foscarnet https://link.springer.com/article/10.1007/s00430-011-0191-4 doi.org/10.1007/s00430-011-0191-4 Lab induced strain PRA 18/08/2025 OJCharles would this method have found stop codons? Also table 3 lists the mutation as both pol and tk (to my reading) so I am unsure and will make inactive Clinical isolate O 2061 VZV Oka ORF55 K350N 0.8 2500 Single Amino Acid Substitution Within the Helicase of Varicella Zoster Virus Makes It Resistant to Amenamevir https://onlinelibrary.wiley.com/doi/10.1002/jmv.70080 doi.org/10.1002/jmv.70080 Recombinant BAC PRA 18/08/2025 OJCharles A 2062 HSV2 Clinical isolate UL23 R221H 4 51.4 0.4 0.7 Primary HSV-2 Infection in an Immunocompromised Patient Reveals High Diversity of Drug-Resistance Mutations in the Viral DNA Polymerase https://www.mdpi.com/1999-4915/17/7/962# doi.org/10.3390/v17070962 Isolated strain Cytopathic effect 18/08/2025 OJCharles Clinical isolate A 2063 HSV2 Clinical isolate UL30 Q732R 559 1122 1.2 5.4 Primary HSV-2 Infection in an Immunocompromised Patient Reveals High Diversity of Drug-Resistance Mutations in the Viral DNA Polymerase https://www.mdpi.com/1999-4915/17/7/962# doi.org/10.3390/v17070962 Isolated strain Cytopathic effect 18/08/2025 OJCharles Clinical isolate A 2064 HSV2 Clinical isolate UL30 R847C 827 225 1.2 5 Primary HSV-2 Infection in an Immunocompromised Patient Reveals High Diversity of Drug-Resistance Mutations in the Viral DNA Polymerase https://www.mdpi.com/1999-4915/17/7/962# doi.org/10.3390/v17070962 Isolated strain Cytopathic effect 18/08/2025 OJCharles Clinical isolate A 2065 HSV1 KOS UL30 del962 0.9 0.9 1.5 3.7 0.5 0.7 Combined use of pritelivir with acyclovir or foscarnet suppresses evolution of HSV-1 drug resistance https://academic.oup.com/ve/article/10/1/veae101/7907489 doi.org/10.1093/ve/veae101 Lab induced strain Cytopathic effect 18/08/2025 OJCharles KOS A 2066 HSV1 KOS UL5 K356Q 1 0.8 0.9 0.7 31 33 Combined use of pritelivir with acyclovir or foscarnet suppresses evolution of HSV-1 drug resistance https://academic.oup.com/ve/article/10/1/veae101/7907489 doi.org/10.1093/ve/veae101 Lab induced strain Cytopathic effect 18/08/2025 OJCharles KOS A 2067 HSV1 KOS UL5 K356N 1.2 0.9 1 0.8 482 78 Combined use of pritelivir with acyclovir or foscarnet suppresses evolution of HSV-1 drug resistance https://academic.oup.com/ve/article/10/1/veae101/7907489 doi.org/10.1093/ve/veae101 Lab induced strain Cytopathic effect 18/08/2025 OJCharles KOS A 2068 HSV1 KOS UL5 M355I 0.9 0.9 0.5 1 7 6.8 Combined use of pritelivir with acyclovir or foscarnet suppresses evolution of HSV-1 drug resistance https://academic.oup.com/ve/article/10/1/veae101/7907489 doi.org/10.1093/ve/veae101 Lab induced strain Cytopathic effect 18/08/2025 OJCharles KOS A 2069 HSV1 KOS UL30 L702I 0.6 4 4.3 4.6 1 1.6 Combined use of pritelivir with acyclovir or foscarnet suppresses evolution of HSV-1 drug resistance https://academic.oup.com/ve/article/10/1/veae101/7907489 doi.org/10.1093/ve/veae101 Lab induced strain Cytopathic effect 18/08/2025 OJCharles KOS A 2070 HSV1 KOS UL30 V812F 0.9 3.3 1.5 6.2 0.5 0.8 Combined use of pritelivir with acyclovir or foscarnet suppresses evolution of HSV-1 drug resistance https://academic.oup.com/ve/article/10/1/veae101/7907489 doi.org/10.1093/ve/veae101 Lab induced strain Cytopathic effect 18/08/2025 OJCharles KOS A 2071 HSV1 KOS UL23 T65P 44 230 0.8 0.9 0.6 0.8 Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1 https://journals.asm.org/doi/10.1128/aac.00110-24 doi.org/10.1128/aac.00110-24 Lab induced strain Cytopathic effect 18/08/2025 OJCharles KOS A 2072 HSV1 KOS UL23 T96K 47 129 0.6 0.9 1 0.4 Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1 https://journals.asm.org/doi/10.1128/aac.00110-24 doi.org/10.1128/aac.00110-24 Lab induced strain Cytopathic effect 18/08/2025 OJCharles KOS A 2073 HSV1 KOS UL23 L205S 16 32 1 0.7 0.4 0.4 Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1 https://journals.asm.org/doi/10.1128/aac.00110-24 doi.org/10.1128/aac.00110-24 Lab induced strain Cytopathic effect 18/08/2025 OJCharles KOS A 2074 HSV1 KOS UL23 M231I 2 3.1 0.8 0.9 0.9 0.7 Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1 https://journals.asm.org/doi/10.1128/aac.00110-24 doi.org/10.1128/aac.00110-24 Lab induced strain Cytopathic effect 18/08/2025 OJCharles KOS A 2075 HSV1 KOS UL23 A167T 2.4 2.4 1.1 0.8 1.2 1.2 Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1 https://journals.asm.org/doi/10.1128/aac.00110-24 doi.org/10.1128/aac.00110-24 Lab induced strain Cytopathic effect 18/08/2025 OJCharles KOS A 2076 HSV1 KOS UL23 C336Y 40 190 0.5 0.9 0.6 0.8 Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1 https://journals.asm.org/doi/10.1128/aac.00110-24 doi.org/10.1128/aac.00110-24 Lab induced strain Cytopathic effect 18/08/2025 OJCharles KOS A 2077 HSV1 KOS UL23 C336Y 111 27 0.6 0.7 0.4 0.3 Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1 https://journals.asm.org/doi/10.1128/aac.00110-24 doi.org/10.1128/aac.00110-24 Lab induced strain Cytopathic effect UL30 H168Y 18/08/2025 OJCharles KOS A 2078 HSV1 KOS UL23 T96I 4.6 12 1.5 0.9 0.5 0.7 Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1 https://journals.asm.org/doi/10.1128/aac.00110-24 doi.org/10.1128/aac.00110-24 Lab induced strain Cytopathic effect UL30 A991T 18/08/2025 OJCharles KOS A 2079 HSV1 KOS UL23 R163H 324 187 1.5 1 1.7 1.6 Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1 https://journals.asm.org/doi/10.1128/aac.00110-24 doi.org/10.1128/aac.00110-24 Lab induced strain Cytopathic effect 18/08/2025 OJCharles KOS A 2080 HSV1 KOS UL23 R222C 10 98 0.7 0.9 0.3 0.3 Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1 https://journals.asm.org/doi/10.1128/aac.00110-24 doi.org/10.1128/aac.00110-24 Lab induced strain Cytopathic effect 18/08/2025 OJCharles KOS A 2081 HSV1 KOS UL30 S1067F 1 0.3 4.4 0.8 0.5 0.7 Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1 https://journals.asm.org/doi/10.1128/aac.00110-24 doi.org/10.1128/aac.00110-24 Lab induced strain Cytopathic effect 18/08/2025 OJCharles KOS A 2082 HSV1 Clinical isolate UL5 K356N 5000 Detection of HSV-1 variants highly resistant to the helicase–primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1 https://academic.oup.com/jac/article-abstract/60/2/274/712728 doi.org/10.1093/jac/dkm182 Isolated strain PRA 18/08/2025 OJCharles A 2083 HCMV AD169 UL54 K805Q 0.8 0.3 Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity https://journals.sagepub.com/doi/10.3851/IMP1565 doi.org/10.3851/IMP1565 Marker Transfer PRA 18/08/2025 OJCharles AD169 A 2084 HCMV AD169 UL54 T821I 5.3 23.3 Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity https://journals.sagepub.com/doi/10.3851/IMP1565 doi.org/10.3851/IMP1565 Marker Transfer PRA 18/08/2025 OJCharles AD169 A 2085 HCMV AD169 UL54 K805Q 2 2 2 2 2 Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity https://journals.sagepub.com/doi/10.3851/IMP1565 doi.org/10.3851/IMP1565 Marker Transfer Functional enzyme kinetic assay 18/08/2025 OJCharles AD169 A 2086 HCMV AD169 UL54 T821I 5.5 5.5 5.5 5.5 5.5 Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity https://journals.sagepub.com/doi/10.3851/IMP1565 doi.org/10.3851/IMP1565 Marker Transfer Functional enzyme kinetic assay 18/08/2025 OJCharles AD169 A 2087 HCMV Clinical isolate UL54 L501F 22 10 Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir https://link.springer.com/article/10.1007/s007050050072 doi.org/10.1007/s007050050072 Isolated strain PRA 18/08/2025 OJCharles 91-7S A 2088 HCMV AD169 UL97 C480R 9.2 Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions https://journals.asm.org/doi/full/10.1128/aac.01726-13 doi.org/10.1128/aac.01726-13 Lab derived mutant PRA 26/08/2025 OJCharles AD169 A 2089 HCMV AD169 UL97 del617 18 Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions https://journals.asm.org/doi/full/10.1128/aac.01726-13 doi.org/10.1128/aac.01726-13 Lab derived mutant PRA 26/08/2025 OJCharles AD169 A 2090 HCMV AD169 UL97 D456N 4.6 Human Cytomegalovirus UL97 Kinase Is Involved in the Mechanism of Action of Methylenecyclopropane Analogs with 6-Ether and -Thioether Substitutions https://journals.asm.org/doi/full/10.1128/aac.01726-13 doi.org/10.1128/aac.01726-13 Lab derived mutant PRA 26/08/2025 OJCharles AD169 A 2091 HCMV Towne UL54 V781I 4.7 4.2 Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity https://www.sciencedirect.com/science/article/pii/S1386653201001603 doi.org/10.1016/S1386-6532(01)00160-3 07/09/2025 OJCharles Given resistance factors in other papers I believe the 2 recombinants in this paper have been mixed up O 2092 HSV1 UL29 P597L 0.7 1 1.9 1.5 1.1 A Mutation in the Herpes Simplex Virus Type 1 (HSV-1) UL29 Gene is Associated with Anti-Herpesvirus Drugs’ Susceptibility https://www.mdpi.com/1999-4915/16/12/1813 doi.org/10.3390/v16121813 Recombinant BAC PRA 31/12/2025 OJCharles The strain is a chimera - ignoring A 2093 HCMV AD169 UL56 V236M 1.4 0.9 0.6 0.9 31 Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in UL56 and UL54 Genes https://journals.asm.org/doi/10.1128/aac.01044-17 doi.org/10.1128/aac.01044-17 Recombinant BAC Gluc reporter assay 31/12/2025 OJCharles AD169 A 2094 HCMV AD169 UL54 E756K 7.1 1.8 3.5 2.8 1.4 Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in UL56 and UL54 Genes https://journals.asm.org/doi/10.1128/aac.01044-17 doi.org/10.1128/aac.01044-17 Recombinant BAC Gluc reporter assay 31/12/2025 OJCharles AD169 A 2095 HCMV AD169 UL54 del981-982 7.5 3.2 3 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354225002669 doi.org/10.1016/j.antiviral.2025.106340 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2096 HCMV AD169 UL54 N498S 1.7 1.8 1.7 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354225002669 doi.org/10.1016/j.antiviral.2025.106340 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2097 HCMV AD169 UL54 D515E 1 1.1 0.9 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354225002669 doi.org/10.1016/j.antiviral.2025.106340 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2098 HCMV AD169 UL54 D542E 3.5 13 0.5 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354225002669 doi.org/10.1016/j.antiviral.2025.106340 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2099 HCMV AD169 UL54 A543V 2.1 3.2 0.7 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354225002669 doi.org/10.1016/j.antiviral.2025.106340 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2100 HCMV AD169 UL54 P598S 1.9 1.7 0.7 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354225002669 doi.org/10.1016/j.antiviral.2025.106340 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2101 HCMV AD169 UL54 A786V 1 1 1.1 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354225002669 doi.org/10.1016/j.antiviral.2025.106340 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2102 HCMV AD169 UL54 A928T 0.9 1 0.9 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354225002669 doi.org/10.1016/j.antiviral.2025.106340 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2103 HCMV AD169 UL54 A928V 1 1 1.1 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354225002669 doi.org/10.1016/j.antiviral.2025.106340 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2104 HCMV AD169 UL54 E949K 1.7 1.6 5.8 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354225002669 doi.org/10.1016/j.antiviral.2025.106340 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2105 HCMV AD169 UL54 E949Q 1.4 1.7 3.7 A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354225002669 doi.org/10.1016/j.antiviral.2025.106340 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2106 HCMV AD169 UL97 F342Y 6.5 4.9 Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354226001956 doi.org/10.1016/j.antiviral.2026.106536 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2107 HCMV AD169 UL97 C592G 3.5 Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354226001956 doi.org/10.1016/j.antiviral.2026.106536 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2108 HCMV AD169 UL27 Q167R 1.1 Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354226001956 doi.org/10.1016/j.antiviral.2026.106536 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2109 HCMV AD169 UL27 L193F 2 Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354226001956 doi.org/10.1016/j.antiviral.2026.106536 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2110 HCMV AD169 UL27 L317V 2 Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354226001956 doi.org/10.1016/j.antiviral.2026.106536 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2111 HCMV AD169 UL27 A375T 0.9 Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354226001956 doi.org/10.1016/j.antiviral.2026.106536 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2112 HCMV AD169 UL97 del381-382 1 1.2 Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354226001956 doi.org/10.1016/j.antiviral.2026.106536 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2113 HCMV AD169 UL97 T400M 1 0.9 Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354226001956 doi.org/10.1016/j.antiviral.2026.106536 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2114 HCMV AD169 UL97 A543T 1 1.1 Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354226001956 doi.org/10.1016/j.antiviral.2026.106536 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2115 HCMV AD169 UL97 R570Q 0.9 1.1 Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354226001956 doi.org/10.1016/j.antiviral.2026.106536 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2116 HCMV AD169 UL97 G598A 1.9 1.3 Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354226001956 doi.org/10.1016/j.antiviral.2026.106536 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2117 HCMV AD169 UL97 K599N 1.1 1.1 Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354226001956 doi.org/10.1016/j.antiviral.2026.106536 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2118 HCMV AD169 UL97 L622M 1 0.9 Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354226001956 doi.org/10.1016/j.antiviral.2026.106536 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A 2119 HCMV AD169 UL97 P706S 1 1 Low level drug resistance linked to cytomegalovirus UL97 and UL27 mutations detected in maribavir clinical trials https://www.sciencedirect.com/science/article/abs/pii/S0166354226001956 doi.org/10.1016/j.antiviral.2026.106536 Recombinant BAC SEAP 25/09/2026 OJCharles AD169 A